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Small cell lung cancer (SCLC) is an extremely aggressive, pulmonary malignancy 
linked to lifetime smoking of cigarette tobacco. Most SCLC is diagnosed in the metastatic 
setting and surgical resection is rarely performed. However, SCLC is one of the most 
chemosensitive tumors, with >50% objective responses observed in de novo disease. 
These responses are impressive, but brief. Median progression free survival remains 
less than 5 months in current clinical trials. Recent studies have characterized the 
genome and epigenome of primary, untreated SCLC tumors. These studies have 
revealed near universal inactivation of the tumor suppressors TP53 and RB1, with 
frequent alterations in chromatin modifying enzymes, Notch signaling and amplification 
of MYC family members. Little in known about what factors permit acquired resistance 
and enable such a rapid shift in chemosensitive to chemorefractory disease within the 
same patient. No studies to date have comprehensively characterized paired sensitive 
and resistant disease states. 
The research presented below describes three studies aimed at determining how 
acquired resistance to chemotherapy is generated in vivo and targeted therapeutic 
approaches to chemoresistant disease. The first study details the discovery of genetic 
and epigenetic mediators of acquired chemoresistance in vivo through the development 
and characterization of paired chemosensitive and chemoresistant patient derived 
xenograft (PDX) models of SCLC. This work establishes a central role for EZH2 in 
promoting resistance to DNA damaging agents by silencing the gene SLFN11 and is 
highlighted by the impressive efficacy of EZH2 inhibition with first or second line 
standard of care chemotherapy. The second study describes a targeted approach to 
overcoming resistance to programmed cell death (apoptosis) by chemically inhibiting a 
protein-protein interaction between BCL-2 family members in SCLC. This study relied on 
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the small molecule ABT-263 and attempts to explain disappointingly transient responses 
in SCLC patients observed in clinical testing. Finally, the third study builds on the second 
study, highlighting the importance of combinatorial strategies to improve the efficacy of 
this targeted agent in vivo, with a focus on potential mechanisms of acquired resistance, 
notably genomic loss of BAX. Research presented in these studies is directly informing 
the design of proposed clinical trials in SCLC. 
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Small Cell Lung Cancer (SCLC) 
 
Lung cancer is the most common cause of cancer death in both men and 
women, responsible for more deaths than colon cancer, breast cancer and prostate 
cancer combined (Siegel et al., 2013). Small cell lung cancer (SCLC) represents 
approximately 15% of all lung cancers, or about 25,000 cases annually in the United 
States. SCLC is strongly associated with tobacco usage and exposure, and is 
anticipated to be a global public health concern over the next several decades, 
particularly in the developing world, mirroring smoking trends. Globally, more than 
200,000 people die from SCLC every year. 
 Median survival for limited stage SCLC (disease confined to one hemi-thorax) is 
approximately 18 months from the time of diagnosis and upwards of 20% of patients are 
curable with a combination of chemotherapy and radiation (Slotman and Senan, 2011). 
However, the majority (>70%) of SCLC patients present with metastatic disease, limiting 
the clinical benefit of gross surgical resection. Median survival for extensive stage 
disease is less than one year. First line systemic therapy for extensive stage SCLC, 
consisting of platinum and etoposide chemotherapy, yields objective responses in >50% 
of patients, placing this cancer among the most chemotherapy-sensitive solid tumors. 
However, chemotherapy-resistant relapse is universal following treatment, resulting in 
uniformly fatal outcomes. 
 The only FDA-approved therapy for second line treatment in SCLC is the 
topoisomerase I poison topotecan (Hycamtin®), where response rates in the relapsed 
setting vary between 10-25%, depending on whether the relapse was initially 
chemosensitive (>3mo progression free interval) or chemoresistant (<3mo) (Horita et al., 
2015). Further, while various classes of chemotherapies have activity in the third line 
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setting and beyond versus best supportive care, they provide little in the way survival 
benefit (Behera et al., 2016; Pelayo Alvarez et al., 2013). Indeed, no progress had been 
made within the last 40 years on extending the survival of patients with extensive stage 
disease (Oze et al., 2009). With several new classes of therapeutics on the horizon for 
clinical testing in SCLC, the time is now appropriate to define the hallmarks of SCLC and 
work to uncover why it is so exceptionally resistant to cytotoxic chemotherapy upon 
relapse (Bunn et al., 2016; Tan et al., 2016; Thomas and Pommier, 2016).  
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Genetic and Epigenetic Hallmarks of SCLC 
 
 Recent genomic characterization of SCLC has revealed near universal, bi-allelic 
inactivation of the tumor suppressors RB1 and TP53 (George et al., 2015; Peifer et al., 
2012; Rudin et al., 2012a) (Figure 1). The tight link between diagnosis of SCLC and 
lifetime tobacco smoking also places SCLC among one of the mostly highly mutated 
cancers, with an average of >10 non-synonymous (coding) mutations per megabase of 
tumor genome (George et al., 2015; Lawrence et al., 2013). SCLC is also characterized 
by a high frequency of genomic amplifications of MYC family members, usually in a 
mutually-exclusive fashion, including MYC, MYCN and MYCL1 and certain MYCL1 
fusions (Little et al., 1983; Makela et al., 1992; Nau et al., 1985; Nau et al., 1986; Rudin 
et al., 2012a; Takahashi et al., 1989). Inhibition of MYC function is thought to be a 
potential therapeutic approach in SCLC, possibly by targeting a long-term proliferative 
population of cells (Fiorentino et al., 2016; Jahchan et al., 2016).  
The first description of spontaneous SCLC in a genetically engineered mouse 
models (GEMMs) was pioneered by Anton Bern’s group in the Netherlands, where 
conditional inactivation of Trp53 and Rb1 in mouse lung epithelial cells produced 
histologically similar disease to human SCLC, with predilection for metastases to the 
liver and bone (Meuwissen et al., 2003). It was later shown that murine SCLC can arise 
from multiple lung cell progenitor lineages and are composed of both neuroendocrine 
and mesenchymal components (Calbo et al., 2011; Semenova et al., 2015; Sutherland 
et al., 2011), without a clear necessity for initiation in type II alveolar cells, as had been 
hypothesized by other groups. Additional genetic alterations are know to decrease the 
relatively long incubation period for tumor formation in these murine models (median 
survival time ~200d for Trp53/Rb1 KO), including:  loss of PTEN (Cui et al., 2014; 
McFadden et al., 2014), gain of MYCL1 (Huijbers et al., 2014), and amplification of NFIB 
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(Denny et al., 2016; Dooley et al., 2011; Semenova et al., 2016; Wu et al., 2016), 
inhibition of Notch1 signaling (George et al., 2015), and activation of Hedgehog signaling 
(Park et al., 2011b).  
Recently, the critical role of the developmental transcription factor ASCL1 has 
been demonstrated in murine tumorigenesis, where a similarly related transcription 
factor NEUROD1 played more of a role in driving metastatic spread through the 
activation of MYC; however, unlike ASCL1, genetic removal of NEUROD1 did not limit 
spontaneous tumor formation in animals (Borromeo et al., 2016). Both transcription 
factors are believed to responsible for driving gene expression of key neuroendocrine 
markers in SCLC, including synaptophysin, CD56/NCAM and CHGA (Chen et al., 1997; 
Jiang et al., 2009; Kosari et al., 2014; Nasgashio et al., 2011; Westerman et al., 2002). 
The relative roles of Ascl1 and NeuroD1 in defining molecularly distinct subsets of SCLC 
have been suggested previously by others, and may correlate with both gene expression 
and DNA methylation patterns in primary tumors (Kalari et al., 2013; Osborne et al., 
2014; Poirier et al., 2013; Poirier et al., 2015). One key difference outside of mutational 
frequency/tobacco signature between human and murine SCLC may lie in the epigenetic 
regulation of tumorigenesis and metastasis. Upwards of 25% of human SCLC cases 
harbor inactivating mutations in CREBBP/CBP, EP300, or MLL2/KMT2D, which at first 
glance in a limited dataset, appear mutually exclusive. It is not clear whether inactivation 
of these genes affects tumorigenesis, metastasis or sensitivity to chemotherapy in 
murine or human models.  
A DNA hypomethylation signature has been recently reported as a potential 
biomarker of sensitivity to small molecular inhibition of lysine demethylase 1 (LSD1) in 
SCLC (Mohammad et al., 2015). LSD1 is a histone-modifying enzyme responsible for 
de-methylating histone H3 lysine 4 (H3K4) and regulates gene expression. One distinct 
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feature of both human and murine SCLC is high-level expression of EZH2, a histone 
methyltransferase enzyme within the Polycomb Repressive Complex 2 (PRC2) 
responsible for catalyzing the conversion of histone H3K27 to the trimethylated state and 
gene silencing (Vire et al., 2006). Dysregulation through either activating somatic 
mutations or overexpression in cancers can confer a DNA hypermethylation phenotype 
observed in aggressive cancers with poor outcomes, including SCLC (Knutson et al., 
2012; McCabe et al., 2012; Morin et al., 2010; Souroullas et al., 2016; Yap et al., 2011). 
In cases of SCLC the near universal loss of RB1 relieves E2F-dependent transcription, 
driving high levels of EZH2 (Bracken et al., 2003). In primary SCLC, levels of EZH2 
transcript are among the highest of all tumor types surveyed within the TCGA, as well as 
some of the highest in cancer cell lines included in the CCLE (Barretina et al., 2012; 
Poirier et al., 2015) (Figure 2). Taken together, these data suggest that while core 
losses in tumor suppressor genes define a hallmark of SCLC, currently mutational data 
does not suggest the presence of additional driver genes, in stark contrast to NSCLC 
where KRAS and EGFR driving alterations broadly classify more than 45% of histologic 
disease and are used to inform therapeutic treatment. What emerges is the presence of 
distinct subsets of SCLC via transcriptional and epigenetic profiling of cell lines and 
primary tumors that may be differentially susceptible to emerging classes of therapeutic 





Figure 2. High level RNA expression of EZH2 is a defining feature of SCLC 
Above:  RNAseq expression of EZH2 in a cohort of SCLC (Rudin et al., 2012a) as 
compared to other histologies included in the TCGA 
Below: Microarray expression of EZH2 from CCLE datasets; SCLC subsets called out in 
red for both panels. 
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Mechanisms of Cell Death  
 
 Disciplines focused on cell death have progressed over the years to identify 
unique definitions of both programmed pathways and relatively disjointed pathways by 
which a cell can die. In reality, these processes occur together, involving the turnover of 
billions of cells in unique compartments of the human body each day. Traditional 
cytotoxic chemotherapy that damages DNA, directly or indirectly, is a good example of a 
therapeutic process where both programmed and disjointed cell death occur. Whereas 
immunogenic cell death involves the release of materials processed by the body to 
antigenic peptides from dying cells and activation of cellular pathways downstream of 
pattern recognition receptors, programmed cell death, or apoptosis, is though to be a 
relatively compartmentalized process that triggers a minimal immune response, at best 
(Galluzzi et al., 2015; Krysko et al., 2013). 
 Apoptosis is activated in a committed process triggered by at least two broad 
classes of cues, termed the extrinsic pathway and intrinsic pathway. Where the extrinsic 
pathway involves signaling through various classes of death and TNF-α/ TNF-α-related 
classes of receptors leading to an intracellular cascade that ultimately activates pro-
caspase 8, intrinsic cell death is regulated at the level of the mitochondria where the B-
cell lymphoma 2 (BCL2) family of pro-/anti-apoptotic proteins interact on the 
mitochondrial outer membrane to regulate mitochondrial health/function, while 
preserving integrity. Abundant displacement of pro-apoptotic effectors from various 
binding partners can lead to oligomerization of pro-apoptotic proteins BAX and BAK, 
leading to channel formation and permeabilization of the mitochondrial outer membrane. 
This then leads to release of both cytochrome c and second mitochondria-derived 
activator of caspases (SMACs) from mitochondria into the cytosol, the former being 
critical for pro-caspase activation leading to an effector caspase cascade, and the latter 
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being important in inhibiting proteins that normally function to inhibit apoptosis (IAPs). 
Together, both pathways converge on phenotypic observations critical to apoptosis of 
nuclei condensation, cytosolic blebbing and coordinated destruction of protein/DNA 
components contained within apoptotic bodies (Green, 2016).   
 New mechanisms continue to emerge, but to date, have been broadly 
characterized by qualitative differences in cell or sub-cellular membrane composition 
during the execution of the given process, drawing comparisons or specifying differences 
between apoptosis (non-lytic), necroptosis (lytic) and/or autophagy (lysosomal; non-
lytic). For example, necroptosis is a relatively recent description of a process thought for 
decades to be passive cellular lysis, releasing/lysing cellular components into 
intercellular space, and indeed, is currently not distinguishable from passive 
destruction/crush artifact in samples examined by electron microscopy. However, at the 
molecular levels, it is becoming established that necroptosis has at least two defined 
cellular paths activating either the downstream pseudokinase mixed lineage kinase 
domain like protein (MLKL) or gasdermin-D (pyroptosis; activation of inflammatory non-
apoptotic caspases). Although these two components represent a divergence in 
signaling pathways between the two necrotic programs, it is unclear whether they 
represent terminal events. Another distinguishing feature of pyroptosis is the conversion 
and release of proinflammatory IL-18 and IL-1β, conversion from the zymogen state by 
the “inflammatory” caspases 1, 4, 5 and 11 (human/mouse). While the intracellular 
effectors are still being discovered, it has been shown that TNF family members can 
drive classic necroptosis, where pathogen derived agents such as LPS or nucleic acids 
may preferentially activate pyroptosis in cell line models (Wallach et al., 2016); however, 
it should be made clear that much is still to be discovered and uncovered in the field of 
programmed cell death and its impact on cancer and inflammatory disease.  
 10 
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Chapter 1. Modeling Human Cancer in a Mouse Host:  Applications of Patient-




 Historically, studies investigating human cancers have relied on repositories of 
banked clinical samples embedded in paraffin or kept in a freezer. Successful generation 
of immortalized cell lines from primary tumor tissue is still a challenge and plagued with 
clonal bottlenecking. Application of genetically engineered mouse models of cancers 
have rapidly advanced and taught the community much about disease development and 
dependencies, but murine systems may represent only a fraction of the heterogeneity 
seen within a single human cancer. All of these scenarios present limitations in one way 
or another to the problem – studying and manipulating human cancer as it lives:  within a 
human host, with a functional immune system and supportive tumor microenvironment. 
The chapter that follows is intended to briefly introduce PDX model systems and serve 
as an application note when using PDX models to study human cancer.  
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Maintaining Genetic and Epigenetic Integrity 
 Several large PDX-focused consortia have recently established the utility of PDX 
generation and screening en masse, including the EuroPDX working group and the 
Novartis Institute for Biomedical Research (Gao et al., 2015; Hidalgo et al., 2014). 
Research teams have approached the task of screening in vivo tumor sensitivity to 
experimental therapeutics using small numbers of animals per group(s) as well as large 
numbers per treatment, to determine the extent of response heterogeneity in a given 
model system (Gao et al., 2015; Tentler et al., 2012; Townsend et al., 2016). In addition 
to engraftment and propagation in murine hosts, other groups have explored the 
development of tumor organoids from primary tumor tissue or from successfully 
engrafted PDX models, most notably in prostate, lung and colorectal cancers (Crystal et 
al., 2014; Gao et al., 2014; Karthaus et al., 2014). What consistently emerges from these 
efforts are the attempts of research teams to generate models systems that more closely 
resemble that of an actual tumor and preservation of the intratumoral heterogeneity over 
multiple in vivo passages. These degrees of similarity are usually lost in cell line 
xenograft (CLX) models where the relationship between the primary tumor of origin and 
resulting immortalized cell lines can be highly divergent due to clonal bottlenecking in 
vitro. 
 Our research team was one of the first groups to suggest that establishing cell 
lines from PDX models caused irreversible gene expression changes that did not revert 
to the “parental” signature (Daniel et al., 2009). These data suggested that in order for a 
PDX system to truly emulate the parental tumor of origin, it must be maintained in the 
murine host, and not placed into cell culture where irreversible changes, perhaps in 
adaptation to in vitro growth conditions, can occur. Other groups have gone on to 
establish the importance of passage number in vivo, where the Novartis Institute has 
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conclusively shown using several hundred PDXs of various histology that >6 rounds of in 
vivo passage, new single nucleotide polymorphisms (SNPs) are gained in the tumor that 
were not present in the principal, or primary, engrafted tumor tissue (Gao et al., 2015). 
This is did not appear to be a function of limited sequencing depth where certain low 
presence sub-clones were below the limit of detection, but rather the acquisition of new 
mutations in the PDX due to unstable genome maintenances across models, collectively. 
While it is unclear whether the changes in gene expression patterns and gaining of new 
SNPs yield models that are less useful to discovery efforts, the fact that they occur and 
can be quantitated has led other groups to establish hard cutoffs for passage numbers of 
given tumors, where most report “low passage” numbers below 8-10 in vivo rounds of 
passaging (Hidalgo et al., 2014; Tentler et al., 2012). 
 Scaling up the propagation of a given PDX can impose some technical restraints 
on their utility, as several rounds of in vivo passage may be required to expand tumor 
material to the point that it can be used to engraft 100s of animals for a large screening 
effort. Therefore, an alternative strategy has been to use PDX-derived materials in short-
term ex vivo culture, so called patient-derived tumor cells (PDTC). Recently, several 
groups have shown that screening drug sensitivity in short term culture can largely 
recapitulate in vivo drug response, although these assays are largely limited to agents 
that have quick onsets or are grossly cytotoxic, such as receptor tyrosine kinase 
inhibitors (RTKi) and DNA damaging agents, respectively (Bruna et al., 2016; Crystal et 
al., 2014; Witkiewicz et al., 2016). Part of the reason PDX models are more 
representative of patient tumor biology versus traditional cell line xenografts may stem 
from a preservation of the epigenetic integrity of the primary tumor during direct 
transplantation into the murine host. Our group has shown PDXs to more closely 
resemble and cluster with primary, unmatched tumors than tumor cell lines or even cell 
 14 
lines derived directly from paired PDXs (Poirier et al., 2015). Using CpG methylation 
arrays, these data strongly suggest that at the level of epigenetic similarity, only PDX 
systems approach the epigenetic landscape maintained in primary tissue of origin. The 
defining characteristics of PDX models versus other systems begin to highlight the 
advantages to using PDX models to understand the likely clinical response of a patient 
to an investigational therapy using a patient-derived “avatar” model (Hidalgo et al., 2011; 
Izumchenko et al., 2016), as well as the likely prevalence of certain subclones, whether 
they are genetically or epigenetically defined, within a tumor bulk population to drive 
therapeutic resistance or metastasize (Bertotti et al., 2015; DeRose et al., 2011; 
Forshew et al., 2012; Kreso et al., 2013; Murtaza et al., 2013).  
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Tumor Microenvironment Differences and Limitations 
 Approaches towards reconstructing the human tumor microenvironment in a 
murine host have largely taken one of two routes: co-engraftment of human tumor 
component with matched/paired immune tissues into a highly immunocompromised 
mouse strain (e.g. NSG) or humanization of genomic loci on the current background of 
an otherwise highly immunocompromised mouse strain. The former strategy requires the 
isolation of CD34+ stem cells via the bone marrow or circulating in the periphery, gross 
isolation of peripheral blood mononuclear cells from whole blood (PBMCs) or the most 
intense approach being to biopsy the thymus/liver and bone marrow compartment to 
completely repopulate the irradiated immunocompromised host (Morton et al., 2016; 
Shultz et al., 2012). The later strategy involves “knocking-in” humanized loci for specific 
cell lineage defining receptors or growth factors on the background of a highly 
immunodeficient mouse strain.  
Recently, the Falvell group had demonstrated the utility of humanizing 
components of the innate immune system, developing the MITRG/MISTRG strains on 
the background of Rag2-/-Il2rg-/- mice knocking in genes for human M-CSF, IL-3/GM-CSF 
and TPO into their respective murine loci (Rongvaux et al., 2014). Engraftment of human 
tumor xenografts into these animals produced human macrophage infiltration into the 
xenograft, matching the polarization phenotype observed in primary samples. Moreover, 
it’s logical to envision a combination of approaches for both genetically-engineered and 
co-engrafted murine models, where specific lineages can be interrogated for their impact 
on disease state or xenograft growth, while receiving the necessary growth signals and 
support from the humanized cytokine loci. Taken together, approaches utilizing PDX 
models are focusing on ways to better recapitulate the immune infiltrate and supportive 
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environment that have traditionally been neglected when engrafing human tissue into 
highly immunocompromised animals.  
 Another limitation that most current PDX models do not address deals with the 
contribution of stromal components to tumor response and growth in vivo. It is well 
established that many solid tumors have a large fibroblast component to them, the 
cancer associated fibroblast (CAFs), and these fibroblasts play a role in remodeling 
extracellular matrix of the tumor, and perhaps even contribute to therapeutic resistance 
and response via tumor cell-stroma paracrine loops (Augsten, 2014; Kalluri, 2016; 
Straussman et al., 2012; Wilson et al., 2012). What is also clear is that these human 
stromal components are gradually phased out of the tumor through multiple in vivo 
passages and effectively replaced by murine stroma (Schneeberger et al., 2016). The 
presence of a murine component/contaminant within a human tumor population can also 
lead to technical challenges down the road when interrogating genomic differences 
between the primary/archival tissue and that which successfully engrafted into murine 
host. The high degree of variability of stromal components in a given PDX model has the 
potential to cause error rates in mutation calling algorithms if the user is not aligning 
sequencing data against a human/mouse hybrid genome or not taking some steps to 
ensure the majority of mouse tissue has been removed prior to DNA extraction (Figure 
3). However, it is less clear whether the murine stroma contributes the same degree of 
functionality and tumor support as that of the human origin, leading some groups to 
attempt co-engraftment of paired/matched tumor and stromal components from primary 
surgical samples. Taken together, this first Chapter introduces the utility of the PDX 
models as a highly concordant model system to that of the primary tissue in terms of 
genomic and epigenomic architecture. The inability to completely recapitulate the human 
microenvironment and immunologic infiltrate should be taken into consideration when 
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choosing how to apply findings from experiments using PDX models as a tool for 




Figure 3. Impact of murine cellular components on human mutational calling by 
next-generation sequencing. 
Example flow cytometry data of human tumor cells and mouse stromal components from 
two human non-small cell lung cancer (NSCLC) PDX models – MSK-LX27, a G12D Kras 
mutant tumor, and MSK-LX29, an L858R EGFR mutant tumor. Established hind flank 
tumors of indicated early passage (p+1) were enzymatically dissociated with a Miltenyi 
human tumor dissociation kit on an octoMACS dissociator before staining ~20M viable 
cells with limiting dilutions of antibodies against human CD326 (APC-hEpCAM; y-axis) 
and mouse H2kD (PE-mH2Kd; x-axis). Both models contain varying degrees of stroma, 
which our group has shown to negatively influence downstream sequencing approaches 
by increasing the rate of false mutation calls, even when compared to human-murine 
hybrid genomes (Schneeberger et al., 2016). Inset table comparing murine and human 
DNA contribution from extractions of bulk and sorted/purified populations of cells using 
species-specific primers. MCD=mouse cell depletion beads (cited in Materials and 




Considerations in Preclinical Experimental Design – Case Study of Sunitinib 
Oncologists are all too familiar with the challenges of translating findings from 
animal models into patients. In a previous study, Henderson and colleagues (Henderson 
et al., 2013) identified what they believed to be the most-common threats to preclinical 
experimental validity, which were classified as internal, construct and external threats 
(Table 1). In a recent meta-analysis, this group takes as an informative case study the 
preclinical testing of sunitinib, an oral multitargeted tyrosine kinase inhibitor that is 
licensed as a monotherapy for advanced-stage renal-cell carcinoma, gastrointestinal 
stromal (GIST) and pancreatic neuroendocrine tumors (Henderson et al., 2015). Using 
sunitinib as an example, these authors describe how underpowered or poorly designed 
experiments in animals, together with reporting biases, can conspire to construct 
misleading results. The interpretation of these results can lead scientists and clinicians 
to overestimate the preclinical therapeutic efficacy of sunitinib. This wrong judgment 
might be partially to blame for the disappointing activity sunitinib has shown in early 
stage clinical trials across multiple malignancies (Henderson et al., 2015). For example, 
the authors note the disappointing results of a phase II study in relapsed or refractory 
small cell lung cancer (Han et al., 2013) where the observed efficacy was minimal and 
responses were partial at best, yet the preclinical evidence – again, albeit minimal – 
suggested modest tumor growth inhibition. However, one should note that a recent study 
has also shown sunitinib to be clinically beneficial in SCLC for chemosensitive relapse 
(Abdelraouf et al., 2016) as well as reports in specific scenarios, one of these scenarios 
possibly following prophylactic cranial irradiation (Salama et al., 2016). Nonetheless, 
both studies were early phase trials in limited numbers of patients, and the benefit 
conferred has been called into the question of practicality by others (Di Maio et al., 
2016). 
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Not surprisingly, when interrogating the published literature on preclinical studies 
examining the efficacy of sunitinib as a single agent, Henderson et al. found that most 
studies fell short on taking–or disclosing–appropriate measures to reduce threats to 
internal and construct validity, such as blinded outcome assessment and using more 
than one model system, respectively. The ability of this meta-analysis to compare 
multiple, divergent study types relied on inferring effect sizes as standardized mean 
differences (SMDs) using Hedges’ g score. In total, 74 studies, describing 332 
experiments in animals in which tumor volumes or volume responses were indicated, 
were included in the capture step. The dataset was further reduced to 158 experiments 
by selecting only those that met the criteria for data extraction applicable to a g-score 
calculation. The authors then summarized all of the experimental data with respect to 
identified threats to internal, external and construct validity. The internal validity of a 
study pertains to the efforts taken to reduce experimental/experimenter bias, such as 
blinded outcome assessment, whereas the external validity of a study is scored based 
on numbers of models and species tested (Henderson et al., 2015). Finally, construct 
validity metrics help shed light on the relevance a given model system has to the end 
application – e.g. predictive power of a model. The majority of studies contained threats 
that might, across or within certain malignancies, lead to an overestimation of sunitinib 
efficacy. They further demonstrated that all of the preclinical studies that explored the 
dose–response relationships between tumor volume and sunitinib dose failed to show 
associations comparable to those observed in the cited clinical studies (Faivre et al., 
2006)—albeit this was a difficult comparison to perform owing to the limited number of 
studies. Finally, by comparing the effect size calculated per study using a trim and fill 
method, Henderson and colleagues showed that, in specific malignancies with results 
from >20 preclinical studies available for analysis, their data fitting indicated an overall 
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publication bias, as compared with the reported effect from studies for renal-cell 
carcinoma (the indicated positive control). 
The authors have subsequently called for an overhaul of the way in vivo 
preclinical oncology experiments are designed and reported, making note of the ARRIVE 
guidelines (Kilkenny et al., 2010) and suggesting immediate, actionable changes. These 
and other (Landis et al., 2012) recommendations in the preclinical arenas comprise 
useful standard operating procedures for optimizing preclinical study design. For certain 
preclinical questions, conducting limited analyses in a single species or not exploring a 
wide range of doses is appropriate. For example, proof of principle studies focused on a 
single disease, using a drug for which doses and schedules have been previously 
explored, may opt for a previously validated regimen in the model of choice, rather than 
repeat an extensive dose-finding experiment. Depending on the context in which the 
work is being performed, however, researchers should at least consider these 
recommendations when planning, conducting, analyzing and reporting preclinical 
experimental data. An important consideration that might ultimately drive this field 
forward would be the adoption of good practice standards by all peer-reviewed 
publication outlets. 
So, how can we translate the findings of this meta-analysis of sunitinib to our 
current work? The predictive value attributable to a given animal model system must be 
taken into account before actively researching experimentally which model is optimal for 
each study, because each system is both limited and complex (Day et al., 2015). What 
should be recognized is that no model system is ideal, nor can any model be completely 
predictive across and within therapeutic categories in oncology (Gould et al., 2015). 
Because of these limitations, there is a real need to utilize multiple nonhuman models, 
reflective of the complex biology of the conditions that clinicians aim to treat. The 
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standard models based on human cell-line xenografts that grow easily in 
immunocompromised mice do not need to be abandoned, but should be used with 
acknowledgement of the limitations of the system, and a realization that complementary 
genetically-engineered mouse models (GEMM) and patient-derived xenografts (PDX) 
exist; certain models are more appropriate for discovery applications whereas others are 
suitable for prediction of clinical efficacy. Make no mistake; underpowered studies that 
use single models will be an old habit that dies hard in the research community. 
Henderson and colleagues should be commended for acknowledging the 
limitations of any potential recommendations based on the results of their own study. 
Indeed, the authors note that they were limited only to studies that reported data in a 
manner useful for calculating standardized mean differences. They further note that 
implementing more rigorous preclinical standards such as testing therapeutic agents in 
multiple model systems or blinded outcome assessment would certainly come at a 
greater monetary and time cost to those who adopt such practices. However, the benefit 
of implementing more-rigorous standards upfront becomes evident when considering the 
already staggering levels of clinical trial attrition in oncology (Begley and Ellis, 2012). 
The results of a follow-up analysis from the same group demonstrated that performing 
additional clinical testing of sunitinib in other tumor types was of minimal benefit, and 
further investigation beyond the original, approved indication worsened the risk–benefit 
ratio (Carlisle et al., 2016) of this therapy across all examined malignancies, when 
viewed in aggregate. This analysis of data for sunitinib is one specific and dated 
example of the preclinical and clinical legacy of an approved therapeutic agent. 
However, similar conclusions would likely result from examination of the past and current 
threats to clinical inference across preclinical studies examining the efficacy of small 
molecules, biologic agents and radiotherapeutic regimens. Looking forward, the need for 
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appropriately powered and diversified preclinical animal studies becomes even more 
relevant in an age when investigators seek to combine multiple targeted therapies to 
combat resistance mechanisms in genetically-annotated tumor types—including 
contexts in which agents that might have minimal efficacy as monotherapies are given in 
combination. 
For future analyses of preclinical efficacy in oncology drug development to be 
appropriately powered and to avoid overestimating the magnitude of the effect of a given 
therapeutic agent, researchers should adhere, whenever possible, to recommended best 
practices for in vivo preclinical oncology research (Table 2). Whether such 
recommendations become adopted as requirements for the publication of preclinical 
therapeutic findings will likely depend on the active engagement of journal peer-
reviewers and editors to hold our feet to the fire. 
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Table 1. Preclinical Reporting Metrics for Studies Examining Tumor Volume Responses 
in Animals 
 
Pre-specified metrics Active metrics 
Sample size calculation Blinded assessment 
Power calculation Blinded treatment allocation 
Inclusion criteria Statistical comparisons 
Exclusions criteria (e.g. ouliers) Study replication 









Threat Category application example 
Internal reduce experimental bias random allocation 
External transfer of a cause-and-effect relationship 
across systems 
# of model systems used 
Construct Validity relevance of model system(s) to end 
application 
predictive power of model 
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Intended to be blank 
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Chapter 2. Epigenetic Silencing of SLFN11 Defines a Recurrent Mechanism of 




Small cell lung cancer is among the most lethal human malignancies. Typical 
progression of this disease is characterized by a rapid shift between initial 
chemoresponsive and subsequent chemoresistant states. The mechanisms responsible 
for acquired therapeutic resistance in small cell lung cancer have not been defined.  
Using patient-derived tumor xenografts to closely model clinical acquired resistance, this 
work:  (1) defines a mechanism of chemoresistance operant across multiple, 
independent small cell lung cancers, (2) identifies an epigenetic regulator controlling the 
mechanism of acquired resistance, and (3) establishes a novel therapeutic strategy to 
both prevent and treat acquired resistance in vivo (Figure 4). These observations have 
immediate clinical implications, describing an approach that may lead to a durable and 




Figure 4. Chapter 2 Brevis.  
PDX models are generated by directly engrafting human tumor cells into 
immunocompromised mice, without any intervening cell culture (e.g. ex vivo). Once 
stably established and passage in animals, groups of chemonaïve tumor-bearing 
animals were challenged with a schedule of chemotherapy used as first line in patients, 
until their tumors were robustly chemoresistant. Comparing conserved gene expression 
changes between multiple chemonaïve and chemoresistant models revealed down 
regulation of SLFN11, a gene implicated in sensitivity to DNA damaging agents, 
particularly topoisomerase I poisons. Herein we show that the histone methyltransferase 
EZH2 is responsible for this silencing event in vivo, depositing H3K27me3 throughout 
the gene body of SLFN11, and this can be reversed by inhibition EZH2’s catalytic activity 
with the clinical stage EZH2 inhibitor EPZ011989.  
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Study Introduction 
Small cell lung cancer (SCLC) affects an estimated 270,000 individuals per year 
worldwide, and is metastatic at the time of diagnosis in approximately two thirds of cases 
(Shepherd et al., 2007; Torre et al., 2015). Metastatic SCLC is exceptionally lethal, 
associated with a median survival from the time of diagnosis of 9 to 10 months, and a 5-
year survival of less than 2% (Shepherd et al., 2007). Even when detected prior to 
metastasis, most patients with localized disease will suffer disease recurrence and death 
within the first 2 years. More effective treatment approaches to SCLC are desperately 
needed. 
The standard first line treatment for metastatic SCLC consists of a platinum doublet, 
cisplatin or carboplatin, generally paired with the topoisomerase II inhibitor etoposide 
(Kalemkerian et al., 2013). Standard approaches to recurrent SCLC include treatment 
with a topoisomerase I inhibitor, topotecan or irinotecan. There are no approved 
therapies for SCLC after progression on a second line regimen. De novo SCLC is 
remarkably sensitive to first line platinum doublet chemotherapy, with objective response 
rates of over 50% in patients without substantial co-morbid conditions. These impressive 
responses are also disappointingly transient:  median progression-free survival in current 
trials remains less than 5 months (Belani et al., 2016). The response rates to second line 
topoisomerase I inhibitor therapy are substantially lower, below 20% overall (Horita et 
al., 2015). 
The molecular mechanisms responsible for the remarkable shift between de novo 
chemosensitive disease and rapidly emergent chemoresistant disease in SCLC have not 
been defined. Recurrent SCLC is rarely biopsied:  recurrence is expected and repeat 
biopsy is not known to be useful in guiding decisions regarding second line therapy. 
Defining these mechanisms would both provide novel insights into the biology of SCLC 
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and inform clinical strategies to prevent or delay therapeutic resistance. More broadly, 
characterizing mechanisms of acquired resistance in this cancer that undergoes a 
dramatic shift between chemosensitivity and chemoresistance could have implications 
for understanding acquired resistance to DNA damaging cytotoxic therapy in other 
malignancies. 
We and others have characterized the mutational landscape of SCLC (George et al., 
2015; Rudin et al., 2012a). This disease is tightly linked to heavy tobacco smoking. 
Chronic mutagenic exposure, coupled with essentially universal loss of tumor suppressor 
genes RB1 (RB transcriptional corepressor 1) and TP53 (tumor protein 53), translates 
into an exceptionally high burden of mutations and genomic rearrangements. A simple 
comparison of disparate models representing de novo and recurrent SCLC could limit 
sensitivity to detect causal alterations due to the high background mutational load and 
inter-tumoral genomic heterogeneity of SCLC. We hypothesized that a more informative 
approach would be to conduct a pair-wise comparison of changes in individual tumor 
models prior to, and following, acquired chemotherapy resistance. 
We sought to characterize mechanisms of acquired resistance to first line cisplatin 
and etoposide therapy in SCLC by mimicking clinical practice as closely as possible 
through in vivo treatment of a set of chemosensitive SCLC patient-derived xenograft 
(PDX) models. Over the past decade, our research group has established and 
characterized a library of lung cancer PDX models, including tumors from both 
chemonaïve and previously treated SCLC patients (Daniel et al., 2009). We have 
demonstrated that these SCLC models more closely resemble the human disease than 
do cell line-based xenografts, in global gene expression and genome-wide methylation 
profiles (Poirier et al., 2015). In this study we selected ten SCLC PDX demonstrating 
initial in vivo chemosensitivity to cisplatin and etoposide. Through repeated cycles of 
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cisplatin and etoposide in tumor-bearing mice, we derived tumors that progressed 
through treatment. Progressing tumors were disaggregated, transplanted into second 
and third generations of mice, and retreated to verify that these tumors in fact 
represented acquired, intrinsic chemotherapeutic resistance. Here we describe the 
results of detailed genomic analyses of these chemosensitive and subsequent 
chemoresistant pairs. We discovered that epigenetic silencing of SLFN11, a gene 
involved in DNA damage repair sensitivity, was a recurrent event in acquired 
chemoresistance. Chemically inhibiting EZH2 prevented in vivo acquired resistance and 
sensitized resistant tumors and cell lines to DNA damaging agents. These observations 
put forth an epigenetic mechanism to explain the dramatic change in chemosensitivity 
observed in primary SCLC.  
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Materials and Methods 
PDX model use and characterization 
All animal experiments were approved by the Memorial Sloan Kettering Cancer Center 
(MSKCC) Animal Care and Use Committee. All primary tumors and whole blood 
samples collected for generation of patient-derived xenograft (PDX) models were 
obtained under protocols approved by the MSKCC Institutional Review Board (IRB). 
Subcutaneous flank tumors were generated as previously described (Daniel et al., 
2009), engrafting ~1x106 viable cells in a 50% Matrigel (BD; 356231) mixture per 8-10 
week old female NSG mouse (Jackson Labs; #005557 NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ). 
All animal experiments using PDX models were performed in female NSG animals that 
did not exceed 8 months in age at any point on study. When tumors reached volumetric 
or toxicity/exposure limits on study, tumors were resected and tissue was enzymatically 
dissociated using a gentleMACS tissue dissociator and a human tumor dissociation kit 
(Miltenyi; 130-095-929). Animal weights and tumor volumes were monitored 2-3 times 
per week, with volumes calculated from manual caliper measures using a modified 
ellipsoid formula: tumor volume = (Length × Width2) / 2. A list of PDX model treatment 
history can be found in (Table 3). 
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In vitro and in vivo generation of acquired resistance to cisplatin/etoposide 
Mouse DKO and TKO cells were cultured under increasing concentrations of etoposide, 
refreshing media and drug twice weekly, until stable cultures were capable of 
proliferating in the presence of 1μM etoposide. Parental and resistant versions of the 
DKO and TKO cell lines were confirmed by STR, as lines were in continuous culture for 
~6 months. In vivo, cohorts of tumor-bearing animals were challenged weekly with 
cycles of cisplatin (5 mg/kg IP d1) and etoposide (8 mg/kg IP d1-3) as long as the 
following conditions were met: 1) tumor volumes were greater than 100mm3 and actively 
progressing and 2) animals did not lose >20% body weight when compared to the point 
of randomization (starting weights). The morning of d1 of each cycle, animals were given 
0.8-1.0cc of normal saline subcutaneously to facilitate renal clearance of the cisplatin, as 
cumulative dehydration from platinum was the dose-limiting toxicity. Where toxicity 
(usually uniform within a treatment cohort) was encountered, animals were given a one-
week holiday from treatment to allow recovery of weight. All animals were maintained on 
Sulfatrim diet throughout the period of study. 
 
Use of mSCLC (TKO) allograft model 
All in vivo mSCLC experiments were performed using an allograft of the triple 
(Rb/p53/p130) knockout mouse model of SCLC (Park et al., 2011a; Schaffer et al., 
2010), maintained in female, 2-3 month old athymic nude mice (Envigo; Hsd:Athymic 
Nude-Foxn1nu). Flank tumors were engrafted and maintained as described for PDX 
models with the exception of using a mouse tumor dissociation kit to process these 
tumors into single cell suspensions (Miltenyi; 130-096-730) for engraftment.  
  
In vivo irradiation 
 35 
Once tumor volumes reached approximately 150mm3, mice were randomized to control 
and treatment arms. Flank irradiation was administered at 2Gy/fraction to anesthetized 
mice for 4 consecutive days delivered by an X-Ray irradiator (XRAD 320, Precision X-
Ray) with secondary collimation by custom lead cut-outs. 
 
Tumor Micro Array (TMA) construction and immunohistochemistry 
Tumor cores were obtained from embedded PDX tumors tissue in donor blocks using a 
1mm biopsy punch needle (IHC World; W-125-0) then embedded/inserted into paraffin 
recipient block/negative mold (IHC World; 10*17 Quick Ray mold	 IW-UM01-1). Empty 
slots were filled with blank paraffin cores. All cores were gently tamped down using 
biopsy punch needle then the entire block was placed face down on a glass slides and 
heated to 50°C for 2hrs to merge donor cores with the recipient block. Block and glass 
slide were then placed on ice for 30 minutes before sectioning. Two tissue microarrays 
(TMAs) made of primary and metastatic SCLC specimens were prepared from formalin-
fixed paraffin-embedded (FFPE) tissue blocks following previously reported methods 
(Kononen et al., 1998; Ocak et al., 2010). Pathology blocks were retrieved from the 
archives of the Department of Pathology at Vanderbilt University Medical Center, 
Nashville VA Medical Center and St-Thomas Hospital in Nashville, Tennessee. They 
were obtained between 1996 and 2008 from patients who had surgery or bronchoscopy 
prior to medical treatment. SCLC diagnosis was confirmed on hematoxylin and eosin-
stained (H&E) sections by an experienced lung cancer pathologist. Treatment was 
administered on an individualized basis according to disease stage and patient 
performance status (PS) as per standard of care therapy (chemotherapy and 
radiotherapy). All patients were followed through chart review until death or until data 
analysis of this manuscript. Clinical data were obtained from tumor registry and hospital 
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charts. The study was approved by Institutional Review Boards at each medical center. 
Staining and H-score calculations, a weighed score that ranges from 0 - 300 and 
integrates IHC staining intensity and area, was performed as previously described (Lok 
et al., 2016). 
 
Cell culture, in vitro viability assays and chemical inhibitors 
All cell lines were obtained from the American Type Culture Collection (ATCC), were 
confirmed by STR (DDC Medical) and tested negative for mycoplasma (Lonza MycoAlert 
PLUS; LT07-710) within 6 months of use. All cell lines were maintained in RPMI-1640 
supplemented with 10% FBS, 2mM L-glutamine and 1x penicillin/streptomycin. Ex vivo 
cell culture of PDX tumors was performed as previously described (Poirier et al., 2015). 
EPZ011989 was provided by Epizyme and formulated as previously described 
(Campbell et al., 2015). Cisplatin (APP), etoposide (Teva) and irinotecan (Hospira) for in 
vivo use were obtained from the MSKCC hospital pharmacy and formulated in normal 
saline immediately before use. Topotecan (Selleck Chem), GSK126 (Selleck Chem) and 
5-azacitidine (Sigma) were purchased commercially and formulated in DMSO. Cell 
viability experiments were performed at 72hrs post-dosing, where 1-5x104 viable cells 
were seeded in 100μL/well of fresh media in black 96-well plates and drugs added to a 
final volume of 200μL one day after seeding plates (Corning; 3916). Cell viability 
experiments were monitored using AlamarBlue (Life Technologies), allowing the reagent 
to develop overnight (~16hrs) before reading plates on a compatible plate reader 
(BioTek; Synergy Neo). Throughout the text DMSO is used as the vehicle control for in 
vitro or ex vivo experiments.  
 
Plasmids and generation of lentiviral supernatants 
 37 
SLFN11 (HsCD00082389) and human TWIST1 (HsCD00042456) cDNAs in pDONR 
vectors were purchased from DNASU plasmid repository. Mouse Twist1 cDNA was 
purchased from Origene (MR227370). Polymerase chain reactions (PCRs) were 
performed using a GeneAmp PCR System 9700 Thermocycler (Applied Biosystems). 
Competent Stbl3 cells were purchased from Invitrogen. Plasmids were isolated and 
purified from bacteria using QIAquick Spin Miniprep Kit (Qiagen). SLFN11 was cloned 
into plasmid pDONR 221 (Life Technologies). Using primers with the following 
sequences 5’- TGATGATAATGATACCCAGCTTTCTTGTACAAAGTGGGCATT-3’ and 
5’- TCATTATCATCAATGGCCACCCCACGGAAAAATATACAGGTG-3’, the pDONR201-
SLFN11 plasmid was used as a PCR template to add 4 tandem stop codons between 
the C-terminal end of SLFN11 cDNA and the Myc-DDK tag sequence to ensure 
termination after the SLFN11 cDNA translation. Site-directed mutagenesis of mouse 
Twist1 cDNA to the DNA-binding mutant K145E (Maia et al., 2012) was performed using	
a	QuikChange Site-Directed Mutagenesis Kit (Agilent) and the following primers:  forward 
5’-GGACAAGCTGAGCGAGATTCAGACCC-3’ and reverse 5’-
GGGTCTGAATCTCGCTCAGCTTGTCC-3’. Gateway® cloning was performed according 
to manufacturer’s recommendations (BP/LR clonase enzyme mixes; Life Technologies). 
The plasmid pLIX_402 was a gift from David Root (Addgene plasmid # 41394) and 
pLT3GEPIR (Fellmann et al., 2013) was obtained from the MSKCC RNAi core facility. A 
list of tested shRNA sequences is available in Table 4. Lentiviral supernatants in HEK-
293T/17 cells were generated as previously described (Lok et al., 2016; Moffat et al., 
2006). Sanger sequencing of plasmids was performed by Genewiz, Inc. Nucleotide and 
protein sequence alignments were performed in Geneious Pro 4.7.6. 
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Table 4. List of shRNA sequences tested and used within Chapter 2. 
Target Species Library ID Text ID 97mer sequence (5’-3’) 

























































































































































A detailed list of antibodies and dilutions used in this Chapter is available in Table 5. 
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Table 5. List of antibodies and dilutions used throughout Chapter 2. 
Target Source Product# Application Fold Dilution 
EZH2 Cell Signaling 5246 WB 1000 
EZH2 Active Motif 39901 ChIP 5ug/reaction 
H3K27me1 Active Motif 61015 WB 1000 
H3K27me2 Cell Signaling 9728 WB 2500 
H3K27me3 Active Motif 39155 WB 2500 
H3K27me3 Millipore 07-449 ChIP 4ug/reaction 
H3K36me3 Cell Signaling 4909 WB 1000 
H3K4me3 Cell Signaling 9751 WB 1000 
H3K27Ac Active Motif 39685 WB 1000 
H3K27Ac Active Motif 39133 ChIP 4ug/reaction 
actin (mouse) Cell Signaling 3700 WB 5000 
actin (rabbit) Cell Signaling 8457 WB 5000 
H3 (mouse) Cell Signaling 14269 WB 5000 
H3 (rabbit) Cell Signaling 4499 WB 5000 
vinculin Cell Signaling 13901 WB 1000 
TWIST1 Abcam ab50887 WB 1000 
SLFN11 Santa Cruz sc-374339 WB 250 
cleaved-PARP Cell Signaling 5625 WB 1000 
γH2A.X (phospho-S139) Cell Signaling 9718 WB 1000 
H2A.X Cell Signaling 2595 WB 1000 
GFP Cell Signaling 2956 WB 5000 
donkey anti-rabbit IRDye 
800CW 
LI-COR 926-32213 WB 25000 
donkey anti-mouse IRDye 
680LT 
LI-COR 926-68022 WB 25000 
donkey anti-mouse IRDye 
800CW 
LI-COR 926-32212 WB 25000 
donkey anti-rabbit IRDye 680LT LI-COR 926-68023 WB 25000 
SLFN11 Santa Cruz sc-374339 IHC 2ug/mL 
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Protein extraction, near-infrared Western blotting and protein quantitation 
Whole cell lysates were prepared from frozen cell pellets or flash frozen tissue using 
RIPA lysis and extraction buffer (Thermo; 89901) supplemented with Halt protease and 
phosphatase inhibitor cocktail (Thermo; 78440). For extraction from frozen tissue, 50-
100mg of tissue was placed into gentleMACS M tube (Miltenyi; 130-094-392) in ~2mL of 
ice-cold extraction buffer and processed using a pre-specified protein extraction cycle, 
followed by a 10 sec. sonication setup using 200V microtip sonicator set to 40% 
amplitude (QSonica; CL18). Crude lysates were clarified at 14,000rpm for 10 minutes in 
a refrigerated bench top centrifuge (Eppendorf; 5340 R). Protein lysates were quantified 
using a micro BCA protein assay kit (Pierce; 23235) and then diluted with extraction 
buffer, NuPAGE® LDS sample buffer and reducing reagent (Life Technologies) prior to 
resolving on 4-12% Bis-Tris gradient gels. Gels were wet-transferred to 0.45μm 
Immobilon-FL PVDF membrane (Millipore; IPFL00010, lot#R5GA0255H for all blots 
reported). All primary antibodies were incubated overnight with membranes in TBS 
Odyssey blocking buffer supplemented with 0.1% Tween-20 (LI-COR; 927-50000), while 
secondary antibodies were incubated at room temperature with agitation for 1 hour in 
primary blocking buffer supplemented with 0.01% SDS. Membranes were dried at 37C 
and protected from light before imaging (LI-COR; Odyssey Sa). The same instrument 
gain settings were used for all targets examined (3.0 for 700nm channel; 6.0 for 800nm 
channel), with normalization of the 800nm channel against the 700nm channel, where 
indicated in the text. Images were analyzed in ImageStudio (LI-COR; version 3.1.4) 
Recombinant GST-SLFN11 (Abnova; H00091607-P01) was used to determine the limit 
of detection for SLFN11 in cell lines and PDX tissue. 5μg of total, clarified cell lysate was 
determined to be optimal for detection of 4 logs of dynamic range of for SLFN11 from in 
vivo sources (SCRX-Lu149 chemonaïve tumor used to benchmark). 
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DNA/RNA extraction and sequencing 
DNA and RNA were extracted from flash frozen tissue using AllPrep DNA/RNA mini kits 
(Qiagen; 80204), homogenizing tissue using a gentleMACS M tube containing ~2mL of 
RLT Plus buffer (Qiagen; 1053393) supplemented with 2-mercaptoethanol (Fisher) and 
processing samples on a pre-specified RNA extraction cycle. Samples were passed 
through QIAshredder columns (Qiagen; 79656) and DNA and RNA components were 
eluted in water before storing DNA at -20C and RNA at -80C for future analyses. RNA 
library preparation (w/ polyA selection), multiplexing and sequencing on an Illumina 
HiSeq2500 in RapidRun mode (50bp single end reads) was performed by Genewiz. 
SureSelect Human All Exon V4 and SureSelect Mouse All Exon enrichment kits (Agilent) 
were used for whole exome library preparation. MSK-IMPACT (Cheng et al., 2015; 
Wagle et al., 2012) and whole exome sequencing were performed by the MSKCC 
integrated genomics operation (iGO) core facility.  
 
Mutation and copy number analysis 
Raw reads were aligned to a custom hybrid reference genome using BWA 0.7.12-r1039 
with default settings (Li and Durbin, 2009). The hybrid index was generated using a 
FASTA file consisting of all human GRCh38 and mouse GRCm38.p3 reference contigs. 
Mapped reads were piped to SAMBLASTER 0.1.22 and samtools 1.2 for on-the-fly 
duplicate removal and sorting, respectively. Sorted reads were processed through the 
Genome Analysis Toolkit (GATK) 3.6, according to standard practices, including 
generation of depth of coverage analysis statistics (DePristo et al., 2011; McKenna et 
al., 2010). Each sample was genotyped at >1,000 common SNP sites using 
HaplotypeCaller to generate a fingerprint. SNP concordance was confirmed by bcftools 
1.2. Mutations were called using MuTect2 the subset of common SNPs in dbSNP 147 
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found in >1% of the population. Variants that did not pass a MuTect2 filter, had a variant 
frequency <10%, or were a common SNP were excluded. Filtered mutations were 
annotated with snpEff. Final mutations and their annotations were loaded into the R 
statistical computing environment for final analysis. For novel mutation discovery, genes 
were rank ordered by the number of models in which a gene was mutated in the 
chemoresistant setting, but not the chemonaïve setting. Copy number plots were 
generated using the copy number package for R (Nilsen et al., 2012). 
 
Gene expression analysis 
Raw reads were aligned to a custom hybrid reference genome using STAR 2.4.1b 
(Dobin et al., 2013). The hybrid index was generated using a FASTA file consisting of all 
human GRCh38 and mouse GRCm38.p3 reference contigs and the human GENCODE 
gene set (release 20) transcript model. Mapped reads were assigned to GENCODE 20 
genes using Subread 1.5.0-p2 to generate a raw counts table (Liao et al., 2014). Raw 
counts were read into the R statistical computing environment for further analysis (R 
Core Team (2016). R: A language and environment for statistical computing. R 
Foundation for Statistical Computing, Vienna, Austria. URL: https://www.R-project.org/). 
Downstream analysis was performed with the limma package for R (Ritchie et al., 2015). 
Genes with ≥5 counts per million in ≥3 samples were considered for analysis. Counts 
were normalized to library size and transformed to log2 counts per million with upper 
quartile normalization. Weights were calculated based on a combination of 
observational-level weights determined from an estimate of the mean-variance 
relationship within all samples and sample-level weights reflecting the degree to which 
each sample follows the linear model (Ritchie et al., 2006). A linear model was fit for 
each contrast and standard errors were moderated using an empirical Bayes method. T 
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statistics B statistics and p-values were generated for each gene. P-values were 
corrected for multiple testing by the method of Benjamini and Hochberg. To identify 
genes with biologically significant effect sizes, statistically significant p-values, and 
recurrent alterations, we chose to highlight genes with a fold change of ≥2 that were 
significant in ≥3 models. 
Robust Multi-array Average (RMA) and quantile normalized gene expression 
microarray data for 1,037 cancer cell lines was downloaded from the Cancer Cell Line 
Encyclopedia (Barretina et al., 2012). The gene expression signal distribution of SLFN11 
is distinctly bimodal. The minor mode comprises cell lines in which the gene is not 
expressed while the major mode, having a greater standard deviation, comprises cell 
lines in which SLFN11 is expressed at varying levels. To discriminate between cell lines 
based on SLFN11 expression, a gene expression cutoff was established using two 
independent approaches: the method of Zilliox et al. (Zilliox and Irizarry, 2007), which 
estimates a gene expression cutoff based on the standard deviation of the minor mode 
based on the left side of the mean, and by fitting a finite mixture of 2 Gaussian 
components. Both approaches were in agreement in establishing a cutoff of 5. 
 
ChIP-seq and ChIP-qPCR 
Tumor tissue was submersed 1% formaldehyde in PBS, cut into small pieces and 
incubated at room temperature for 15 minutes. Fixation was stopped by the addition of 
0.125M glycine (final concentration). The tissue pieces were then treated with a 
TissueTearer and finally spun down and washed twice in PBS. Chromatin was isolated 
by the addition of lysis buffer, followed by disruption with a Dounce homogenizer. NCI-
H446 cells were fixed with 1% formaldehyde for 15 min and quenched with 0.125 M 
glycine. Chromatin was isolated by the addition of lysis buffer, followed by disruption with 
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a Dounce homogenizer. Lysates were sonicated and the DNA sheared to an average 
length of 300-500 bp. Genomic DNA (Input) was prepared by treating aliquots of 
chromatin with RNase, proteinase K and heat for de-crosslinking, followed by ethanol 
precipitation. Pellets were re-suspended and the resulting DNA was quantified on a 
NanoDrop spectrophotometer. Extrapolation to the original chromatin volume allowed 
quantitation of the total chromatin yield. 
Aliquots of chromatin (20-30μg) were pre-cleared with protein A agarose beads 
(Invitrogen). Genomic DNA regions of interest were isolated using 5μl antibody against 
EZH2 (Active Motif; 39901), or 4μg of antibody against H3K27Ac (Active Motif; 39133) 
and H3K27me3 (Millipore; 07-449). Complexes were washed, eluted from the beads with 
SDS buffer, and subjected to RNase and proteinase K treatment. Crosslinks were 
reversed by incubation overnight at 65C, and ChIP DNA was purified by phenol-
chloroform extraction and ethanol precipitation. 
Quantitative PCR (qPCR) reactions were carried out by Active Motif in triplicate 
using SYBR Green Supermix (Bio-Rad; 170-8882) on a CFX Connect™ Real Time PCR 
system. The SLFN11 primer pair targeting upstream of the first exon are as follows:  
forward 5’-CGAGCCAGAGTGGGATTTAAC-3’ and reverse 5’ 
TTTCATATCACTAGCAGCGTGAC3’. The resulting signals were normalized for primer 
efficiency by carrying out qPCR for each primer pair using Input DNA (pooled 
unprecipitated DNA from cells or tissues). Test sites were run alongside the positive 
control sites targeted to the ACTB promoter (Active Motif; 71023) and CCND2 gene 
(Active Motif; 71008) and a negative control primer pair that amplifies a region in a gene 
desert on chromosome 12 (Active Motif; 71001). Data are reported as “binding events 
per 1000 cells” which considers chromatin input, ChIP volumes and primer pair 
efficiencies. 
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Illumina sequencing libraries were prepared from the ChIP and Input DNAs by 
the standard consecutive enzymatic steps of end-polishing, dA-addition, and adaptor 
ligation. After a final PCR amplification step, the resulting DNA libraries were quantified 
and sequenced on Illumina’s NextSeq 500 (75nt reads, single end). Reads were aligned 
to the human genome (hg19) using the BWA (Li and Durbin, 2009) algorithm (default 
settings). Duplicate reads were removed and only uniquely mapped reads (mapping 
quality >= 25) were used for further analysis. Alignments were extended in silico at their 
3’-ends to a length of 200bp, which is the average genomic fragment length in the size-
selected library, and assigned to 32nt bins along the genome. The resulting histograms 
(genomic “signal maps”) were stored in bigWig files. ChIP target enriched regions were 
identified using the SICER (Zang et al., 2009) algorithm (FDR 1E-10, gap = 600bp). 
Drosophila genome spike-in was used to downsample and normalize tag counts for 
comparisons across treated and untreated samples (Active Motif; ChIP Normalization 
Strategy) (Orlando et al., 2014). For the spike-in adjusted analysis, the downscaling of 
H3K27me3 in the EPZ011989-treated samples was >5-fold, compared to the vehicle 
controls. In addition, the resistant vehicle H3K27Ac data was downscaled by ~2.5-fold as 
compared to all other samples. The EZH2 data was only normalized by <1.5-fold across 
all samples based on the spike-in tag counts. All plots were generated using the R 
statistical computing environment 
 
Statistics 
Sample sizes per in vivo groups were at a minimum of 5 per condition, unless specified 
within the text for purposes of target analysis/pharmacodynamics. Power calculations 
and sample size estimates were not performed. Student’s t-tests, one-way ANOVA, 
Pearson’s correlation and log-rank tests were performed using GraphPad Prism version 
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6.00 for Mac, GraphPad Software, La Jolla California USA, www.graphpad.com. Where 
indicated, degrees of p-value significance are as follows: <0.05*, <0.005**, <0.0005***, 





Modeling acquired resistance in vivo 
Patients with SCLC are typically treated with a regimen of up to 6 cycles of 
chemotherapy, each cycle consisting of cisplatin on day 1, and etoposide on days 1, 2, 
and 3, at near maximally tolerated doses. To study mechanisms that may govern 
acquired chemoresistance in vivo, we adopted an analogous approach of repeated 
chemotherapy cycles in tumor bearing animals in order to select populations of tumor 
cells that could effectively grow through chemotherapy (Figure 5A). We determined that 
we could safely administer 6-8 cycles of a schedule of cisplatin day 1 and etoposide 
days 1, 2, and 3 (C/E) on a weekly schedule in tumor-bearing NSG mice, achieving 
major tumor regression without dose-limiting toxicity. We applied this approach to ten 
independent PDX models of SCLC, the majority of which were derived from treatment-
naïve patients (Table 3). We observed a spectrum of response across models, with 2/10 
models achieving complete responses (complete regression of flank tumor), and 8/10 
showing a broad index of partial responses, ranging from 65% to 95% tumor growth 
inhibition (Figure 5B and Figures 6A-C). To ensure that tumors progressing through 
multiple cycles of chemotherapy would develop intrinsic chemoresistance, these tumors 
were harvested, disaggregated, and re-implanted into a second generation of mice, and 
selected again through multiple cycles of chemotherapy (Figure 5C). To assess the 
extent of acquired chemoresistance, progressing tumors re-implanted in a third 
generation of mice were again randomized to chemotherapy or vehicle control arms. 
Comparing the chemonaïve to the chemoresistant state across all models, we observed 
a significant (p=0.0008) difference in the median survival time, defined herein as time to 
reach a volumetric endpoint of 1,000mm3 (Figure 5D). Further, we observed a clear 
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difference between the total cycles of C/E administered to naïve versus resistant models 
(p=0.026*, Figure 5E); this was not due to a change in the time to randomization of 
these models (Figure 5F), or mitotic index as measured by Ki-67 staining (Figure 5G), 
but rather reflects the ability of the chemoresistant derivative tumors to grow through the 





Figure 5. Modeling acquired resistance to standard of care chemotherapy in 
patient-derived xenograft (PDX) models of small cell lung cancer. 
(A) Graphical depiction of model generation and workflow. Cohorts of 5 tumor-bearing 
animals were administered weekly cycles of cisplatin/etoposide (C/E) or vehicle, 
randomizing animals as tumor volumes approached 150mm3. Treatment continued 
weekly, as tolerated, for a total of 6-8 cycles. Surviving tumor cells were pooled and re-
engrafted into a secondary cohort of 5 animals to be challenged with C/E as before, 
enriching for a resistance phenotype. As tumors grew through treatment in the 
secondary cohort, tumor cells were pooled and re-engrafted into a tertiary cohort of 10 
animals, 5 to be challenged with C/E and 5 serving as vehicle controls. Vehicle-treated 
tumors in the primary (naïve) and tertiary (resistant) cohorts were compared using the 
indicated next generation sequencing approaches. 
(B) Indices of observed responses to C/E across 10 SCLC PDX models. Comparisons 
per animals (5 per cohort) are shown as individual bars for vehicle (black) and C/E-
treated (grey) at the last comparable day on study for both arms. Where the majority (≥ 3 
of 5) of mice showed complete regressions of flank tumors, we considered these models 
complete responses, whereas all others with any measurable residual tumor mass were 
considered partial responses. 
(C) Average tumor growth kinetics of representative PDX models JHU-LX102 and 
SCRX-Lu149 while on study. Average traces for tumor-bearing animals during the initial 
C/E challenge, vehicle (black dotted line) and treated (grey solid line). Vertical ticks 
along the x-axis indicate d1 of a weekly C/E cycle. Dashed vertical lines with 
corresponding x-axis values indicate the time on study treated tumors were collected, 
pooled and re-engrafted into either secondary (pink solid line) or tertiary (red; vehicle-
dotted, C/E-solid line) cohorts. Total time on study between primary and tertiary 
engraftments did not exceed 300d for any model. Survival events for each model are 
reported as the time to reach 1000mm3 in volume, or where a volumetric endpoint was 
not obtained, the last day on study prior to re-engraftment (censored point). Statistical 
comparisons between survival of chemonaïve and chemoresistant cohorts were 
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performed using a log-rank (Mantle-Cox) test. Model chemosensitivity conversion status 
is indicated above p-value; CR=complete response, PR=partial response, 
PD=progressive disease, SD=stable disease, NR=no response. See Figure 6 A-C for 
more details 
(D) Median survival time in days for chemonaïve and chemoresistant settings. Median 
survival times were calculated from survival curves of treated chemonaïve (naïve-grey) 
or chemoresistant (resistant-red) cohorts. P-values are reported for paired t-tests for all 
naïve versus resistant comparisons. 
(E) Cycle of C/E administered to the chemonaïve and chemoresistant cohorts. 
(F) Time to randomization (e.g. time post-engraftment to treatment) in the chemonaïve 
and chemoresistant settings. 
(G). Ki67 IHC positivity of tumors in the chemonaïve and chemoresistant setting. Three 
independent tumor cores were evaluated per model, per setting. The pathologist scoring 





Figure 6. Complete response criteria of remaining 8 of 10 PDX models.  
(A) Average tumor volume trace curves for all ten models included in study. Five animals 
per treatment group, per PDX model. JHU-LX102 and SCRX-Lu149 were included in 
Figure 1C, thus are omitted in these data. 
(B) Survival for chemonaïve and chemoresistant versions of models on C/E treatment. 
Model chemosensitivity conversion status (>) indicated above p-values for Log-rank 
(Mantle-Cox) tests; CR=complete response, PR=partial response, PD=progressive 
disease, SD=stable disease, NR=no response 
(C) Animal weight on study. Data are reported as averages +/- SEM. 
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Acquired chemoresistance is not associated with emergence of novel, recurrent 
mutations 
We hypothesized that the development of acquired resistance to chemotherapy 
in these models could be caused by changes in their genetic landscapes. To investigate 
this possibility, we performed whole exome sequencing in 8 paired models. We first 
confirmed by examining more than 1,000 common single nucleotide polymorphisms 
(SNPs) that the acquired resistance models were from the same individuals as the 
parental models and did not arise from cross-contamination with other cell lines, PDX, or 
spontaneous murine malignancies (Figure 7A). In all cases, >90% of bases could be 
called based on a read depth of ≥15 (Figure 7B). We observed the expected pattern of 
genetic alterations consistent with SCLC, including frequent alterations in TP53 and RB1 
(Figure 8A), as well as frequent mutations in CREB binding protein (CREBBP). 
Importantly, in each case the key genetic alterations identified in the chemonaïve model 
were maintained through acquisition of chemoresistance. We next sought to determine 
to what extent the total mutational burden was shared between the chemonaïve and 
chemoresistant models. In all cases, a majority of called mutations were shared, while 
only a minority of mutations was private to either the chemonaïve or chemoresistant 
setting (Figure 7B). The number of private mutations was consistently greater in the 
chemoresistant setting, suggesting that additional mutations were acquired during 
treatment. However, we were not able to identify recurrent acquired mutations across 
independent tumor models: no putative causal mutations of acquired resistance were 
found, leading us to conclude that private mutations in the chemoresistant setting are 
passengers, not directly driving resistance (Figure 7C). Consistent with apparent 
stability of key mutations, we found copy number alterations to be concordant between 
chemonaïve and chemoresistant models and failed to identify any significant focal copy 
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number alterations (Figure 8C). Without clear evidence of a genetic basis for the 
chemoresistance phenotype, we chose to focus subsequent analyses on potential 




Figure 7. Credentialing exome sequencing data from paired PDX models. 
(A) Concordance of genotypes for >1,000 common SNPs confirm that sample identity 
was maintained throughout the experiment. 
(B) The proportion of bases in the exome capture region covered to a given depth. The 
intersection of the horizontal (90%) and the vertical lines (15) indicate that for all samples 
>90% of bases were covered to the minimum depth for mutation calling using MuTect2. 
(C) A mutation plot indicating the most common mutations occurring in the 
chemoresistant setting.  
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Figure 8. Genomic characterization of paired chemonaïve and chemoresistant 
SCLC PDX models 
(A) Mutational analysis of paired naïve and resistant PDX models by whole exome 
sequencing. Shown are identifiable mutations by class with respect to several of the 
most frequently mutated genes in primary SCLC (George et al., 2015). Top panel shows 
mutation density per Mb of mapped reads. Right panel shows frequency of mutations for 
each gene in the cohort. 
(B) Private versus shared mutations between paired naïve and resistant PDX models by 
whole exome sequencing. Colors indicate mutations called as unique to the naïve (grey) 
or resistant (red) tumor, with shared mutations in white. 
(C) Copy number variation in somatic chromosomes for paired chemonaïve and 
chemoresistant models.  
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SLFN11 suppression and TWIST1 induction characterize distinct subsets of 
chemoresistant disease 
 We hypothesized that there could be epigenetically driven recurrent changes in 
gene expression in the setting of acquired chemoresistance. To pursue this hypothesis, 
we performed RNA-sequencing (RNAseq) on 3 biological replicates for each of the 10 
paired models. Principal component analysis suggested that gene expression patterns 
were remarkably consistent between the chemonaïve and chemoresistant setting and 
could easily discriminate between PDX models derived from different patients (Figure 
9A and Figure 10A). Due to the high degree of similarity betweenpaired models, we 
hypothesized that changes in the expression of a minority of genes, as opposed to broad 
transcriptional changes, could drive the chemoresistance phenotype we observed. We 
therefore performed differential gene expression analysis on all paired samples to 
identify significantly differentially expressed genes. To identify recurrently differentially 
expressed genes, we generated a meta p-value for each gene based on the degree of 
differential expression in each of the individual models. The empirical cumulative 
distribution function (ECDF) of the p-value of each gene was then plotted, highlighting 
the top 10 genes significantly differentially expressed in at least 3 independent models 
(Figure 9B). Schlafen family member 11 (SLFN11), a gene that we and others 
(Barretina et al., 2012; Lok et al., 2016; Sousa et al., 2015; Stewart et al., 2014; Tang et 
al., 2015; Zoppoli et al., 2012) have reported as being critical to sensitivity to DNA 
damaging agents, was among the most significantly down-regulated genes. Cancer-
testis antigens, a family of genes that are highly sensitive to epigenetic perturbation (De 
Smet et al., 1999), were significantly up-regulated, as well as twist family bHLH 
transcription factor 1 (TWIST1), a gene previously described to play an important role in 
acquired resistance to a variety of chemotherapies in vivo (Fischer et al., 2015; Zheng et 
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al., 2015). In addition to its role in therapeutic resistance, TWIST1 is also a well-known 
mediator of epithelial-mesenchymal transition (EMT), metastasis, and stemness (Beck et 
al., 2015; Schmidt et al., 2015; Yang et al., 2004; Yang et al., 2012) (Figures 9C-E). The 
potential mechanisms identified are mutually exclusive and together are represented in 7 
of 10 chemoresistance models. 
 We extended these results by modeling acquired resistance to C/E in murine 
models of SCLC (mSCLC), including two cell lines (Rb1/Trp53 null, DKO and Rb1/ 
p130/Trp53 null, TKO) previously generated by others (Jahchan et al., 2013; Park et al., 
2011b) and one chemonaïve allograft directly isolated from a tumor and passaged 
exclusively in NSG mice (Rb1/p130/Trp53 null, TKO-A). Robust in vitro acquired 
resistance to etoposide was associated with a strong change in phenotype, converting 
from primarily suspension, floating spheroid cultures to exclusively adherent culture 
(Figure 10B). In vivo, acquired resistance to the same schedule to C/E used in PDXs 
was strongly associated with a decrease in survival of hind flank tumor bearing animals 
on treatment when comparing the naïve to the resistant models (p=0.0026, Figures 
10C-E). Principal component and differential gene expression analysis suggested 
conserved EMT-like changes in all three models tested, with the first principal 
component strongly separating parental and resistant versions of the models (Figures 
8F-H).  
Given the consistent up-regulation of TWIST1 in both human and mouse models 
of SCLC upon acquired resistance, we assessed whether directly gaining or losing 
TWIST1 could affect chemosensitivity in both model systems. We infected the parental 
and resistant versions of the allograft ex vivo with lentiviruses expressing doxycycline-
inducible murine Twist1 constructs and generated stable cell lines in culture. Notably, 
conditional gain of wild type or the DNA-binding mutant K145E of mouse Twist1 (Maia et 
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al., 2012) did not robustly change the sensitivity to etoposide, in contrast to the shift we 
observed ex vivo between the naïve and resistant allograft lines (IC50 naïve TKO-A 
~0.15μM, versus IC50 resistant TKO-AR ~3.0μM; Figure 10I). Moreover, conditional 
suppression of Twist1 by shRNA could neither rescue chemosensitivity in mouse or 
TWIST1High human SCLC cell lines or influence other features of EMT observed in the 
resistant mSCLC cell lines, such as down regulation of E-cadherin (Figures 10J,K). 
Taken together, these results suggest that while increases in TWIST1 may be 
associated with acquired resistance to cytotoxic therapy in multiple models of SCLC, this 




Figure 9. Paired RNA sequencing identifies conserved changes SLFN11 and 
TWIST1 across multiple models. 
(A) Principal Component Analysis (PCA) of RNA sequencing (RNAseq) data from 
chemonaïve (circles) and chemoresistant (downward triangles) replicate samples from 
the 10 paired PDX models included in this study. For color legend, see Figure 6C or 
Figure 7A. 
(B) Empirical cumulative distribution function (ECDF) of combined p-values of 
differentially down- or up-regulated genes. The top ten significantly down-regulated (top 
panel) or up-regulated (bottom panel) genes that occur in at least 3 of 10 models with a 
log2 change >1.5-fold are highlighted. 
(C) Individual gene expression changes in each model for SLFN11 (top panel) and 
TWIST1 (bottom panel) by RNAseq. Models with down-regulated SLFN11 and up-
regulated TWIST1 are indicated by red and green backlighting, respectively. 
(D) Volcano plots demonstrating down-regulation of SLFN11 in the chemoresistant 
setting, JHU-LX102 (left) and SCRX-Lu149 (right) 
(E) Volcano plots demonstrating up-regulation of TWIST1 in the resistant setting, JHU-
LX33 (left) and JHU-LX108 (right).  
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Figure 10. TWIST1 is recurrently up regulated in the chemoresistant setting but 
does not drive acquired resistance to cisplatin/etoposide in SCLC. 
(A) Hierarchical clustering of correlation coefficients of RNAseq data from triplicates of 
chemonaïve and chemoresistant paired PDX samples. Samples clearly cluster by model. 
(B) Shift in etoposide sensitivity from in vitro acquired resistance modeling in DKO and 
TKO mSCLC cell lines. Change in morphologic appearance and culture conditions of 
chemonaïve (suspension/spheroid) and chemoresistant (adherent) cell lines Images 
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collected using 40x objective lens; scale bar 200μm. Experimental results are shown for 
72hrs post-dose of etoposide. 
(C) Average tumor volume progression plot for TKO allograft mSCLC model, when 
engrafted as a hind flank tumor – naïve-vehicle (black dotted line), naïve-C/E (grey solid 
line), C/E re-challenge (pink solid line), resistant-vehicle (red dotted line), resistant-C/E 
(red solid line). Points of re-transplant are indicated along the x-axis with vertical dashed 
lines. Day 1 of C/E cycles are indicated as vertical ticks along the x-axis. 
(D) Average animal (n=5 per group) weights on study reported in grams +/- SEM 
(E) Survival of naïve versus resistant C/E-treated cohorts of mSCLC TKO allograft (TKO-
A) models. Model conversion from partial response (PR) to progressive disease (PD) 
indicated in margin. Difference in survival reported as a p-value from log-rank (Mantle-
Cox) test.  
(F) Relative expression for select genes involved in EMT between naïve or parental (P) 
and resistant (R) cell lines, calling out Twist1 (red circle). 
(G) Principal component analysis for naïve and resistant versions of mSCLC models 
broken down by component. The first component of epithelial-mesenchymal transition 
(EMT) strongly separates model, with the second component separating parental and 
resistant cell lines, but to a lesser extent the allograft. Legend colors and shapes shown 
for cell lines (cl) and allograft (ag). 
(H) Volcano plot for differential gene expression across all mSCLC paired naïve/parental 
as compared to resistant models (pooled analysis). TWIST1 called out in red. 
(I) Conditional gain of TWIST1 or the K145E DNA-binding mutant of TWIST1 in the naïve 
setting or conditional suppression of TWIST1 in the resistant setting of the TKO allograft 
model does not change ex vivo sensitivity to etoposide. Ex vivo resistance did not 
separate as strongly as in vitro resistance (compare 7B or 7L IC50 values), but 
nonetheless produced > 1 log difference in IC50 to etoposide (LogEC50; one-way ANOVA 
p<0.0001). Doxycycline (1μg/mL) was added to the culture media every other day for 5d 
before plating for experiments. Experimental results are shown for 72hrs post-dose of 
etoposide. 
(J) Conditional suppression of TWIST1 in the resistant DKO cell lines (DKO-R) does not 
change sensitivity to etoposide. Experimental results are shown for 72hrs post-dose of 
etoposide. Conditional suppression of TWIST1 does not rescue EMT-associated 
changes in E-cadherin, N-cadherin or vimentin expression. Shown are western blot 
results for resistant DKO cells on doxycycline (1μg/mL) for 1d or 5d. 
(K) Conditional suppression of TWIST1 in the TWIST1High human SCLC cell lines NCI-
H446 and NCI-H196 does not change sensitivity to etoposide. Doxycycline (1μg/mL) 
was added to the culture media every other day for 5d before plating for experiments. 
Experimental results are shown for 72hrs post-dose of etoposide. Both shRNAs tested 
against human TWIST1 show modest suppression at 72hrs after a single dose (1μg/mL) 
of doxycycline in NCI-H446.  
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SLFN11 expression is decreased in cell lines and clinical samples from previously 
treated patients 
 We further interrogated the role of SLFN11 in the context of acquired 
chemoresistance, as it had been previously implicated as a factor regulating DNA 
damage repair (Mu et al., 2016), was shown to correlate with responses to DNA 
damaging agents in cell lines (Barretina et al., 2012; Sousa et al., 2015) and patients 
(Tang et al., 2015), and may have unique biology in human cancer as there is no murine 
ortholog (Li et al., 2012). To further test the relevance of our model system, we assessed 
whether the observed suppression of SLFN11 from in vivo-selected chemoresistant 
PDXs was reflected in cell lines and tumors derived from previously treated versus 
untreated patients. SLFN11 is bi-modally expressed when examined across cancer cell 
lines within the CCLE, as well as within SCLC in both primary tumor (Lok et al., 2016) 
and cell line samples (Figure 11A). Many SCLC cell lines have been established and 
annotated with regards to their primary source (Carney et al., 1985). If suppression of 
SLFN11 is associated with chemoresistance, we might expect cell lines generated from 
treated patients to have lower levels of SLFN11 expression relative to cell lines 
generated from patients that were untreated. Indeed, we observed this difference 
(p=0.031; Figure 11B), which also held true when comparing all chemonaïve PDX 
models with all derivative chemoresistant models (p=0.003; Figure 11C). We observed 
similar results when examining SLFN11 protein expression by IHC using an H-score as 
the comparative metric, including either all models or only model with detectable SLFN11 
at baseline (Figures 12D,E). In 2 models where chemoresistance was associated with a 
substantial decrease in SLFN11 expression by immunohistochemistry (Figure 11F), we 
confirmed quantitative decreases in SLFN11 expression at both the transcript level by 
RNAseq and protein level by quantitative Western blotting (Figure 11G & Figures 12A-
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C). Interestingly, an endpoint analysis of the vehicle and C/E treatment groups of both 
the chemonaïve and chemoresistant cohorts in one model revealed a rapid decrease in 
SLFN11 protein expression in progressing tumors (p=0.029; Figure 12D). 
 To assess whether SLFN11 expression was correlated with clinical response to 
C/E in patients with SCLC, SLFN11 immunohistochemistry was performed on clinically 
annotated tumor microarrays including both untreated (Vanderbilt Medical Center; VMC) 
and previously treated (Case Western Reserve University; CWRU) SCLC patients, with 
H-scores for each intact core determined by a pathologist blinded to the sample 
identity/source (Figure 11H). Immunostaining for SLFN11 was low to nearly absent in 
lung squamous cell carcinoma and adenocarcinoma in contrast to SCLC (Figure 11I). 
SLFN11 expression was modestly associated with stage of disease when viewed in 
aggregate, with SLFN11 intensity being greater in limited stage versus extensive stage 
patients (p=0.0397; Figure 11J). Consistent with a role in determining chemosensitivity, 
among all treated patients, SLFN11 expression was higher in tumors from patients who 
responded to therapy, versus those who did not (p=0.0192; Figure 11K). When 
evaluating SLFN11 as a pretreatment predictor of response in untreated patients (Figure 
11L) and as a post-treatment correlate of response (Figure 11M), we found that 
SLFN11 expression was greater in patients categorized as treatment responsive; 
however, the test was underpowered to demonstrate a statistically significant difference 
in these subsets. Notably, among untreated patients, 83% (10/12) of patients with a 
SLFN11 H-score >75 responded to treatment:  using the same threshold among 
previously treated patients, all 6 patients with an H-score >75 responded to treatment. 
Applying a dichotomized H-score of 68.8 using Youden’s index (Youden, 1950) 
demonstrated greater overall response rate (ORR) in patients with an H-score >68.8 
(p=0.023, Fisher’s exact test), but did not show a difference in overall survival (p=0.884, 
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Log-rank test; Figure 12E). Taken together, these data suggest that high SLFN11 
expression in SCLC confers greater sensitivity to chemotherapy, but does not confer an 
overall survival benefit in this clinical cohort.  
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Figure 11. SLFN11 is down regulated at the transcript and protein level in SCLC 
following exposure to chemotherapy. 
(A) SLFN11 gene expression across the CCLE dataset as compared to SCLC cell lines. 
Cell lines within the CCLE are shown as density distributions of those that express little 
to no SLFN11 (grey distribution) versus the broad distribution of SLFN11 levels in other 
lines (green distribution). SCLC cell lines are shown in red (lower panel). 
(B) Comparison of SLFN11 expression in SCLC cell lines derived from patients that had 
never been treated or who had received at least one prior therapy before the sample for 
cell line generation was collected (Polley et al., 2016) (p=.031, Fisher’s exact test). 
(C) SLFN11 gene expression compared between all chemonaïve and chemoresistant 
PDX models. Three independent samples per model, per condition are plotted. P-values 
shown for two-tailed paired Student’s t-test.  
(D) SLFN11 IHC scoring metric (H-score) compared between all chemonaïve and 
chemoresistant PDX models. Three independent core samples per model, per condition 
are plotted. Exact p-values are reported from a Mann-Whitney test for PDX SLFN11 IHC 
staining comparisons. 
(E) H-score comparison including only models with detectable SLFN11 IHC reactivity at 
baseline (IHC positivity ≥1+ and at least one of three core samples with an H-score >20) 
(F) Representative SLFN11 IHC and H&E stained tumors for two models (SCRX-Lu149 
and JHU-LX102) demonstrating strong reduction in SLFN11 expression in the 
chemoresistant, relative to the chemonaïve, setting. All images shown are at 50x 
resolution of cores punches from constructed TMAs. Scale bars 100µm. 
(G) Concordance between SLFN11 gene expression by RNAseq and SLFN11 protein 
expression by actin-normalized quantitative Western blot. Symbols are color-coded by 
model and plotting symbols represent the in the chemonaïve (circles) or chemoresistant 
(downward triangle) setting.  
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(H) Representative IHC staining for SLFN11 in two independent, clinically-annotated 
SCLC TMAs. VMC=Vanderbilt Medical Center, CWRU=Case Western Reserve 
University. 
(I) SLFN11 expression by IHC in SCLC as compared to lung adenocarcinoma (LUAD) 
and squamous cell carcinoma (LUSC). 60/215 untreated VMC and 12/22 previously 
treated CWRU cores were evaluable for analysis and pooled for comparison. Primary 
and metastatic samples were included. P-values shown for unpaired two-tailed t-tests. 
(J) Comparison of SLFN11 H-score by clinical stage of patient from pooled analysis of 
VMC and CWRU TMAs. 
(K) Comparison of SLFN11 H-score by clinical response of patients from both cohorts. 
Responses include CR and PR, where no response includes PD and SD. 
(L) Comparison of SLFN11 H-score by clinical response of patients from untreated 
cohort; p-value not significant. 
(M) Comparison of SLFN11 H-score by clinical response of patients from previously 
treated cohort; p-value not significant.  
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Figure 12. SLFN11 is rapidly down regulated in vivo and expression by IHC H 
score does not correlate with survival. 
(A) Western blot images from triplicate chemonaïve and resistant PDX tumor samples 
used for calculating data included in Figure 9, normalizing SLFN11 signal (800nm 
channel) to actin (700nm channel). 
(B) Standard curve for detection of recombinant SLFN11 establishes conservative upper 
(ULD) and lower limits of detection (LLD) in pure versus crude experimental samples 
under the assumption <1:10,000-fold natural abundance in RIPA-extracted proteomes; 
GST-SLFN11 ULD was ~10ng, whereas the LLD was ~10pg with an R2 value of 0.9988. 
(C) RNAseq versus SLFN11 H-score for available PDX naïve and resistant tumors. 
Paired triplicates are color-coded in the naïve (circles) or resistant (downward triangle) 
and correspond to the color grid used above. 
(D) Example of LI-COR image readout for triplicate tumors from vehicle or C/E-treated 
arms of chemonaïve or resistant SCRX-Lu149 model in color and gray scale. 800nm 
channel for SLFN11 signal in green; 700nm channel for actin in red. Relative near-
infrared fluorescence units (RFU; abbreviation used hereon within text, unless 
normalized in time course samples) as a function on time on treatment in PDX model 
SCRX-Lu149. P-values shown for paired t-tests. 
(E) Survival of SCLC by dichotomized H-score. The best cutoff of H score for predicting 
ORR is 68.8 based on maximizing the Youden’s J index (J =sensitivity + specificity – 1). 
H score is then dichotomized at >68.8 and associated with OS. Table below shows 
usable clinical cases from H-score on TMAs analyzed in aggregate.  
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EZH2 inhibition restores SLFN11 expression and chemosensitivity in vitro 
 A recent report suggested that SLFN11 expression is partly regulated by an 
epigenetic silencing mechanism, which could be reversed by broad DNA methylation 
inhibitors such as 5-Azacitidine (5-Aza) (Nogales et al., 2016). We chose to examine 
whether EZH2 (Enhancer of zeste homology 2) could have a similar role in silencing 
SLFN11 in SCLC for several reasons:  1) there is evidence for an EZH2 binding site 
upstream of the first exon of SLFN11 from human cell line data reported by the 
ENCODE project (Gerstein et al., 2012; Wang et al., 2013), 2) our group has shown 
EZH2 levels to be higher in SCLC than in any of the tumor types included in TCGA, with 
expression correlating with high level promoter methylation patterns in SCLC (Poirier et 
al., 2015), and 3) other groups have shown that PRC2 target gene repression correlates 
with shorter survival in primary SCLC (Sato et al., 2013). Overall, these lines of evidence 
prompted us to examine whether chemical inhibitors targeting DNA or histone 
methyltransferase enzymes, specifically DNMTs and EZH2, could play a role in 
regulating SLFN11 expression. 
 Using short term ex vivo culture, we exposed chemonaïve and chemoresistant 
versions of select PDX models that had demonstrated the most striking down-regulation 
of SLFN11 in the chemoresistant setting to 1μM of either 5-Aza or the EZH2 inhibitor 
EPZ011989 (abbreviated EPZ in Figures). After 7 days of continuous daily exposure, we 
noted striking increases in SLFN11 expression in the EPZ011989-treated cells versus 
DMSO-treated controls, whereas 5-Aza treatment appeared to have minimal effect, 
suggesting that SLFN11 expression may be regulated at the level of histone methylation, 
rather than DNA methylation, in SCLC (Figure 13A). Moreover, treatment with 
EPZ011989, but not 5-Aza, effectively restored ex vivo etoposide sensitivity of the 
chemoresistant model to that of the chemonaïve model (IC50 reduced from 4.65μM to 
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0.59μM in chemoresistant versus 0.51μM in chemonaïve; Figures 13B,C). We next 
interrogated the kinetics of SLFN11 re-expression in the SCLC cell line NCI-H82, which 
was derived from a previously treated patient and shows minimal expression of SLFN11 
protein. We monitored the re-expression of SLFN11 over a 21d period in suspension 
culture, during which time cells were treated daily with 1μM EPZ011989 for 10d and then 
cultured in fresh media without compound for an additional 10d to monitor target 
dynamics. We noted striking re-expression of SLFN11 after ~7-10d of drug exposure, 
with concomitant suppression of H3K27me2/3, consistent with on-target activity of 
EPZ011989 inhibiting EZH2’s repressive methylation in a global fashion (Figure 13D). 
Re-expression of SLFN11 was dose-dependent and stable under acute DNA damage 
(Figure 14A). This re-expression was sustained even as global H3K27me2/3 levels 
returned to baseline levels during a 10d washout period. In 7d treatment assays, we 
noted a dramatic increase in SLFN11 protein expression in cell lines with little to no 
detectable SLFN11 at baseline. This was in contrast to cell lines with high de novo 
expression of SLFN11, such as NCI-H526, in which no further increase above baseline 
was observed, suggesting a threshold effect (Figure 13E). The extent to which SLFN11 
protein levels were increased by EPZ011989 was strongly correlated to an increase in 
topotecan sensitivity across all cell lines tested (Pearson r=0.916; Figure 13F & Figure 
14B). SLFN11 protein re-expression was suppressible with shRNAs targeting SLFN11 
and was observed with another distinct EZH2 inhibitor, although EPZ011989 did show 
greater potency for SLFN11 re-expression when compared to another EZH2 chemical 
inhibitor GSK126 (McCabe et al., 2012) (Figures 14C,D). 
 A shift in global repressive histone methylation will have pleiotropic effects on 
gene expression that manifest in a cell line specific manner (Jadhav et al., 2016). To 
directly address whether re-expression of SLFN11 was sufficient to sensitize SCLC cell 
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lines with low levels of SLFN11 to DNA damaging agents, such as topotecan, an agent 
approved for recurrent SCLC, we used a doxycycline-inducible expression vector to 
express SLFN11 or an empty vector control in NCI-H82 and NCI-H446. Both of these 
cell lines were derived from previously treated patients and are highly resistant to 
etoposide. Exogenous expression of SLFN11 was capable of sensitizing these cell lines 
to topotecan, relative to non-induced or empty vector controls, although this effect was 
less pronounced than that of the EPZ011989-mediated sensitization (Figure 13G). 
Consistent with this observation, shRNA-mediated suppression of SLFN11 in NCI-H526, 
a cell line with high baseline SLFN11 expression, modestly decreased sensitivity of this 
line to topotecan, although we note that complete suppression of SLFN11 was not 
possible even with a highly potent shRNA (Figure 14E). Remarkably, while EPZ011989-
treatment shifted the sensitivity of this cell line to topotecan by approximately one log, 
this shift was mostly reversed by concurrent shRNA suppression of SLFN11. While we 
did not note changes in markers of acute DNA damage response (yH2A.X), we found 
that EPZ011989-treated cells showed increased markers of programmed cell death 
(cleaved-PARP), that were suppressed when co-targeting SLFN11 by shRNA. Taken 
together, these data strongly implicate SLFN11 as a determining factor in sensitivity to 
DNA damaging agents in SCLC (Figure 13I).  
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Figure 13. Chemical EZH2 inhibition rescues SLFN11 expression and sensitizes 
SCLC to DNA damage. 
(A) Chemical inhibition of EZH2 rescues SLFN11 expression in chemoresistant PDX 
models ex vivo. Chemonaïve and chemoresistant PDX models JHU-LX102 and SCRX-
Lu149 were cultured ex vivo for 7d and treated daily with 1μM of 5-azacitidine (5-Aza) or 
EZP011989 (EPZ) and then assayed for expression of SLFN11 by Western blot. 
(B) Ex vivo differences in sensitivity to etoposide and cisplatin in chemonaïve and 
chemoresistant (acquired in vivo) versions of JHU-LX102. IC50 values are colored 
accordingly throughout panels. Data traces are shown as normalized responses of 
nonlinear fits; data points and error bars removed for clarity of comparisons. n=4 data 
points per dose from 8-point dose series. All ex vivo experiments were in culture (ex 
vivo) for no more than 3 weeks and were not re-engrafted into mice. 
(C) Chemical rescue of chemoresistant sensitivity to etoposide and topotecan, treated as 
in 2B. Cells were treated as above for 7d before re-plating and exposing to either 
etoposide or topotecan for 72hrs before assaying. Additional EPZ or 5-Aza was not 
added beyond the d7 time point.  
(D) EZH2 chemical inhibition displays time-dependent rescue of SLFN11 and persists 
despite re-establishment of basal H3K27me3 levels in NCI-H82. Cells were treated daily 
for 10d with 1μM EPZ011989 before washing in media and releasing into fresh media for 
an additional 10d. Media was changed every other day. SLFN11 is normalized to actin; 
H3K27me3 is normalized to total H3; RFU data normalized to day 0 signal. 
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(E) Chemical inhibition of EZH2 rescues SLFN11 protein expression in SCLC cell lines 
lacking baseline protein expression. Cells were cultured in the presence of 1μM 
EPZ011989 for 7d, refreshing the compound everyday and the media every other day 
prior to collection of samples. 
(F) Re-expression of SLFN11 under chemical EZH2 inhibition is correlated to a shift in 
sensitivity to topotecan. Pearson correlation r=0.916. Red lines represent 95% 
confidence intervals. 
(G) Conditional re-expression of SLFN11 increases topotecan sensitivity in two SCLC 
cell lines. Doxycycline (DOX) at 1μg/mL was added to the media every other day for 4d 
before re-plating for 72hrs sensitivity to topotecan. IC50 values are colored per arm. 
(H) shRNA-mediated suppression of SLFN11 can partially reverse the sensitizing effects 
of chemical EZH2 inhibition on sensitivity to DNA damage. The SCLC cell line NCI-H82 
was exposed to DMSO, 1μM EPZ011989 (EPZ) or a combination of 1μM EPZ and 
1μg/mL DOX for 7d before exposure to topotecan. Times post-washout of the topotecan 
dose where cells were collected spanned 0.5-48hrs. Cells in suspension were released 
into fresh media after washing with serum free media following the 1hr exposure to 
topotecan. 
(I) IC50 shift in topotecan sensitivity for NCI-H82-pLT3GEPIR-shSLFN11.1 cell line after 
7d of conditional run-in treatment with DMSO, 1μM EPZ011989 (EPZ) or 1μM 
EPZ011989 and doxycycline (EPZ/DOX). Below: normalized RFU for cleaved-PARP. 
Signals were normalized against un-damaged controls per 7d run-in condition (DMSO, 
EPZ, or EPZ/DOX) in far left lanes per the three conditions shown.
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Figure 14. EZH2 chemical inhibition shows dose-dependent re-expression of 
SLFN11 and the re-expression is suppressible by shRNA. 
(A) SLFN11 re-expression is dose-dependent. NCI-H82 cell lines was treated for 7d with 
DMSO, 100nM or 1μM EPZ011989 in culture, adding compound every day. Cells were 
then split, exposed to 1μM topotecan for 1hr, washed and then released into fresh media 
for a 48hr chase. Gradient bar indicates time post-release/washout. 
(B) Individual IC50 curve traces for the 9 human SCLC cell lines used for the construction 
of Figure 13G. Cells were split every 3d, adding 1μM EPZ011989 (EPZ) or vehicle 
(DMSO) every day for 7d, before plating 1-5x104 cells in a black, opaque bottom plate as 
described in Materials and Methods for determining a 72hr kill curve for select agents. 
Average curve traces are shown from normalized data, restricting the Hill coefficient to 1. 
(C) SLFN11 re-expression is suppressible by shRNA. NCI-H82 treated with 1μM 
EPZ011989 in culture for 7d with or without a 72hr co-treatment period with 1μg/mL 
doxycycline (DOX). Two independent shRNA’s targeting SLFN11 are shown versus a 
non-targeting shRenilla control. 
(D) SLFN11 re-expression under chemical EZH2 inhibition is not compound specific. 
Shown is NCI-H82 treated in culture for 7d with DMSO, 1μM EPZ011989 or 1μM 
GSK126 with or without a 72hr co-treatment period with 1μg/mL doxycycline (DOX) to 
suppress SLFN11. 
(E) Conditional shRNA suppression of SLFN11 in the SLFN11High SCLC cell line NCI-
H526 modestly decreases sensitivity to topotecan. As in 13H, 1μg/mL doxycycline 
(DOX) was added to cell lines for 4d before re-plating for sensitivity assays. IC50 values 
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are colored accordingly per arm. Extent of knockdown of SLFN11 indicated before for 
two independent SLFN11 targeting shRNAs (shSLFN11.1 and shSLFN11.2, 
respectively), as well as an shRNA targeting Renilla luciferase (shRenilla). GFP is co-
expressed from an independent promoter upon exposure to doxycycline in the 3rd 
generation doxycycline inducible vector pLT3GEPIR (Fellmann et al., 2013).  
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EZH2 silences SLFN11 expression in SCLC 
 To further define the mechanistic relationship between EZH2 and SLFN11 
expression, we sought to explore the effects of EZH2 inhibition on local chromatin 
structure in the vicinity of the SLFN11 locus. We examined the efficacy of EPZ011989 in 
4 PDX models at two dose schedules over a treatment period of 3 weeks. As a single 
agent, EPZ011989 was well tolerated at 250 milligrams per kilogram body weight (mpk) 
administered orally, twice a day (PO bid) and slowed tumor growth rate to a modest 
extent in 3 of 4 models tested, including a chemorefractory model, JHU-LX44 (Figures 
15A-C). Our ability to observe single agent efficacy in vivo may have been limited by the 
duration we were able to treat hind flank tumors, relative to the time required to remodel 
the epigenome with such agents, which is thought to require weeks to months (LaFave 
et al., 2015). We further assessed the contribution of time-dependence for efficacy in 
vivo by re-engrafting equivalent viable cell numbers from tumors that had previously 
been treated for 21d with or without 250mpk EPZ011989 and then re-treating tumors 
with vehicle or a secondary round of EPZ011989 as the tumors became palpable 
(Figure 15D). These results suggest that prolonged exposure of SCLC tumors to EZH2 
inhibition may have a greater effect on decreasing proliferative capacity, not easily 
observed within the first few weeks of conventional pre-clinical efficacy experiments. 
 To demonstrate the ability of EPZ011989 to modulate the SCLC chemoresistant 
epigenome in vivo, we performed chromatin immunoprecipitation followed by sequencing 
(ChIP-seq) from flash frozen tissue obtained from chemonaïve or chemoresistant SCRX-
Lu149 tumors treated for 21d with either vehicle or 250mpk EPZ011989. ChIP-seq was 
performed on three targets:  EZH2, H3K27me3, and H3K27Ac (Figure 16A). While total 
EZH2 levels were not significantly altered in any condition (red), we observed increased 
global H3K27me3 in the chemoresistant setting that could be abolished by EPZ011989 
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(blue), as well as decreased global H3K27Ac in the chemoresistant setting that could be 
rescued by EPZ011989 (green). As expected, global H3K27Ac levels were increased by 
EPZ011989 in both the chemonaïve and chemoresistant settings with concomitant loss 
of H3K27me3. The global reduction of H3K27Ac in the chemoresistant setting prompted 
us to explore differential intensities within genomic regions termed “super-enhancers” 
(Loven et al., 2013; Pott and Lieb, 2015), thought to be critical for SCLC proliferation 
(Christensen et al., 2014; Lin et al., 2012). We observed differential signal intensities in 
such regions, consistent with global loss of H3K27Ac that could be restored by 
EPZ011989. However, selective loss or rescue of discrete super-enhancer regions was 
not observed (Figure 16B). 
Focusing specifically on the SLFN11 locus, these data demonstrate focally 
concentrated EZH2 and H3K27me3 in the immediate vicinity of the transcription start site 
(TSS) in vehicle-treated tumors, with spreading of H3K27me3 across the gene body in 
the context of acquired chemoresistance (Figure 16C). Coordinate with the increase in 
H3K27me3 across the gene body in the chemoresistant derivatives, there is almost 
complete loss of H3K27Ac, a mark associated with transcriptionally active chromatin, at 
the TSS of SLFN11 that we confirmed by ChIP-qPCR (p<0.0001; Figure 15E). 
Interestingly, EPZ011989 treatment appears to increase the density of EZH2 bound near 
the SLFN11 TSS, and while EPZ011989 treatment was able to largely erase H3K27me3 
throughout the gene body of SLFN11, levels of H3K27me3 near the TSS, presumably 
tightly bound by EZH2, were largely unchanged. However, EPZ011989 treatment also 
resulted in a concomitant increase in levels of H3K27Ac near the SLFN11 TSS. While 
speculative, these data suggest that re-expression of this target gene via chemical EZH2 
inhibition also requires cooperation with placement of histone modifications that promote 
gene expression.  
 81 
 
Figure 15. EZH2 inhibition by EPZ011989 has limited single agent activity in PDX 
models of SCLC and EZH2 directly targets SLFN11 for silencing. 
(A) Single agent activity of EPZ011989 across three independent chemonaïve and one 
chemoresistant PDX models (JHU-LX44), using two separate dose schedules. Areas in 
grey represent the times on continuous treatment. EPZ011989 was administered on a 
10AM/6PM schedule, 7 days a week for 14-21d, depending on tumor growth kinetics 
during treatment. Error bars shown +/- standard error of the mean (SEM); n=5-6 per arm. 
250mpk arm for JHU-LX44 was not performed. 
(B) Average animal weight on study above plots. 
(C) Chemorefractory model JHU-LX44 does not respond to the schedule of C/E used to 
generate in vivo acquired resistance models. Shown are mean tumor volume curves, 
weights on study and survival as a function of time to 1,000mm3  
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(D) Left:  Efficacy of continuous dosing through engraftment period. Tumors at the end of 
a three-week efficacy experiment for SCRX-Lu149 were engrafted from either vehicle or 
250mpk treatment arms into mice and two weeks following engraftment, mice from 
previously treated tumors were either not treated with EPZ011989 (washout) or treated 
for 3 additional weeks. Middle:  Comparison of tumor volume changes at week 3 on 
treatment versus baseline for 3 arms. Individual data points shown +/- SEM. Right:  
Average animal weight on study for left panel. Continuous arm approaches limits of 
protocol weight loss.  
(E) ChIP-qPCR for SLFN11 (upstream of first exon) in various tumor samples used in 
Figure 16 (follows) as compared to positive and negative control primer pairs. ChIP 
target indicated in color: EZH2 (red), H3K27me3 (blue) and H3K27Ac (green). Each 
ChIP-qPCR series is shown for three targets in the order of negative control, positive 
control and SLFN11 (left-to-right): Chr12 refers to a gene desert region in chromosome 
12, not known to bind any transcription factor (Active Motif; 71001). P-value indices 
(***<0.0001) reported for paired t-tests between groups within the H3K27Ac (green) 
sample set; n.s.=non-significant   
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Figure 16. Epigenetic changes acquired in chemoresistance are reversible with 
chemical EZH2 inhibition in vivo.  
(A) Cluster analysis of ChIP-4seq results from four SCRX-Lu149 tumor groups: 
chemonaïve or chemoresistant, treated with either vehicle or 250mpk EPZ011989 PO 
bid for 21d. Chromatin was pooled from three independent tumor samples per arm prior 
to IP. 
(B) Scatter plots of super-enhancer signal intensity demonstrate global loss of super-
enhancer signal (spike-in normalized H3K27Ac binned region) in the chemoresistant 
setting. 
(C) SLFN11 ChIP-seq gene tracks for the indicated sample treatment arms. Y-axes 
limits are scaled to drosophila spike-in for each sample for peak height comparisons. 
The SLFN11 gene model is oriented right-to-left along the x-axis as indicated.  
 84 
Pharmacologic EZH2 inhibition prevents emergence of chemoresistance and augments 
chemoresponse in vivo 
 The down regulation of SLFN11 in acquired chemoresistance, and its apparent 
regulation by EZH2, suggest a model in which EZH2, as part of the Polycomb 
Repressive Complex 2 (PRC2) is induced by cytotoxic chemotherapy. This induction 
yields SLFN11 silencing, a decrease in SLFN11 protein expression and concomitant 
acquired chemoresistance. To test this hypothesis and evaluate time-dependent 
changes in EZH2 activity, we performed DNA damage time course experiments in NCI-
H446, following exposure to topotecan, in the presence or absence of EPZ011989. Over 
the course of 48hrs following DNA damage, we noted a progressive increase in EZH2, 
as well as H3K27me3, that was suppressed by acute EPZ011989 treatment (Figure 
17A). Further, we could demonstrate that the effect on H3K27me3 was a function of 
EZH2, as shRNA-mediated suppression of EZH2 during a similar DNA damage time 
course abolished any increase in H3K27me3, and the accompanying loss of H3K27me2 
(Figure 17B). These data support a global methylation event in which di-methylated 
H3K27 is converted to the tri-methylated state. The effect of DNA damage increasing 
global H3K27me3 levels was not cell line specific (Figure 18A), demonstrated dose-
dependence (Figure 18B), and was more pronounced for topoisomerase I poisons when 
compared to either cisplatin or etoposide on an equimolar basis (Figure 18C). These 
shifts in EZH2 activity and resultant H3K27me3 could also be observed in vivo, using a 
single dose-chase approach in tumor-bearing animals treated with irinotecan and 
quantitatively evaluating time-dependent changes in several H3 methyl marks, 
demonstrating specificity for the induction of H3K27me3, with contemporaneous 
decreases in H3K27me2 (Figure 17C).  
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These data support the hypothesis that EZH2 activity is an important determinant 
of acquired chemotherapy resistance in SCLC, in part through suppression of SLFN11 
and, conversely, that targeted EZH2 inhibition might prevent or reverse acquired 
resistance to cytotoxic chemotherapy. To examine the combinatorial activities of 
EPZ011989 with cytotoxic regimens in vivo, we chose to approach this in two clinically 
translatable scenarios:  1) combining EPZ011989 with standard of care in the first line 
setting for SLFN11 expressing (SLFN11+) chemonaïve models and, 2) combining 
EPZ011989 with a standard second line agent in the chemoresistant setting, in which 
the silencing of SLFN11 has been established. Addition of EPZ011989 to 6 cycles of C/E 
strongly enhanced disease control in the chemonaïve setting in both JHU-LX102 and 
SCRX-Lu149 relative to either EPZ011989 or C/E alone (Figures 17D,E & Figures 
18D,E). To examine the benefit of EZH2 inhibition in tumors actively progressing on C/E, 
after three cycles we randomized 5 of 10 animals in the C/E arm to receive EPZ011989 
in combination with three additional cycles of C/E. Remarkably, the addition of 
EPZ011989 potently induced tumor regression relative to C/E alone during the remaining 
3 cycles, supporting the role of EZH2 in the development of chemorefractory disease 
(Figures 17D,E orange group).  
 We next assessed the efficacy of irinotecan, a topoisomerase I poison 
administered in the setting of relapsed SCLC, with or without EPZ011989 in two models 
that had acquired resistance to C/E, chemoresistant JHU-LX102 and SCRX-Lu149. 
Importantly, we observed strong cross-resistance to irinotecan, but not ionizing radiation 
(IR) in the chemoresistant setting, further supporting that the mechanism of acquired 
resistance operant in these models had specificity to the selection agents used (cisplatin 
and/or etoposide) (Figures 18F,G). The addition of EPZ011989 to irinotecan in the 
chemoresistant setting resulted in potent combinatorial activity that could control disease 
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to a greater extent than either agent alone through 6 weekly cycles of treatment 
(Figures 17F,G & Figures 18H,I). 
To further assess active repression and de-repression of SLFN11 in vivo, we 
engrafted an additional cohort of animals bearing either chemonaïve or chemoresistant 
versions of JHU-LX102 and randomized these animals to the indicated treatment arms 
for 3 cycles of chemotherapy with or without EPZ011989. Strikingly, we noted 
quantitative suppression of SLFN11 protein levels in tumors after as few as 3 cycles of 
C/E in the chemonaïve setting and further suppression after 3 cycles of irinotecan in the 
chemoresistant setting (Figure 17H). Critically, EZH2 inhibition could rescue SLFN11 
protein expression to baseline levels in the chemoresistant setting, even in the presence 
of concurrent chemotherapy (chemonaïve vehicle vs. chemoresistant 250mpk 
EPZ011989 + 3 cycles irinotecan).  
We find that the greatest degree of chemosensitization by EZH2 inhibition in 
SCLC is with respect to topoisomerase I poisons. In the models tested in vivo, this effect 
was independent of CREBBP mutations, which are frequent events among all major 
forms of lung cancer (Campbell et al., 2016; George et al., 2015). Recent evidence 
suggests that loss of CREBBP function predisposes certain cancers to p300-HAT 
inhibition, in a synthetically lethal relationship (Ogiwara et al., 2016). Along a similar line, 
mutations in the SWI/SNF complex are known to define sensitivity to single agent EZH2 
inhibition, and are currently being used as inclusion criteria in certain clinical trials (Kim 
et al., 2015b; Wilson et al., 2010). While we cannot definitively limit the combinatorial 
activity of EPZ011989 and irinotecan to a genetic subtype of SCLC, in the experiments 
performed, the combination appears to be potently active independent of detectable 
alteration in the SWI/SNF complex or CREBBP status. In combining EPZ011989 with 
irinotecan in the chemonaïve setting, we could completely ablate hind flank tumors 
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through 6 cycles of combination (5/5 animals with CRs). Moreover, the activity of the 
combination was greater, even when administered for a shorter duration of time (3 
cycles), than the equivalent schedule of irinotecan when administered for a full 6 cycles 
(Figures 17I,J). However, we did not observe additional benefit when initiating adjuvant 
EPZ011989 as a single agent at the point of maximal consolidative effect of single agent 
irinotecan (post cycle 3), as this was inferior to 3 additional cycles of irinotecan at the 
point of comparison.  
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Figure 17. H3K27me3 is increased following DNA damage and is an actionable 
target in combination with first or second line chemotherapy in SLFN11+ SCLC. 
(A) EZH2 and H3K27me3 are induced post-DNA damage and can be chemically 
inhibited with a single dose of EPZ011989. NCI-H446 was exposed to 1μM topotecan for 
1hr in the presence of absence of 1μM EPZ011989, before washing out topotecan and 
collecting time points as indicated. EZH2 (normalized to actin) and H3K27me3 
(normalized to H3) signal intensity (RFU) are normalized to the 72hrs DMSO control lane 
(far left sample). 
(B) Genetic suppression of EZH2 can suppress the acute accumulation of global 
H3K27me3, and conversion of H3K27me2 to H3K27me3. NCI-H446-pLT3GEPIR-
shEZH2.1 was treated with or without 1μg/mL doxycycline for 48hrs before damaging 
cells with 1μM topotecan, as before. On right, quantified H3K27me3 and H3K27me2 
signal increases overtime (normalized to H3), normalized to the initial time point on the 
blot (0.5hrs). 
(C) In vivo DNA damage of a SCLC PDX tumor displays acute H3K27me3 accumulation 
with coincident H3K27me2 decreases. The chemonaïve JHU-LX102 model was 
engrafted and tumor-bearing mice were IP dosed with a single injection of 100mpk 
irinotecan and then tumors were collected at the indicated time points post-dose. All 
tumors were 400-500mm3 at the time of dosing to preserve tumor integrity and yield 
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enough tissue for downstream analyses. Quantitation of indicated histone H3 methyl 
marks normalized to total histone H3 from independent two-channel blots. 
(D) Combining EPZ011989 with standard of care cisplatin/etoposide (C/E) provides 
durable disease control in SLFN11+ SCLC PDX models. Dashed vertical lines indicate 
d1 of a weekly C/E cycle (8mpk etoposide d1-3 + 5mpk cisplatin d1; all IP q7d). Dotted 
line at 4 weeks post-C/E 5 of the 10 animals within the C/E group were randomized to 
now receive EPZ011989 with 3 additional cycles of C/E. Grey areas indicate the dosing 
periods for EPZ011989 (250mpk; PO bid). n=5 animals per arm (n=10 in C/E arm 
through 3 cycles, before adding on EPZ) 
(E) Results for chemonaïve SCRX-Lu149 as in D 
(F) Combining EPZ011989 with a second line cytotoxic agent provides disease control in 
the chemoresistant setting. Dashed horizontal lines indicate d1 of a cycle. Six weekly 
cycles of irinotecan were administered with or without EPZ011989, as well as single 
agent EPZ011989. 
(G) Results for chemoresistant SCRX-Lu149 as in I 
(H) EPZ011989 rescues the expression of SLFN11 in chemoresistant PDXs and 
prevents down-regulation in the presence of chemotherapy. A separate 
pharmacodynamic (PD) cohort of animals was engrafted with either the chemonaïve 
(grey bar; n=6) or chemoresistant (red bar; n=12) versions of JHU-LX102. When tumors 
approached 400mm3 three animals were randomized to each treatment arm, collecting 
triplicate samples at week 4 on study (dosing weeks 1-3). Expression of SLFN11 is 
normalized to vinculin and plotted as RFU, as before. Paired t-tests were performed to 
compare differences between various groups indicated. 
(I) Addition of EPZ011989 to a potent DNA damaging agent is superior to the DNA 
damaging agent alone and shows cumulative efficacy in vivo. Cohorts of chemonaïve 
JHU-LX102 were randomized to treatment arms (n=5 per arm) of either short periods – 3 
weekly cycles – of 100mpk irinotecan (IRI) or in combination with EPZ011989 (EPZ/IRI), 
or full periods (6 cycles). Horizontal dashed lines indicate starting (green) and ending 
(red) tumor volume metrics per protocol with treatment period for 3 and 6 cycles shown 
along the x-axis. Vertical dashed lines indicate d1 of a weekly cycle of IRI. 
(J) Changes in tumor volume from baseline as a measure of treatment and schedule. 
Comparisons were made at 6 weeks post-treatment initiation between cohorts (day 72). 
EPZ maintenance refers to single agent EPZ011989 being administered 250mpk PO bid 
for 21d after completion of 3 weekly cycles of irinotecan. All tumors in the EPZ/IRI 6 
week treatment cohort were ablated at the final point of study shown (d72). P-values 
shown for paired t-tests.   
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Figure 18. Combining EPZ011989 with first or second line chemotherapy is well 
tolerated in vivo 
(A) EZH2 and H3K27me3 are induced following DNA damage in NCI-H446 and NCI-H69 
cell lines. EZH2 signal normalized to actin and H3K27me3 normalized to H3. Data are 
plotted from 0.5-48hrs post-damage, normalizing to undamaged control (DMSO) at 
48hrs. 
(B) EZH2 and H3K27me3 are induced following dose-dependent DNA damage in NCI-
H446. Time points shown post-damage are 0.5, 6, 24 and 48hrs. Data normalized to 
undamaged control at 48hrs. 
(C) EZH2 and H3K27me3 are strongly induced by topoisomerase poisons in NCI-H446 
(D) Average animal weights on study +/- SEM for each treatment arm indicated 
(E) as in D 
(F) Acquired resistance to C/E does not confer cross-resistance to radiation. As 
chemonaïve and chemoresistant SCRX-Lu149 tumors approached 150mm3, treated 
groups (RT/IR) received 2Gy for 4 consecutive days and tumor outgrowth was recorded; 
n=5 animals per group. Survival reported as a measure of time post-IR to reach a 
volumetric endpoint of 1000mm3, as established before in the C/E resistance protocol. 
n.s.=non-significant by log-rank (Mantle-Cox) test. 
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(G) Acquired resistance to C/E confers cross-resistance to topoisomerase I poisons. As 
chemonaïve and chemoresistant SCRX-Lu149 tumors approached 150mm3, treated 
groups received weekly cycles of irinotecan (100mpk; IP q7d) for 6 consecutive weeks 
and treated groups were then compared at one week after the final cycle. Dashed 
horizontal lines indicate d1 of a cycle. P-value shown for paired t-test. 
(H) Average animal weights on study +/- SEM for each treatment arm indicated 
(I) as in H  
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Discussion 
SCLC has been singled out by the US National Cancer Institute (NCI) as one of two 
designated “recalcitrant” cancers (the other being pancreatic cancer) based on incidence 
rate, exceptionally high lethality, and the lack of substantial therapeutic progress made 
over several decades. The 2014 Scientific Framework for Small Cell Lung Cancer, an 
NCI report to Congress, outlined major research priorities in SCLC (National Cancer 
Institute, 2014). Three of the five priorities noted included developing better models 
reflecting phases of SCLC found in the clinic, characterization of mechanisms 
responsible for the rapid emergence of drug resistance, and the identification and 
targeting of novel therapeutic vulnerabilities in SCLC. The work described here 
addresses all three of these critical needs. By attempting to mimic as closely as possible 
the clinical experience of repeated cycles of cisplatin and etoposide exposure in PDXs, 
we have generated a set of novel paired SCLC models representing initial 
chemosensitive and subsequent chemoresistant disease. We have used these models 
to define two mutually exclusive mechanistic classes of acquired resistance, including an 
EMT shift associated with TWIST1 up-regulation, and epigenetically mediated 
suppression of SLFN11. Finally, we have identified a novel and therapeutically tractable 
vulnerability of SCLC:  dependence on EZH2 for development of acquired 
chemotherapeutic resistance in vivo. 
In a cancer type with the high mutational load and resultant inter-patient 
heterogeneity of SCLC, it is not surprising that multiple mechanisms of acquired 
resistance are operant, and that different SCLCs may preferentially use different 
resistance pathways. What is perhaps more surprising, and encouraging, is that 
consistent gene expression and epigenetic changes, not mutations, are found to be 
associated with acquired chemoresistance across multiple independent SCLC models, 
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and indeed are reflected in primary human tumor samples. In the set of 10 PDX models 
examined here, TWIST1 induction was observed in three; this pathway was additionally 
reflected in multiple murine models of SCLC. While initial data point to TWIST1 as a 
biomarker rather than a driver of resistance per se, further exploration of therapeutic 
vulnerabilities associated with an EMT signature in this set of tumors is warranted. In 4 
of the 10 PDX models, acquired resistance was associated with specific suppression of 
SLFN11 expression. Most notably, our data point to SLFN11 suppression as a primary 
contributor to acquired chemotherapy resistance in SCLC – one that can be prevented 
and/or actively remodeled through targeting of the key epigenetic regulator EZH2. 
We recently reported that median SLFN11 expression is higher in SCLC when 
compared to most other tumor types studied in the TCGA (Lok et al., 2016). Recent work 
has begun to focus on the molecular functions of the SLFN11 protein (Mu et al., 2016). 
These emerging data offer insight into how high-level expression of SLFN11 in SCLC 
might contribute to the initial exceptional chemosensitivity of this disease, and why 
SLFN11 down-regulation would increase therapeutic resistance. Essentially all the 
therapeutic agents used to treat SCLC are DNA damaging agents that directly or 
indirectly result in double strand breaks (DSBs) – this list includes the platinum 
compounds, the topoisomerase inhibitors, alkylating agents such as temozolomide, and 
ionizing radiation. Resolution of DSBs is necessary for cell survival and occurs through 
two main DNA repair pathways:  non-homologous end-joining (NHEJ) and homologous 
recombination (HR). HR is an important pathway as it is generally considered to be 
error-free. An important step in HR involves binding and protection of overhanging DNA 
by the single-strand binding protein replication protein A (RPA) to allow recruitment of 
HR mediators (i.e. BRCA2 and RAD51). SLFN11 has been shown to localize to sites of 
DSBs and displace RPA from single strand overhangs:  high levels of SLFN11 thereby 
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result in HR deficiency, a state in some ways analogous to BRCA1/2 deficiency (Mu et 
al., 2016). Consistent with this framework, we found that SLFN11 expression, as a 
surrogate biomarker of HR deficiency, was a particularly strong predictor of SCLC 
sensitivity to PARP inhibitors (Lok et al., 2016). 
We have demonstrated here that SLFN11 suppression during selection for acquired 
resistance in SCLC is associated with a global increase in H3K27me3 with modest 
reductions in global H3K27Ac, and that SLFN11 gene expression can be restored and/or 
maintained by pharmacological inhibition of EZH2, even in the presence of DNA 
damaging agents. While we have shown that SLFN11 is both necessary and sufficient 
for sensitivity to DNA damaging agents in SCLC, we fully recognize that EZH2 inhibition 
alters expression of many genes. We fully anticipate that factors beyond SLFN11 will be 
identified that contribute to the ability of EZH2 inhibition to restore chemosensitivity in 
SCLC. Defining the relative contributions of SLFN11 vs. other EZH2-modified factors 
remains an area for future investigation. 
We find that the greatest degree of chemosensitization by EZH2 inhibition in SCLC is 
with respect to topoisomerase I poisons. From models tested in vivo, this effect was 
independent of CREBBP mutations, which are frequent events among all major forms of 
lung cancer, thought to remodel the epigenetic landscape of these cancers (Campbell et 
al., 2016; George et al., 2015). Recent evidence suggests that loss of CREBBP function 
predisposes certain cancers to chemical inhibition of p300’s HAT domain, displaying a 
synthetically lethal relationship (Ogiwara et al., 2016). Along a similar line, mutations in 
the SWI/SNF complex are known to define sensitivity to single agent EZH2 inhibition, 
and are currently being used as inclusion criteria in certain clinical trials (Kim et al., 
2015b; Wilson et al., 2010). While we cannot definitively limit the combinatorial activity of 
EPZ011989 and irinotecan to a genetic subtype of SCLC, in the experiments performed, 
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the combination appears to be potently active independent of detectable alteration in the 
SWI/SNF complex or CREBBP status. The remarkable combinatorial activity of an EZH2 
inhibitor with standard first line chemotherapy for de novo disease, and with standard 
second line chemotherapy for recurrent, chemoresistant disease, has immediate 
translational relevance.  
Several potent and selective EZH2 inhibitors are now in different stages of clinical 
development, including phase 2 (Epizyme) and phase 1 (Constellation, GSK) trials in 
multiple solid tumor and hematological indications. Epizyme recently updated the phase I 
experience and ongoing phase II experience (Ribrag et al. and, Morschhauser et al., 
ASH Lymphoma 2016) for their lead inhibitor tazemetostat (EPZ-6438, a closely related 
structural homolog of the tool compound inhibitor EPZ011989 described in this paper) 
(Fillmore et al., 2015). Clinical responses have been observed with tazemetostat in 
multiple patient populations, including diffuse large B-cell lymphoma (with and without 
EZH2 activating mutations), follicular lymphoma, malignant rhabdoid tumors, and small 
cell carcinoma of the ovary hypercalcaemic type (SCCOHT). The safety profile of 
tazemetostat in 82 patients with non-Hodgkin lymphoma on the ongoing phase II study 
was favorable, with the most frequent treatment-related adverse events being grade 1 or 
2 nausea and asthenia. Myelosuppression was observed infrequently with only 11% and 
6% of patients experiencing grade ≥3 thrombocytopenia and grade ≥3 neutropenia, 
respectively, suggesting tazemetostat may be safely combined with cytotoxic 
chemotherapy in SCLC. Importantly, the work presented here suggests that targeted 
EZH2 inhibitors should be anticipated to have minimal single agent activity in SCLC, and 
that evaluation of relevant combination therapies should be considered early in clinical 
development of these agents in SCLC. Clinical trials testing the therapeutic strategies 
defined here are now being designed with these considerations in mind.  
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Chapter 3. Targeted Inhibition of BCL-2 Has Limited Utility in SCLC and Combined 




Over-expression of the anti-apoptotic protein BCL-2 is observed in the majority of 
small cell lung cancer (SCLC) cases and is associated with resistance to chemotherapy. 
While targeting BCL-2 in hematologic malignancies continues to show signs of promise, 
translating the BH3 mimetic ABT-737 (or ABT-263; navitoclax) to the clinic for solid 
tumors has remained problematic, with limited single agent activity in early phase clinical 
trials. Here we used patient-derived xenograft (PDX) models of SCLC to study ABT-737 
resistance and demonstrated that responses to ABT-737 are short-lived and coincide 
with decreases in HIF-1α regulated transcripts. Combining the mTOR inhibitor 
rapamycin with ABT-737 rescued this resistance mechanism, was highly synergistic in 
vitro, and provided durable tumor regressions in vivo without notable hematologic 
suppression. In comparison, tumor regressions did not occur when ABT-737 was 
combined with etoposide, a gold standard cytotoxic for SCLC therapy. Rapamycin 
exposure was consistently associated with an increase in the pro-apoptotic protein BAX, 
whereas ABT-737 caused dose-dependent decreases in BAX. As ABT-737 triggers 
programmed cell death in a BAX/BAK-dependent manner, we provide pre-clinical 
evidence that the efficacy of ABT-737 as a single agent is self-limiting in SCLC, but the 
addition of rapamycin can maintain or increase levels of BAX protein and markedly 
enhance the anti-cancer efficacy of ABT-737 (Figure 19). These data have direct 
translational implications for SCLC clinical trials.  
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Figure 19. Chapter 3 Brevis 
Single agent BCL2-/xL inhibitor ABT-737 has limited utility in SCLC. The BH3 mimetics 
ABT-737/263 were developed to trigger programmed cell death (apoptosis) in tumors 
that express high levels of the anti-apoptotic proteins BCL-2 and BCL-xL. Pre-clinical 
data in chronic lymphocytic leukemia (CLL) and small cell lung cancer (SCLC) warranted 
clinical investigation; however, single agent responses to ABT-263 in extensive-stage 
SCLC were minimal. Here, using patient-derived xenograft (PDX) models of SCLC, it 
was found that responses to single agent ABT-737 were acute in duration and 
accompanied by decreases in HIF-1α target genes. Using transcriptome signatures of 
ABT-737 responses, we identified that classes of PI3K/mTOR inhibitors were synergistic 
when combined with BH3 mimetics in vitro and provided durable tumor regressions in 
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BCL-2 expressing PDX models of SCLC in vivo. Interestingly, the mTOR inhibitor 
rapamycin preserved levels of BAX protein in vivo, a requisite gateway for programmed 
cell death by ABT-737. These data add a new light on acute resistance mechanisms to 




Small cell lung cancer (SCLC) represents 12-15% of all lung cancers and 
accounts for nearly 30,000 deaths in the US annually (Siegel et al.). Etoposide plus 
cisplatin was established as the standard of care for SCLC in the 1980s and can confer 
high response rates (>60%) as initial therapy (Kalemkerian et al.). However, therapy-
refractory recurrence is nearly universal and, as a consequence, SCLC has one of the 
highest case-fatality rates among cancer – a statistic that has not changed significantly 
over the past 30 years (Oze et al.). Since 2003, only one agent, topotecan, has received 
FDA approval for SCLC. New therapies are in critical need.  
One targetable opportunity is in the over-expression of the anti-apoptotic protein 
BCL-2 where between 60-90% of SCLC cases have been reported to express high BCL-
2 protein (Ikegaki et al., 1994; Jiang et al., 1995) and this is thought to be a mechanism 
by which SCLC resists programmed cell death. Through structure-guided medicinal 
chemistry efforts, the BCL-2 inhibitor ABT-737 emerged as the prototypic small molecule 
candidate to exploit over-expression of BCL-2 in cancer (Oltersdorf et al., 2005). ABT-
737 most closely simulates the pro-apoptotic protein Bad from a functional standpoint 
and serves as a competitive BH3 mimetic with high affinity to the anti-apoptotic proteins 
BCL-2, Bcl-xL and Bcl-w. Thus, when targeting BCL-2 was possible with ABT-737 and 
the orally-bioavailable derivative ABT-263 (navitoclax), efforts were made to translate 
pre-clinical findings in SCLC to patients (Gandhi et al., 2011; Park et al., 2008). 
 However, early phase clinical trials investigating ABT-263 as a single agent in 
SCLC failed to show the dramatic responses that were observed in pre-clinical SCLC cell 
line xenograft models (Gandhi et al.; Rudin et al., 2012b; Shoemaker et al., 2008). In 
clinical studies of ABT-263, the inhibition of Bcl-xL in platelet populations yielded dose-
dependent thrombocytopenia and has somewhat limited the utility of this high affinity 
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BCL-2/xL inhibitor. It is becoming increasingly evident that targeting certain BCL-2 family 
members in a tumor must be considered in the context of other lineage-specific 
dependencies to minimize toxicities (Juin et al., 2013). Moreover, while lead-in dosing 
strategies with ABT-263 could lessen the observed thrombocytopenia, inhibiting both 
BCL-2 and Bcl-xL with concurrent cytotoxic chemotherapy has added complexity to 
maximizing therapeutic combinations with ABT-263.  
Strategies to model resistance to ABT-737/263 in SCLC and other tumor types 
have identified the anti-apoptotic protein MCL-1 as a major culprit, where MCL-1 can 
serve a functionally-redundant role in sequestering the pro-apoptotic proteins BAX and 
BAK and is not targeted by ABT-737. Efforts to increase the sensitivity of various 
cancers to ABT-737 have focused on mechanisms that impact MCL-1, either through 
direct targeting or exploiting the relatively short half-life of the MCL-1 protein (Inuzuka et 
al., 2011; Wei et al., 2012). Many compounds shown to synergize with ABT-737 in SCLC 
and other cancers are global transcriptional or translational repressors, such as 
anthracyclines (Chen et al., 2011; Xu and Krystal, 2010); however, combination of these 
agents in the clinic could prove challenging due to toxicity. While other anti-apoptotic 
proteins not targeted by ABT-737 have been implicated in resistance to ABT-737, the 
major anti-apoptotic players observed to be amplified across many cancer types are 
BCL-2, Bcl-xL and MCL-1 (Beroukhim et al., 2010). How these anti-apoptotic regulators 
govern the activity of pro-apoptotic BAX and BAK with other apoptotic effectors in the 
context of a given tumor help to define a cancer hallmark – resistance to programmed 
cell death (Hanahan and Weinberg, 2011).   
We previously reported that ABT-737 could induce dramatic responses in SCLC 
cell lines, in agreement with what others have shown; however, ABT-737 alone failed to 
produce substantial tumor responses in SCLC patient-derived xenograft (PDX) models 
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that express low levels of BCL-2 (Hann et al., 2008). Here we show that BCL-2 
expressing SCLC PDXs initially respond to ABT-737, but the responses are not durable 
and the addition of etoposide does not improve responses. We used these PDX models 
to investigate the transcriptional changes that occur during initial responses to ABT-737 
in order to develop strategies to increase the efficacy of ABT-737. We found that the 
mTOR inhibitor rapamycin could enhance the antitumor activity of ABT-737 in vitro and 
in vivo, rescuing the self-limiting effects of single agent ABT-737. We further observed 
that this combinatorial activity correlated with an increase in pro-apoptotic BAX.  
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Materials and Methods 
 
Cell lines and reagents 
SCLC cell lines were purchased from American Type Culture Collection (ATCC) 
and maintained as recommended. All cell lines tested negative for mycoplasma (Lonza; 
MycoAlert™) and were STR verified at the Johns Hopkins Fragment Analysis Facility 
within 6 months of use. ABT-737 was obtained from Abbott Laboratories (now Abbvie) 
and purchased from Active Biochem (A-1002). For in vivo use, ABT-737 and etoposide 
(Accord Healthcare, Inc) were prepared as previously described (Hann et al., 2008). 
Rapamycin (LC Laboratories) was stored in 100% ethanol at 50 mg/ml. For in vivo use, 
rapamycin vehicle was 82% PBS/5% Tween-80/5% PEG 400/8% ethanol. AZD8055 
(S1555), BEZ235 (S1009), everolimus (S1120), LY294002 (S1105) and wortmannin 
(S2758) were purchased from Selleck Chemicals. DMSO was used as a vehicle for all in 
vitro experiments. 
 
Cell proliferation and viability assays 
Cells were plated 24 h before treatments in 96-well plates at 1,000-5,000 
cells/well. Proliferation (CellTiter 96® AQueous One; Promega) and viability (CellTiter-
Glo®; Promega) assays were quantified on a compatible plate reader (SpectraMax M2e; 
Molecular Devices). All combination and drug synergy experiments were performed for 
72hrs before assaying. 
 
Assessment of drug synergy 
Drug synergy was determined quantitatively using the combination index (CI) 
method of Chou and Talalay (Chou and Talalay, 1984). Viability was calculated across a 
wide range of doses for both ABT-737 and each compound of interest using a non-
 104 
constant ratio. CI was calculated as a function of response or fraction affected (Fa) using 
the formula [CI = (D1)/(Dx)1 + (D2)/(Dx)2] where D1 and D2 are the doses used to achieve 
a specific response in combination and (Dx)1 and (Dx)2 are individual drug doses needed 
to achieve similar response. A CI >1 indicates antagonism, while a CI <1 indicates 
synergism. 
 
Pimonidazole staining and immunohistochemistry 
 Mice were injected with Hypoxyprobe™-1 solution (Hypoxyprobe, Inc.) 
approximately 1 h before sacrifice. Tumors were fixed in formalin, embedded in paraffin, 
and sectioned at 5 µm thickness. Sections were de-waxed and incubated in citrate, pH 
6.0 (Vector Laboratories, H-3300) for 25 min. Sections were stained using the Dako 
EnVision Plus Detection System with rabbit PAb2627 (Hypoxyprobe, HP3-100Kit) for 45 
min at 25 ºC and were visualized with 3,3’-diaminobenzidine (DAB) reagent (Sigma, 
D423). H&E staining was performed with an automated slide stainer (Leica) with 
Modified Harris Hematoxylin (Richard-Allan Scientific).  
 
Isolation of heavy membranes 
Separation of crude mitochondria (“heavy membranes”) from cytosol in cell lines 
and tumor tissue was performed using a QProteome™ Mitochondrial Isolation Kit 
(Qiagen). Samples were lysed in RIPA buffer supplemented with protease/phosphatase 
inhibitor cocktails (Sigma-Aldrich) for 30 min on ice before clarification at 13,000 rpm for 
10 min at 4 ºC. Protein concentrations were determined using the BCA method 
(microBCA; Pierce).  
 
Antibodies and Western Blot 
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The following primary antibodies were purchased from Cell Signaling 
Technology, Inc. (Danvers, MA) and used at a 1:1000 dilution according to 
manufacturer’s instructions:  BCL-2 (#4223), Bcl-xL (#2764), Bcl-w (#2724), Mcl-1 
(#4572), Bim (#2933), Bad (#9239), Bid (#2006), β-actin (#4967), mTOR (#2972), p-
mTOR S2448 (#2971), rictor (#2114), raptor (#2280), Akt (#4691), p-Akt S743 (#4060), 
p-Akt T308 (#9275), Puma (#12450), VEGF-B (#2463), S6 (#2217), p-S6 S235/6 
(#4858), BAK (#6947), BAX (#2774), GβL (#3274), cytochrome c (#4272), VDAC 
(#4661), SDHA (#5839) cleaved-Parp (#9541), 4E-BP1 (#9452), p-4E-BP1 T37/46 
(#9459), and eIF4E (#2067). Primary antibodies to NOXA (Imgenex; IMG-349A), VEGF-
A (Abcam; ab51745), CXCR4 (ab58176), GAPDH (Santa Cruz; sc-25778) and FKBP8 
(sc-166607) were used at a 1:500 dilution. Anti-mouse or anti-rabbit HRP-conjugated 
secondary antibodies (GE Healthcare) were used at a 1:5000 dilution. Blots were 
stripped and re-probed using standard techniques. All western blot film images were 
cropped to show adequate bandwidth above and below relevant bands; where western 
panels are shown, loading control bands were confirmed to be similar across multiple 
blots. 
 
SCLC Patient-Derived Xenograft (PDX) models and dosing 
All in vivo experiments were performed in accordance with protocols approved by 
the Johns Hopkins University Animal Care and Use Committee. The LX33 and LX48 
PDXs were isolated and passaged as previously described (Daniel et al., 2009; Hann et 
al.; Poirier et al., 2013). LX47 PDXs were passaged as tumor tissue sections (~2-3 mm) 
coated in Matrigel™ and implanted via subcutaneous flap incisions. All treatment 
experiments were performed in female C.B-17 scid mice, 4-6 weeks old at time of PDX 
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injection/implantation (Taconic; C.B-Igh-1b/IcrTac-Prkdcscid). The LX33 and LX47 PDXs 
were derived from chemotherapy-naïve SCLC patients and the LX48 PDX from a patient 
previously treated with platinum plus etoposide. Tumor volumes were calculated from 
manual caliper measurements with an ellipsoid formula where volume (mm3) = (xy2)/2. 
Once tumor volumes reached ~150 mm3, mice were randomized to treatment arms and 
treated daily via intraperitoneal (IP) injections with vehicles, ABT-737 (100 mg/kg), 
rapamycin (20 mg/kg), etoposide (12 mg/kg on days 1, 4 and 9) or combinations of two 
agents. 
 
RNA isolation and genome-wide transcriptional profiling 
Total RNA was prepared using an RNeasy Mini Kit (Qiagen) with on-column 
DNase I digestion. RNA quality was assessed with a Nanodrop-1000 for OD260/280 and 
OD260/230 ratios and an Agilent 2100 Bioanalyzer. Total RNA (500 ng) from each 
sample was amplified and labeled using an Illumina® TotalPrep™ RNA amplification kit 
according to manufacturer’s protocol (Ambion). Biotinylated RNA (750 ng) was combined 
with hybridization buffer and hybridized to HumanHT-12 v4 Expression BeadChip arrays 
(Illumina®) for 16-20 h at 58 ºC. Arrays were washed at 55 ºC and blocked at 25 ºC. 
Bound biotinylated RNA was stained with streptavidin-Cy3 and washed. Dried arrays 
were protected from light until scanning with an iScan System. Data were extracted 
using the Gene Expression Module in GenomeStudio Software. 
 
Gene expression analysis 
Using the Bioconductor suite for R (Gentleman et al., 2004) and the limma 
package (Smyth, 2005), raw gene expression data were quantile normalized, then log-2 
transformed. Differentially expressed genes were identified by fitting a linear model for 
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each feature. Standard errors of log-2 transformed changes were moderated using an 
empirical Bayesian approach. For each feature, moderated t statistics, B statistics, raw 
and adjusted p values (corrected for multiple testing by the Benjamini and Hochberg 
method) were calculated. Permutation based gene set enrichment was performed using 
GSEA, a sample permutation-based method, and CAMERA, a competitive gene set 
testing method that accounts for inter-gene correlation (Mootha et al., 2003; Wu and 
Smyth, 2012). The gene set database used was MSigDB 3.1 from the Broad Institute 
(Subramanian et al., 2005). 
 
Hematology 
Whole blood was collected immediately following cervical dislocation in C.B-17 scid mice 
via cardiac puncture using tuberculin syringes flushed with 1M EDTA, immediately 
transferred to K2EDTA lavender tubes (BD microtainer®) and stored at 4 ºC for less than 
24 h before analysis. Complete blood count with differential parameters were measured 
on a Hemavet 950FS (Drew Scientific) at the Johns Hopkins Phenotyping Core 
 
Statistical analysis of drug efficacy experiments 
All animal data are reported as average tumor volumes +/- standard deviation 
(SD). Tumor volume comparisons between treatment groups utilized data from weekly 
time points using a two-sided Student’s t test; throughout the text unless indicated: *, 
p<0.01 and **, p<0.001. All graphs in figures were created using GraphPad Prism 6.0c 
(GraphPad Software, Inc.). Figures for drug combination matrix outputs and drug 




Treatment with ABT-737 results in short-lived tumor responses and is associated with a 
decrease in HIF-1α transcripts. 
We previously reported that ABT-737 had limited activity alone and in 
combination with etoposide in SCLC PDXs that express low levels of BCL-2 (Hann et al., 
2008). To further assess the activity of ABT-737 in a more representative set of PDXs, 
we extended these studies to include three BCL-2 expressing SCLC PDX models - 
LX44, LX47 and LX48 – as well as a SCLC PDX model that does not express 
appreciable BCL-2 for historic control (LX33). Treatment with ABT-737 resulted in 
modest anti-tumor activity with statistically significant tumor growth inhibition (TGI) in 
LX47 and LX48, but minimal effects in LX44 and LX33 over a period of 3 weeks where 
ABT-737 was administered daily (Figure 20A). As shown in Figure 20B, all PDX 
models express other anti-apoptotic targets of ABT-737, as well as MCL-1. Treatment 
with ABT-737 was more effective than etoposide, a standard of care therapeutic agent 
for SCLC. Of great important to this study, the addition of etoposide to ABT-737 did not 
improve responses in a chemo-naïve/sensitive model (LX47) nor a chemo-
resistant/treatment-experienced model (LX48). Further, this combination appeared to be 
poorly tolerated by mice as evidenced by weight loss while on treatment (Figures 21A, 
B). Notably, we observed that responses to ABT-737 in these PDXs were short-lived – 
minimal regressions during continuous treatment progressed at growth rates comparable 
to vehicle-treated tumors after treatment discontinuation. 
To investigate potential acute resistance mechanisms to ABT-737 we selected 
LX47 and LX48 for further characterization of responses. We hypothesized that during 
tumor response, a sensitivity signature may exist and precede tumor outgrowth in such 
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models. Using whole genome transcriptional profiling, we compared the gene expression 
profiles of tumors from vehicle and ABT-737-treated mice collected at points of maximal 
response (Table 6). Transcriptional profiling results comparing ABT-737-treated to 
vehicle-treated tumors revealed that some of the most differentially expressed genes 
were well-established HIF-1α transcriptional targets, such as LDHA and BNIP3L (Figure 
20D and Table 7). Gene set enrichment analysis (GSEA) revealed that HIF-1α gene 
sets comprised the majority of the most statistically significant gene sets down regulated 
in ABT-737-treated tumors (Table 8). To further illustrate the changes observed in HIF-
1α transcripts we generated an MA plot to visualize how genome-wide transcriptional 
profiling data from the ABT-737-treated PDX models compared to a benchmark HIF-1α 
regulated gene set (Elvidge et al., 2006). Many transcripts that are normally up regulated 
by hypoxia (Figure 20D bottom; green) were decreased upon ABT-737 treatment, 
whereas transcripts down regulated by hypoxia (Figure 1D bottom; magenta) were 
unchanged. There are data supporting that ABT-737 is more effective under hypoxic 
conditions in vitro as well as in vivo and that hypoxia is a negative regulator of MCL-1 
half-life (Harrison et al., 2011; Klymenko et al., 2011). We did not observe changes in 
MCL-1 transcript or protein levels during acute treatments with ABT-737 in LX47 or 
LX48. While transcriptional profiling data suggested that ABT-737-treated tumors lack 
expression of hypoxia induced genes, pimonidazole staining to assess regions of 
physiological hypoxia at time points within the window of maximal response to ABT-737 
revealed no appreciable difference between treatment groups (Figure 20E).  
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Figure 20. Responses to ABT-737 in PDX models of SCLC are short-lived and 
progression is preceded by a decrease in HIF-1α transcripts.  
(A) Tumor response curves in three Bcl-2 expressing (left-to-right; LX44, LX47 and 
LX48) and one Bcl-2 non-expressing (LX33) SCLC PDX models treated with ABT-737 or 
vehicle. Dashed line along x-axis indicates duration of treatment (21 days) with shaded 
area corresponding to standard deviation from the indicated averages; n=5-6 mice per 
arm.  
(B) Western blot for protein expression of select Bcl-2 family members in PDX models 
used in this study. PDX tumor lysates were prepared from banked tumor tissue that had 
been propagated in untreated NOD scid mice without evidence of tumor necrosis. β-
actin provided for loading control.  
(C) Response of Bcl-2 expressing SCLC PDX models LX47 (top) and LX48 (bottom) to 
etoposide, ABT-737 or the combination of agents.  
(D) Heatmap visualization of differentially expressed (log2) genes between paired ABT-
737 (yellow) and vehicle-treated (blue) tumors from LX47 and LX48 tumors at points at 
or before maximal response. Below, an MA plot for the distribution of select HIF-1α 
responsive genes (e.g. “Elvidge Hypoxia” gene set) as a function of ABT-737 treatment 
in LX47 and LX48.  
(E) Representative H&E and pimonidazole IHC of whole LX48 tumor capsules at the 
point of maximal response to ABT-737, paired with vehicle counterparts (n=3 tumors per 
arm); scale bar is 3 mm (above) or 200 μm (below).  
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Figure 21. Combining ABT-737 with etoposide is not well tolerated in vivo. 
Average mouse weights +/- standard deviation for (A) LX47 and (B) LX48 while on study 
treated with ABT-737, etoposide or the combination of ABT-737 and etoposide. Dashed 
lines indicate treatment period duration (21 days). Two of six mice in the combination 
arm that had lost weight in excess of 20% of starting body weight were euthanized at 
days 15 and 18 per protocol. 
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engraftment PDX Line Treatment Timepoint Description 
384 4-6wks JHU-LX47 ABT-737 D4 Time of maximal response 
368 4-6wks JHU-LX47 ABT-737 D8 Time of maximal response 
370 4-6wks JHU-LX47 ABT-737 D8 Time of maximal response 
377 4-6wks JHU-LX47 ABT-737 D8 Time of maximal response 
376 4-6wks JHU-LX47 Control D4 
Matched control for D4 ABT-
737 tumors 
378 4-6wks JHU-LX47 Control D8 
Matched control for D8 ABT-
737 tumors 
380 4-6wks JHU-LX47 Control D8 
Matched control for D8 ABT-
737 tumors 
840 4-6wks JHU-LX48 ABT-737 D12 Time of maximal response 
844 4-6wks JHU-LX48 ABT-737 D12 Time of maximal response 
906 4-6wks JHU-LX48 ABT-737 D12 Time of maximal response 
914 4-6wks JHU-LX48 ABT-737 D12 Time of maximal response 
829 4-6wks JHU-LX48 Control D12 
Matched control for D12 ABT-
737-treated tumor 
831 4-6wks JHU-LX48 Control D12 
Matched control for D12 ABT-
737-treated tumor 
912 4-6wks JHU-LX48 Control D12 
Matched control for D12 ABT-
737-treated tumor 
916 4-6wks JHU-LX48 Control D12 




Table 7. Top 20 differentially expressed genes in ABT-737 treated tumors. 
Gene ID logFC AveExpr t P.Value adj.P.Val Beta-statistic 
LDHA -0.692 11.820 -8.019 0.00000052 0.025 3.365 
VEGFA -0.729 7.220 -6.922 0.00000337 0.040 2.438 
ALDOA -0.719 10.634 -7.207 0.00000204 0.040 2.697 
ZNF581 -0.428 8.331 -7.033 0.00000277 0.040 2.540 
PGK1 -0.536 10.911 -6.651 0.00000547 0.043 2.179 
SLC16A3 -0.518 6.820 -6.727 0.00000477 0.043 2.252 
ADM -1.283 8.886 -6.427 0.00000822 0.049 1.955 
TIGA1 -0.720 9.294 -6.429 0.00000820 0.049 1.956 
HPCAL1 -0.294 9.403 -6.228 0.00001188 0.062 1.748 
SCARB1 -0.880 7.809 -6.074 0.00001585 0.068 1.584 
ZNF395 -0.486 9.585 -6.078 0.00001575 0.068 1.588 
LDHA -0.768 11.510 -5.718 0.00003130 0.123 1.187 
BNIP3L -0.497 8.586 -5.629 0.00003719 0.135 1.085 
NDUFA4L2 -1.541 8.208 -5.493 0.00004848 0.143 0.925 
TRIB3 -0.628 7.610 -5.502 0.00004766 0.143 0.935 
TIMP2 1.326 7.680 5.546 0.00004374 0.143 0.987 
SLC2A1 -1.093 9.941 -5.362 0.00006273 0.148 0.768 
FOS -1.005 7.377 -5.388 0.00005964 0.148 0.799 
LOC652726 -0.486 8.368 -5.365 0.00006239 0.148 0.771 
APOE 2.536 10.748 5.376 0.00006105 0.148 0.785 
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Table 8. Gene Set Enrichment Analysis (GSEA) in ABT-737 treated tumors. 
Gene Set Size ES NES FDR q-val FWER p-val 
GNF2_RAB7L1 32 -0.61147 -2.05170 0.00460 0.00400 
WIERENGA_STAT5A_TARGET
S_GROUP1 133 -0.58572 -1.64160 0.03489 0.66100 
SHAFFER_IRF4_TARGETS_IN_
MYELOMA_VS_MATURE_B_LY
MPHOCYTE 100 -0.56319 -1.64280 0.03502 0.65800 
WINTER_HYPOXIA_METAGEN
E 234 -0.61176 -1.65100 0.03515 0.62500 
HELLER_HDAC_TARGETS_SIL
ENCED_BY_METHYLATION_D
N 268 -0.53805 -1.64360 0.03517 0.65700 
KEGG_STEROID_BIOSYNTHES
IS 16 -0.77407 -1.65180 0.03545 0.62500 
BIOCARTA_NGF_PATHWAY 18 -0.66795 -1.64380 0.03567 0.65700 
HEART_DEVELOPMENT 37 -0.49252 -1.65240 0.03587 0.62400 
REACTOME_GLUCONEOGENE
SIS 32 -0.66656 -1.64800 0.03589 0.63400 
ELVIDGE_HYPOXIA_UP 166 -0.69536 -1.67320 0.03608 0.57100 
GROSS_HYPOXIA_VIA_ELK3_
ONLY_UP 33 -0.66746 -1.65790 0.03621 0.60700 
FLOTHO_PEDIATRIC_ALL_THE
RAPY_RESPONSE_UP 53 -0.58118 -1.65450 0.03623 0.61400 
BIOCARTA_IL6_PATHWAY 22 -0.64319 -1.64390 0.03625 0.65600 
ELVIDGE_HYPOXIA_BY_DMOG
_UP 126 -0.71961 -1.65560 0.03629 0.61000 
QI_HYPOXIA 133 -0.65194 -1.65250 0.03656 0.62400 
VARELA_ZMPSTE24_TARGETS
_UP 40 -0.58802 -1.64460 0.03664 0.65300 
THEODOROU_MAMMARY_TU
MORIGENESIS 31 -0.47996 -1.67350 0.03683 0.57100 
MOOTHA_GLUCONEOGENESI
S 31 -0.68032 -1.65820 0.03690 0.60700 
ADDYA_ERYTHROID_DIFFERE
NTIATION_BY_HEMIN 71 -0.58878 -1.63600 0.03706 0.67800 
ELVIDGE_HIF1A_AND_HIF2A_T
ARGETS_DN 101 -0.75498 -1.65970 0.03708 0.60300 
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A rapamycin signature is predicted to connect with ABT-737 response and shows 
synergy with ABT-737 in vitro 
 To identify agents or pathways that are associated with responses to ABT-737 in 
BCL-2 expressing PDX models, we queried the Broad Institute’s publicly-available 
Connectivity Map database (cMap build 2.0) using the most significantly differentially 
expressed genes between control and ABT-737-treated tumors (Table 7). The cMap 
database attempts to connect gene expression data to chemical perturbation by 
cataloging gene expression changes that result from exposures to bioactive compounds 
in vitro (Lamb et al., 2006). This approach is advantageous in the setting of data from 
whole genome profiling experiments where the contributions of individual transcripts may 
not hold clear significance to an overarching pathway or group of pathways being 
affected, and thus it provides more generalizable strategies to affect an observed profile. 
Several of the highest scoring bioactive compounds identified by our cMap query to align 
with an ABT-737 response were inhibitors of the PI3K/mTOR pathway (Table 9) – 
pathways known to regulate and interact with HIF-1α (Laplante and Sabatini, 2012). 
Taken together with literature supporting the combined effect of PI3K/mTOR and 
BCL-2 inhibition in other tumor types (Ackler et al., 2008; Muranen et al., 2012; Rahmani 
et al., 2013; Vaillant et al., 2013) and the mounting evidence for rationally co-targeting 
growth and survival pathways, we tested the combination of rapamycin and ABT-737 in 
two SCLC cell lines that express high levels of BCL-2 (NCI-H146 and NCI-H187) and 
two lines that do not express appreciable BCL-2 (NCI-H82 and NCI-H446) (Oltersdorf et 
al., 2005). As expected, treatment with ABT-737 resulted in dose-dependent decreases 
in viability in lines that express BCL-2 with little effect on lines that do not express BCL-2 
(Figure 22A). BCL-2 expressing lines were also more sensitive than non-BCL-2 
expressing lines to rapamycin. This effect was not dose-dependent after 72 hours of 
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exposure in the dose ranges studied (low nanomolar to micromolar) and we confirmed 
this trend in a larger set of SCLC cell lines (Figure 23A). Combining increasing doses of 
ABT-737 with 100 nM rapamycin had minimal effect on low expressing BCL-2 lines, but 
was at least additive in BCL-2 expressing lines. However, treating ABT-737-sensitive cell 
lines with 100 nM rapamycin for 24 or 72 hours prior to exposure to ABT-737 did not 
dramatically alter the sensitivity of these lines to ABT-737 (Figure 22B), suggesting that 
rapamycin does not acutely sensitize cell lines to ABT-737. 
 To demonstrate whether the combined effect of rapamycin and ABT-737 was 
synergistic, we focused on two cell lines that differed in their expression of BCL-2 (NCI-
H146 and NCI-H82) and treated cells with ABT-737 and drugs targeting PI3K 
(wortmannin, LY294002), mTOR (rapamycin, everolimus, AZD8055) or both (BEZ235), 
selected based on our cMap results (Figures 23B, C). Using broad dose combinations 
we quantitatively calculated synergy for each drug combination across a range of doses 
using the method of Chou and Talalay and a non-constant ratio approach (Chou and 
Talalay, 1984). Representative dose-matrix outputs for the combination of ABT-737 and 
rapamycin in NCI-H82 (above) and NCI-H146 (below) are shown in Figure 22C. The 
agents studied had varying potency that generally segregated by inhibitor class (Figure 
2D). Synergism in NCI-H146 is summarized in Figure 22E by plotting the combination 
index (CI) as a function of fraction affected (Fa) (Chou, 2010). For example, wortmannin 
showed no synergy at any dose, while all other compounds showed quantitative 
synergism. The mTOR inhibitors rapamycin and everolimus displayed strong synergism 
over a wide dose-response range. We felt that these data warranted testing rapamycin in 
combination with ABT-737 in vivo.  
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Table 9. Top 20 connectivity map (cMAP) hits for ABT-737 treatment signature. 
rank cMAP compound mean n enrichment p-value specificity 
1 monorden 0.212 22 0.572 0 0.0107 
2 sirolimus 0.278 44 0.428 0 0.1145 
3 LY-294002 0.267 61 0.423 0 0.094 
4 quinisocaine -0.601 4 -0.87 0.00058 0 
5 dosulepin -0.649 4 -0.85 0.00095 0 
6 thapsigargin -0.751 3 -0.913 0.00116 0.0774 
7 apramycin 0.511 4 0.818 0.00195 0 
8 clemizole -0.539 5 -0.724 0.00344 0 
9 pipemidic acid 0.49 3 0.871 0.00391 0.0159 
10 diphemanil metilsulfate -0.247 5 -0.712 0.00425 0.014 
11 ionomycin -0.577 3 -0.868 0.00453 0.0246 
12 fluticasone -0.607 4 -0.783 0.00454 0.0191 
13 AR-A014418 0.438 3 0.849 0.00645 0.028 




E2 0.31 4 0.75 0.0076 0 
16 methoxamine -0.436 4 -0.749 0.0079 0.0258 
17 flumetasone -0.31 6 -0.627 0.00842 0.0198 
18 wortmannin 0.177 18 0.375 0.00859 0.3355 
19 simvastatin -0.469 4 -0.74 0.00891 0.0133 




Figure 22. Rapamycin has potent in vitro synergy with ABT-737.  
(A) Effect of single agent ABT-737 or rapamycin and fixed dose combinations on cell 
viability after a 72 h exposure in Bcl-2 high (NCI-H146 and NCI-H187) and Bcl-2 low 
(NCI-H82 and NCI-H446) SCLC cell lines; individual data points are shown +/- SD, n=6. 
(B) Changes in ABT-737 sensitivity in NCI-H146 and NCI-H187 pre-treated with 100 nM 
rapamycin for 24 (red) or 72 h (blue) before an overnight (~16 h) exposure to ABT-737; 
n=6 per data point. IC50 values are shown for control (black) and rapamycin (24 h – red; 
72 h – blue) pre-treatment traces.  
(C) ABT-737 and rapamycin dose combination-response output matrices for the Bcl-2 
low SCLC cell line NCI-H82 (above) and the Bcl-2 high SCLC cell line NCI-H146 
(below). Color gradient of percent maximal possible response is shown on right.  
(D) Fractional effect versus dose plot of ABT-737 and several mTOR (AZD8055, 
everolimus, rapamycin), PI3K (LY294002, wortmannin) and dual PI3K/mTOR (BEZ235) 
inhibitors in NCI-H146; data are representative of results obtained from multiple (>3) 
experiments.  
(E) Combination Index (CI) versus fractional effect plot (“synergy plot”) for NCI-H146 
treated with ABT-737 in combination with compounds described above. Levels of in vitro 
synergy are indicated using cutoffs described by others.   
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Figure 23. Rapamycin displays non-monotonic efficacy across a broad range of 
SCLC cell lines. 
(A) Normalized responses in 10 SCLC cell lines exposed to rapamycin for 72 h as 
measured by viability (black) or proliferation (red); n=6 per data point with error bars 
showing standard deviation from the mean. Rapamycin concentrations were between 
~150 picomolar and 10 micromolar. Synergy matrix outputs of proliferation measures in 
(B) NCI-H82 and  
(C) NCI-H146 exposed to dose combinations for 72 h. Top panels y-axes (left-to-right):  
AZD8055, BEZ235 and everolimus. Bottom panels y-axes (left-to-right):  LY294002 and 
wortmannin. ABT-737 dilution series in NCI-H82 began at 10 uM (1 uM for NCI-H146) 
and was diluted 2.5-fold, covering a ~243-fold concentration range. All compounds 
tested in combination with ABT-737 began at 10 uM and were diluted 5-fold, covering a 
~15,000-fold concentration range. Matrices of the paired 49 dose-combinations are 
scaled according to percent response, with a color gradient legend provided on the far 
right.  
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Rapamycin has combinatorial activity with ABT-737 in multiple SCLC PDX models 
We next assessed the combination of ABT-737 and rapamycin in the same PDXs 
where we observed acute resistance to ABT-737 – LX47 and LX48 – as well as in a 
SCLC PDX that does not express appreciable BCL-2 protein (LX33) that we previously 
reported had little response to ABT-737 (Hann et al., 2008). All PDX models examined 
express PI3K/mTOR pathway components and exhibit pathway activation as 
demonstrated by basal levels of phospho-Akt (S473), phospho-4E-BP1 (T37/46) and 
phospho-ribosomal protein S6 (S235/6) (Figure 24A). In both BCL-2 expressing PDXs, 
treatment with either ABT-737 or rapamycin caused significant TGI and the combination 
of ABT-737 and rapamycin caused fairly rapid tumor regressions. Importantly, these 
responses were sustained well beyond the 14-day treatment period, with no detectable 
tumor masses in LX47 PDXs for several weeks after combination treatment was 
discontinued, though tumors eventually returned (data not shown). Consistent with our 
previous report, treatment of LX33 PDXs with ABT-737 did not affect tumor growth. 
Treatment of LX33 with rapamycin resulted in TGI and the addition of ABT-737 to 
rapamycin caused a modest increase in TGI over rapamycin alone (Figure 25C). While 
this combined effect lost statistical significance after one week of treatment, these data 
suggests there was some degree of combinatorial activity in the absence of high BCL-2 
expression.  
Mice tolerated the combination well, with no apparent weight loss across all 3 
PDX models (Figure 24B). As both ABT-737 (Harper and Poole, 2012; Schoenwaelder 
et al., 2011) and rapamycin (Aslan et al., 2011) are known to affect platelets, we 
assessed hematologic measures in mice bearing LX47 after 7 days of treatment. Platelet 
counts in ABT-737 treated mice were significantly lower than those of vehicle-treated 
mice as expected; however, hematologic parameters from combination treated mice 
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were similar to vehicle and rapamycin alone (Figure 25D). All animals that received 
rapamycin were slightly anemic (Figure 24C). Histologically, tumors from mice treated 
with ABT-737 or combination exhibited greater necrosis than did vehicle or rapamycin 
treated tumors as evidenced by H&E sections showing increased eosinophilic regions 
throughout the tumor core (Figure 25E; ABT-737 H&E section). Pimonidazole staining of 
tumors from each treatment arm showed consistent, detectable hypoxic regions in all 
samples except tumors treated with combinatorial therapy. This striking difference was 
observed in multiple tumors treated with combination at early (after 3 days) and later 
(after 7 days) time points. Because this combination appeared to be well tolerated, we 
tested whether we could obtain similar tumor regressions in LX47 PDXs previously 
exposed to either ABT-737 or rapamycin. We observed tumor volume reductions of 
~50% with two weeks of ABT-737 and rapamycin that were sustained after treatment 




Figure 24. Combining rapamycin with ABT-737 (R+ABT) in vivo is well tolerated. 
(A) Western blots for protein expression of several components of the mTOR signaling 
pathway in cell lines or PDX models used in this study or previous studies. Mouse 
weights monitored while on single agent and combination treatment for PDX models  
(B) LX47, LX48 and LX33 as shown in Figure 22. Mice were weighed every 3 days 
before receiving treatment or more frequently if there were signs of distress. Treatment 
duration is indicated with a dashed line as in Figure 22; n=5-6 mice per arm. Effect of 
treatment arms on hematologic measures  
(C) in C.B-17 scid mice with LX47 hind flank tumors and treated for one week with 
indicated arms; n=5-6 per arm. The following abbreviations were used:  platelets (PLT), 
white blood cells (WBC), red blood cells (RBC), hemoglobin (HB), neutrophils (NE), 




Figure 25. Combining rapamycin with ABT-737 (R+ABT) provides durable 
responses in SCLC PDXs that express BCL-2.  
Tumor response curves to single agent ABT-737, rapamycin and combination in  
(A) LX47, 
(B) LX48,  
(C) and LX33 PDXs; n=5-6 mice per arm. Dashed lines indicate treatment periods (14 
days). Statistical comparisons of tumor volumes in combination treatment groups versus 
all other arms were performed at days 8, 15 and 22; where indicated, *p<0.01, 
**p<0.001.  
(D) Effect of treatment arm on platelets counts in whole blood obtained by cardiac 
puncture in C.B.-17 scid mice bearing LX47 hind flank tumors that were treated for one 
week with indicated arms; n=5 per arm. Blood was collected 24 hours after last dose. 
(E) Representative paired H&E and pimonidazole IHC from whole LX48 tumor capsule 
sections treated with indicated arms (y-axes) for 7 days; n=3-4 tumors were analyzed 
per arm. Tumors were collected 24 hours after final dose; scale bar is set to 3 mm.  
(F) Combination arm challenge in LX47 previously treated with single agent ABT-737 or 
rapamycin. LX47-bearing mice that were initially treated for 14 days with indicated single 
agents (dashed line) were subsequently treated at day 34; n=2 per previous treatment 
group. Combination treatments were performed for 14 days (solid orange line) and then 
tumor volumes were monitored for an additional week. Mice did not receive any 
treatment between days 15 and 32. Body weights were not significantly different while 
on combination treatment, nor did they differ by previous treatment arm. 
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Rapamycin induces expression of HIF-1α targets in SCLC PDXs 
To study the effects of rapamycin alone or in combination with ABT-737 on HIF-
1α targets, we compared protein and message expression in LX47 and LX33 PDXs after 
7 days of treatment. In LX33, there was a notable decrease in tumor levels of HIF-1α 
protein and several HIF-1α targets such as CXCR4, Glut1 and VEGF-A in ABT-737-
treated compared to vehicle-treated mice (Figure 26A). Treatment with rapamycin 
increased the protein levels of most targets examined; however, these changes were 
less evident in LX47. In LX47, but not LX33, combination treatment resulted in significant 
decreases in HIF-1α, HIF-1b, LDHA and CXCR4 levels. One reason for these 
observations may relate to differences in tumor response: combination-treated LX47 
tumors lose >70% of their starting volume by day 7, which may complicate analysis of 
protein samples. 
Correlating these findings with transcriptional profiling data, we observed 
decreased levels of six HIF-1α regulate genes in LX47 after treatment with ABT-737 
(Figure 26B); this effect was less pronounced in LX33, but nonetheless, observed for 
most genes. Interestingly, rapamycin increased transcript levels of all highlighted genes. 
In the combination arm, levels of nearly all transcripts were less than vehicle controls, 
and in some cases (i.e. VEGF-A in LX33) lower than ABT-737 treated groups.  
While this paired analysis of changes highlighted several similarities in the few 
targets examined, we sought to better understand whether there was a more general 
transcriptional response to ABT-737. This led us to examine the overall concordance 
between gene expression changes observed in LX33 and LX47 in response to ABT-737, 
as treatment influenced protein and transcript levels in these SCLC PDXs independent 
of BCL-2 expression. We generated a concordance at the top (CAT) plot to compare 
drug treatment effects in each model (Irizarry et al., 2005). This plot relates the 
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concordance between the top differentially expressed gene lists of n length for each 
model compared to what would be expected by chance. The ABT-737 treatment 
signature was more concordant than rapamycin alone, combination treatment, or what 
would be expected by chance (Figure 26C). These results were surprising, as we 
anticipated that there would have been a more pronounced concordance between 
models treated with rapamycin than ABT-737, as the effects on HIF-1α regulated genes 
were similar in the rapamycin-treated groups as compared to the ABT-737-treated 
groups. One potential explanation could be that this ranked approach does not account 
for the magnitude of gene expression differences, nor does it weigh p values for each 
comparison.  
The differences observed prompted further investigation into how the mTOR 
pathway was affected in these two models. In LX33, treatment with ABT-737 decreased 
protein levels of several mTOR components, including near complete loss of GβL by 
western blot (Figure 26D). This may reflect the extent to which the mTOR pathway is 
influenced by HIF-1α in this PDX model, as we observed a similar loss of HIF-1α and 
HIF-1β/ARNT in LX33. In both PDXs, treatment with rapamycin – alone or in 
combination with ABT-737 – decreased levels of phospho-Akt (S473) versus the vehicle 
controls; this effect was most pronounced for the combination treatment in LX33. While 
we observed mTOR inhibition at the level of Akt, the levels of phospho-ribosomal protein 
S6 differed between rapamycin-treated groups, but were similar between combination 
treatment groups. This difference may reflect the degree of Akt feedback that is present 
when treating with rapamycin alone or in combination with ABT-737 (O'Reilly et al., 
2006). Indeed, levels of phospho-Akt (T308) in LX47 treated with rapamycin appear to 




Figure 26. R+ABT differentially affects HIF-1α regulated genes and the mTOR 
pathway in LX33 and LX47.  
(A) Western blot for protein expression of select HIF-1α regulated genes implicated from 
Figure 1 in PDX models LX33 and LX47 after one week of treatment; n=3-4 mice per 
arm with duplicates reflecting the extent of variability within a group. β-actin provided for 
loading control.  
(B) Select gene expression fold changes (y-axis) between treatment arms in LX33 and 
LX47 treated as above; n=3 mice per arm.  
(C) Concordance at the top (CAT) plot shows that a common set of genes are 
differentially expressed in LX33 and LX47 in response to ABT-737 after one week of 
treatment.  
(D) Western blot for select protein expression in the PI3K/mTOR pathway in PDX 
models LX33 and LX47 after one week of treatment.  
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Rapamycin blocks ABT-737 induced decrease in BAX protein levels in SCLC 
 In parallel, we looked at protein expression of candidate BCL-2 family members 
in LX33 and LX47 PDXs at day 7 by western blot. We did not observe consistent 
changes in protein levels of previously reported determinants of ABT-737 sensitivity 
(MCL-1 or pro-apoptotic proteins Puma and Noxa) that correlated with response in our 
PDXs models. However, we did observe that the pro-apoptotic proteins BAX and BAK 
were increased in both PDXs treated with rapamycin alone or in combination with ABT-
737 (Figure 27A).  
As ABT-737 is known to cause programmed cell death in a BAX/BAK-dependent 
manner, and BAX is a key pro-apoptotic binding partner of BCL-2 (van Delft et al.), we 
assessed the effect of ABT-737 or rapamycin on BAX protein levels in vivo. For these 
analyses we selected LX33 that allowed for more control in size matching tumor volumes 
across treatment groups. We treated mice bearing LX33 for 7 days with vehicle, 
escalating doses of ABT-737 (5, 25 and 100 mg/kg), escalating doses of rapamycin (1, 
5, and 20 mg/kg) or the combination of the highest doses of each agent. We observed a 
modest, but dose-dependent decrease in BAX protein from tumors treated with ABT-737 
and an overall increase in BAX protein in tumors treated with rapamycin (Figure 27B). 
This change was also observed in heavy membranes isolated from tumors, enriching for 
mitochondria. Although we had small numbers of mice per dose-escalation group, we 
noted that all rapamycin doses caused TGI to a similar degree, consistent with our in 
vitro data (Figure 28A). We also observed an increase in the anti-apoptotic proteins Bcl-
xL and Bcl-w with increasing doses of rapamycin (Figure 27B). Levels of MCL-1 protein 
were not significantly decreased by rapamycin in vivo, where MCL-1 levels were actually 
greater in combination-treated tumors (Figure 28B). Furthermore, ABT-737 caused a 
dose-dependent decrease in HIF-1β/ARNT (Figure 28C). We also found that in SCLC 
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cell lines, exposure to rapamycin was associated with an increase in the amount of BAX 
present in the heavy membrane fraction of cells, most prominent in NCI-H146 (Figure 
27C). This increase in BAX occurred without an apparent release of cytochrome C into 
the cytosol, suggesting that an increase in membrane-associated BAX in these lines was 
not by itself associated with greater programmed cell death, but that multiple 
mechanisms may be at play for the combined effect of rapamycin and ABT-737.  
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Figure 27. Rapamycin increases levels of BAX protein in vitro and in vivo in SCLC. 
(A) Protein expression of selected Bcl-2 family members in LX33 and LX47 in response 
to one week of treatment with respective arms; n=3-4 mice per arm with duplicates 
reflecting the extent of variability within a group. β-actin provided for loading control.  
(B) Dose-dependent effects of ABT-737 and rapamycin on candidate Bcl-2 family 
members in LX33 PDXs after one week of daily treatment; n=3-4 mice per dosing 
interval arm with duplicates reflecting variability as above; SDHA (complex ii) provided 
as a loading control for membrane-enriched fractions.  
(C) Cell fractionation experiments in NCI-H146 and NCI-H82 exposed to 100 nM 
rapamycin (+100 nM R) for 24 – 72 h (1d – 3d in Figure). Whole cell lysates and vehicle 
control lanes were exposed to vehicle (DMSO) for 72 h before collecting protein; 2.5 μg 
total protein was loaded per lane.  
(D) Schematic representation of combined rapamycin and ABT-737 effect in SCLC PDX 




Figure 28. ABT-737 treatment in vivo leads to destruction of ARNT. 
(A) Relative tumor volume fold increase by treatment arm after one week of treatment in 
LX33. Fold changes are shown because starting tumor volumes were variable (150-600 
mm3); however, variability was represented in each group. Doses are indicated on the x-
axis with n=3-5 per dose grouping; dashed line at y=1 provides a reference for tumor 
growth (+) or reduction (-) from starting volume.  
(B) Change in cleaved PARP and MCL-1 protein levels as a function of rapamycin 
treatment dose and with combination of ABT-737 in LX33 after one week of treatment; β-
actin shown as a loading control.  
(C) Change in HIF-1α and it’s cytosolic chaperone HIF-1β/ARNT as a function of ABT-
737 treatment dose in LX33.  
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Discussion 
 Here we report that the BH3 mimetic ABT-737 has limited single-agent efficacy in 
BCL-2 expressing SCLC PDXs, consistent with the modest clinical activity of ABT-263 
observed in patients with recurrent SCLC. Using PDX models as a platform to study 
ABT-737 resistance, we found that acute treatment with ABT-737 was associated with a 
decrease in many HIF-1α regulated transcripts. Rapamycin effectively blocked this 
decrease and increased message and protein levels of many of these genes. Combining 
rapamycin with ABT-737 was highly synergistic in vitro and provided durable tumor 
regressions in BCL-2 expressing PDX models in vivo. We observed a decrease in BAX 
protein levels upon exposure to ABT-737 that was prevented by rapamycin. As BAX 
protein levels are regulated by hypoxia through HIF-1α dependent and independent 
mechanisms (Erler et al., 2004), we were surprised to see changes in BAX levels upon 
exposure to ABT-737 or rapamycin were not associated with observable changes in 
physiological hypoxia in tumors as compared to controls. This may in part be due to the 
basal levels of hypoxia in these SCLC PDX models, as heterogeneity within a given PDX 
may complicate mechanistic analysis. 
Loss of BAX is a known mechanism of resistance to several classes of anti-
cancer agents (Sarosiek et al., 2013; Zhang et al., 2000) and can promote tumorigenesis 
in certain models (Yin et al., 1997). In human cancers, loss of BAX through mutation 
(Rampino et al., 1997) or regulation of protein stability (Agrawal et al., 2008) is 
associated with events promoting tumor development and correlates with poor 
prognosis. Here, the observed changes in BAX protein after rapamycin exposure align 
well with known mechanisms by which ABT-737 induces apoptosis and with studies of 
genetic determinants of ABT-737 lethality (Carette et al., 2011; Oltersdorf et al., 2005). 
The most straightforward interpretation of these data is that acute treatment with ABT-
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737 is self-limiting in nature, possibly through global decreases in critical HIF-1α 
regulated transcripts and the pro-apoptotic protein BAX, both of which are effectively 
rescued or restored upon the addition of rapamycin (Figure 27D). However, multiple 
mechanisms are likely involved, warranting further investigation.  
Of clinical relevance, the LX47 and LX48 PDXs were derived from 
chemotherapy-naïve and recurrent SCLC patient tumors, respectively; thus, the 
combination of ABT-737 and rapamycin was active independent of prior chemotherapy 
exposure and sensitivity to etoposide in our models. The observations made here have 
clear implications for clinical trials in patients with SCLC. The efficacy of single agent 
ABT-737 or its orally bioavailable derivative ABT-263 is limited, both in PDX models and 
in SCLC patients. Previous efforts to combine ABT-263 with cytotoxic chemotherapy in 
SCLC patients were stopped due to unacceptable levels of hematologic suppression. 
The combination of ABT-737 with rapamycin results in sustained anti-tumor activity in 
PDX models, without significant hematologic toxicity or weight loss, and in fact, the 
thrombocytopenia of single agent ABT-737 was abrogated in the presence of rapamycin. 
The mechanisms responsible for this potent combinatorial activity may include 
maintained tumor expression of BAX, a key regulator of apoptotic induction. These data 
strongly support assessment of combined targeted inhibition of BCL-2 and mTOR 
pathway in patients with SCLC.  
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Chapter 4. Allosteric or Kinase Inhibition of mTOR is Therapeutically Non-inferior 




  A recent report suggested that combining the BCL-2/xL inhibitor ABT-263 with 
the mTOR kinase inhibitor AZD8055 was capable of producing therapeutic responses in 
SCLC models, independent of BCL-2 status. These data furthered a hypothesis that we 
previously, directly rejected based on evidence presented combining ABT-737 with 
various classes of mTOR allosteric or kinase inhibitors in vitro (Figure 29). Moreover, as 
these therapeutic concepts approach clinical testing, it is important to define which SCLC 
patients are likely to benefit from such therapeutic approaches, as well as define 
appropriate treatment schedules, biomarkers of response, expected toxicities and 
mechanisms of acquired resistance to such combinatorial therapies. The experimental 
study that follows provides a comprehensive overview of the inferiority of selectively 
targeting BCL-2 alone (Venetoclax; ABT-199) in SCLC, as well as the non-inferiority of 
combining the dual BCL-2/xL inhibitor with an allosteric (“rapalog”) or kinase-directed 
mTOR inhibitor in preclinical models of SCLC, arguing that loss of BAX will confer 
resistance to single agent ABT-263 or in combination with mTOR inhibitors.  
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Figure 29. Allosteric versus kinase domain mTOR inhibitory small molecules.  
The central difference between the rapalogs (inset top) and the first-in-class mTOR 
kinase inhibitors (bottom) is in their unique mechanism of action. Where the rapalogs 
bind to FKBP12, forming a complex that binds to the TOR FRB domain, the kinase 
domain targeting generation of mTOR inhibitors bind at the TOR kinase domain and 
compete with ATP or allosterically modulate the kinase function. Commonly reported 
side effects with the rapalogs are listed. While data are still emerging from on-going 
early phase clinical trials, reported toxicities for the mTOR kinase inhibitory AZD8055 are 
shown (Asahina et al., 2013; Naing et al., 2012).  
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The Mechanistic Target of Rapamycin (mTOR) Pathway and Therapeutic Targeting 
The mechanistic target of rapamycin (mTOR) pathway has been one of the most 
extensively analyzed eukaryotic growth regulatory programs, and appears to function as 
a critical rheostat for anabolic and catabolic cellular processes. Rapamycin is a 
macrolide antibiotic that was discovered from Streptomyces hygroscopicus isolates from 
Rapa Nui (Easter Island) and was originally characterized as having broad antifungal 
activity (Sehgal et al., 1975; Vezina et al., 1975). The molecular targets of rapamycin in 
yeast, products of the yeast TOR1 and TOR2 genes, were initially identified through 
mutant screens for resistance (Cafferkey et al., 1993; Kunz et al., 1993; Sabatini et al., 
1994). Subsequent work by multiple groups identified the homologous putative 
mammalian target, the atypical serine/threonine protein kinase mTOR. It is now known 
that rapamycin indirectly inhibits mTOR through physically binding to FK506 binding 
protein 12 (FKBP12), and that this complex associates with the FKBP12-rapamycin 
binding (FRB) domain of mTOR to inhibit its kinase function (Yang et al., 2013; Yip et al., 
2010). Moreover, while there is only a single mammalian TOR gene, its protein product 
participates in two distinct complexes – termed mTORC1 and mTORC2 – with unique 
functions and differential sensitivity to inhibition by rapamycin. 
 The mTORC1 complex is perhaps best known for its ubiquitous roles in 
regulating growth and proliferation, integrating cellular environmental cues from at least 
five distinct classes of input, including amino acids, soluble growth factors, ATP levels, 
hypoxia, and stress pathway activation (Laplante and Sabatini, 2012). The tuberous 
sclerosis 1 and 2 (TSC1/2) protein complex negatively regulates mTORC1, serving as a 
GTPase-activating protein complex (GAP) for the Ras homolog enriched in brain (Rheb) 
GTPase.  TSC1/2 stimulates the GTP hydrolysis activity of Rheb to decrease the kinase 
activity of mTOR (Inoki et al., 2003). Not surprisingly, germline mutations in TSC1 or 
TSC2 lead to tumor-prone syndromes (Inoki et al., 2005; Ma et al., 2005). Several 
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upstream kinases belonging to the phosphoinositide 3-kinase (PI3K) and Ras signaling 
pathways, such as protein kinase B (PKB/Akt) and extracellular-signal-regulated kinase 
(ERK1/2), respectively, negatively regulate the TSC1/2 complex through direct 
phosphorylation (Inoki et al., 2002; Manning et al., 2002). Interestingly, while TSC1/2 
can function directly to integrate the majority of cellular cues described above, it cannot 
sense amino acid levels, and mTORC1 cannot be activated by any cues in the absence 
of certain amino acids (Hara et al., 1998; Smith et al., 2005). The sensing of amino acids 
is achieved at the level of the lysosomal surface where accumulating amino acids within 
the lumen of the lysosome affect the vacuolar H+- ATPase (v-ATPase) to then interact 
with a protein complex termed Ragulator. Ragulator provides a docking site for the 
family of Rag GTPases that serves to directly activate membrane localized Rheb and 
trafficked mTORC1 on the lysosomal surface (Kim et al., 2008; Sancak et al., 2010; 
Sancak et al., 2008; Zoncu et al., 2011). What emerges from such complex signaling 
interactions are controlled scenarios in which mTORC1 can only be activated when at 
the lysosomal surface in the presence of sufficient free amino acids. Moreover, various 
feedback loops are likely built into such a system as the expression of the v-ATPase 
appears to be under control of mTORC1-dependent signaling, and deletion of the v-
ATPase inhibits mTORC1 signaling (Duvel et al., 2010; Pena-Llopis et al., 2011). 
Recently, molecular sensing of arginine was discovered to be a highly regulated process 
upstream of mTORC1 involving a protein complex termed the Cellular Arginine Sensor 
for mTORC1 (CASTOR1). CASTOR1 directly binds arginine and releases another 
bound protein complex termed GATOR2 to positively regulate mTORC1 activity (Saxton 
et al., 2016). Providing another level of control is Sestrin2 that functions downstream of 
AMPK to negatively regulate GATOR2 function, inhibiting mTORC1-dependent amino 
acid sensing (Chantranupong et al., 2014; Kim et al., 2015a; Parmigiani et al., 2014). 
While the interactions between GATOR1 and GATOR2 are still being worked out, it is 
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clear that GATOR1 functions as a GTPase activating protein (GAP) for the GTPases 
RagA and RagB, thus negatively regulating mTORC1 activity. Consistent with this 
observation, somatic mutations in GATOR1 in certain human cancers drive mTORC1 
hyperactivity (Bar-Peled et al., 2013). 
 Upon activation, mTORC1 phosphorylates key regulators in protein synthesis, 
including the eukaryotic initiation factor 4E binding proteins (4E-BPs) and the p70 
ribosomal S6 kinase 1 (S6K1), and it is the coordination of these events that lead to 
successful proliferation and growth (Dowling et al., 2010; Richter and Sonenberg, 2005).  
The translational program that activation of mTORC1 initiates appears to show 
preference for transcripts with 5’ terminal oligopyrimidine (TOP) motifs (Thoreen et al., 
2012). Akin to cancer reprogramming of basal metabolism, activation of mTORC1 leads 
to a similar metabolic focus on biomass accumulation. 
 Relative to mTORC1, the more recently described mTORC2 has fewer known 
functions, with early evidence focusing on Rho- and Rac-dependent remodeling of the 
cytoskeleton and regulation of certain members of the AGC family of kinases. In the 
acute setting, mTORC2 is not directly inhibited by the rapamycin-FKBP12 complex; 
however, it is now well established that long-term treatment with rapamycin will inhibit 
mTORC2 (Jacinto et al., 2004; Lamming et al., 2012; Sarbassov et al., 2004).  
Additionally, the function of mTORC2 in insulin signaling has been shown to act through 
a PI3K-dependent interaction with the ribosome, which may posit a critical role for 
mTORC2 in translational control (Zinzalla et al., 2011). Interestingly, no GTPase has 
been described to directly regulate mTORC2 activity (unlike Rheb for mTORC1), further 
limiting current understanding of mTORC2’s role in the eukaryotic growth program. One 
of the direct targets of mTORC2 is the serine/threonine kinase Akt at position Ser473. As 
Akt is fully activated when phosphorylated at Thr308 and Ser473, it became apparent 
that one caveat to chronic rapamycin exposure, even in the presence of modest 
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mTORC2 inhibition, may be that the resulting activation of Akt can promote what initially 
appeared to be a paradoxical activation of available mTORC1 (Peterson et al., 2009; 
Sarbassov et al., 2005). 
 Within cancers, some of the most common oncogenic mutations and tumor 
suppressor losses converge to activate the mTOR pathway, directly and indirectly.  For 
example, PTEN is commonly lost in solid tumors thereby removing some of the feedback 
regulation on PI3K signaling, leading to constitutively activated Akt (Vivanco and 
Sawyers, 2002). Focal amplifications of genes encoding PI3K and Akt as well as 
activating mutations within the p110α catalytic domain of PI3K are also observed and 
confer similar growth advantages. Similarly, mutations within STK11/LKB1 have been 
shown to occur in lung adenocarcinomas, resulting in a mutant Lkb1 that is no longer 
able to activate the family of adenosine monophosphate-activate protein kinases 
(AMPKs) that serve to negatively regulate the action of TSC1/2 on mTOR (Ji et al., 
2007; Levine et al., 2005). Although influenced by multiple complex feedback loops, the 
role of mTOR in cancer is becoming clear – the ability for eukaryotic cells to respond and 
adapt to changes in bioenergetic stimuli involves many levels of regulation that ultimately 
converge on regulation of the mTOR signaling pathway. 
  As accumulating evidence pointed to mTOR as a critical integrator of cancer 
bioenergetics, multiple research groups began simultaneously developing small 
molecule inhibitors of this pathway. Rapamycin (also known as sirolimus) was first 
clinically approved as an inhibitor of transplant rejection due to its ability to suppress 
cytotoxic T cell proliferation, and serves as the founding member of a family of 
structurally related compounds collectively termed “rapalogs.” Sirolimus itself in fact 
does appear to have anticancer activity, but has been less extensively studied in cancer 
patients than its several derivatives, in part due to economic disincentives associated 
with its patent life, and in part due to low and variable oral bioavailability (Dabora et al., 
 140 
2011). Three rapalogs – temsirolimus, everolimus, and ridaforolimus – have been the 
primary focus of clinical drug development in oncology. 
Temsirolimus was the first mTOR inhibitor to be FDA-approved for use in cancer, 
based on its superiority to a prior standard of care (interferon) in patients with advanced 
kidney cancer (Hudes et al., 2007). Everolimus approval followed shortly thereafter, 
initially also for metastatic kidney cancer, and subsequently for a subset of pediatric 
astrocytomas associated with mutations in TSC genes, and for pancreatic 
neuroendocrine tumors (Krueger et al., 2010; Motzer et al., 2008). Temsirolimus also 
gained a secondary approval in Europe for treatment of mantle cell lymphoma.  
Ridaforolimus, the newest of this class of drugs, while showing evidence of activity in 
soft tissue sarcoma and other diseases, has not yet gained regulatory approval (Chawla 
et al., 2012; Hess et al., 2009). 
While demonstrating some clinically relevant anti-cancer efficacy, the magnitude 
of benefit provided by the rapalog agents is limited (e.g. for temsirolimus in renal cell 
carcinoma, 3.6 month improvement in median survival, and response rate 8.6%), and 
the initially hypothesized broad spectrum activity against most common cancers has not 
held up. There are several possible mechanisms of rapalog resistance, including but not 
limited to incomplete inhibition of the mTORC1 complex, and induction of the mTORC2 
feedback loop activating Akt. These agents can be difficult to give in the clinic due to a 
spectrum of toxicities that appear largely as a class effect, including mucositis, 
maculopapular or acneform rash, nail changes, relatively rare, but sometimes severe 
pneumonitis, and metabolic derangements including hyperglycemia, hyperlipidemia, and 
hypophosphatemia (Soefje et al., 2011). 
To address some of the perceived weaknesses of the rapalogs, notably the 
possibility of insufficient suppression of mTORC2-dependent feedback loops, a newer 
generation of ATP-competitive mTOR small molecule inhibitors is now in active clinical 
 141 
development. By inhibiting the kinase activity of mTOR itself, these inhibitors have 
similar high potency against both mTORC1 and mTORC2; some also inhibit the 
homologous kinase domain of PIK3CA, the catalytic domain of PI3 Kinase responsible 
for Akt activation. This has rapidly become a crowded field, with at least eight dual 
mTOR/PI3K inhibitors and five pan-mTOR inhibitors from 11 pharmaceutical companies 
in active clinical trials, and several more in late preclinical testing. For most of these, 
definitive clinical reports on either toxicity or efficacy are not yet available. 
For both the rapamycin derivatives and the mTOR kinase inhibitors, a particularly 
active area of clinical research now focuses on drug-drug combinations (Benjamin et al., 
2011). Therapeutic strategies being actively investigated include concurrent inhibition of 
multiple levels of the mTOR signaling pathway, with the idea of interrupting feedback 
loops leading to resistance, concurrent inhibition of parallel critical pathways such as the 
PI3K/mTOR and RAS/RAF/ERK signaling cascades, and combinations with standard 




Changes in expression of core anti-apoptotic BCL-2 family members are not correlated 
with acquired resistance to cisplatin/etoposide in SCLC 
 To begin to address whether specific genomic amplifications or transcriptional 
increases in anti-apoptotic BCL-2 family members drive acquired resistance to 
cisplatin/etoposide, we compared RNA expression by from paired RNA sequencing data 
for several core BCL-2 family members, thought to be critical mediators of resistance to 
apoptosis in both hematologic and solid tumors (Beroukhim et al., 2010). From triplicate 
tumor samples in the chemosensitive setting across 10 unique PDX models, we found 
no correlation between best response of the tumor to cisplatin/etoposide and expression 
of BCL2, BCL2L1, MCL1 or the pro-apoptotic effector BCL2L11 (Figures 30A-D). 
Further, we analyzed paired chemosensitive and chemoresistant triplicates for these 10 
models in aggregate and were unable to show statistically significant difference in the 
expression of these BCL-2 family members (Figure 30E). These data suggest that gene 
expression alone of BCL-2 (BCL2), BCL-xL (BCL2L1) and/or MCL-1 (MCL1), are not 
indicative of de novo chemoresistance as individual correlates in SCLC in vivo. While 
speculative, previous reports suggesting evidence that BCL-2 permits chemoresistance 
in SCLC may rather reflect artifact in cell lines and underpowered correlative studies, 
without functional interrogation. Moreover, while there is evidence that genes involved in 
the execution of programmed cell death are frequently silenced in NSCLC and SCLC, 
such as caspase-8 (CASP8) and TRAIL (Hopkins-Donaldson et al., 2003; Kaminskyy et 
al., 2011; Shivapurkar et al., 2002; Venturelli et al., 2013), there is no reported evidence 




Figure 30. Expression of core anti-apoptotic BCL-2 family members does not 
correlate with response to cisplatin and etoposide.  
(A) Response data for 5 animals per PDX were compared to vehicle controls at last 
available point on study (before vehicle hit endpoint of ~1000mm3). 100% tumor growth 
inhibition (TGI) is considered a complete response of hind flank tumor. Treatment 
responses were compared to average log2 counts per million (CPM) transcript 
expression of various BCL-2 family members by RNAseq, including BCL2 
(B) BCL2L1 (BCL-xL), 
(C) MCL1, 
(D) and pro-apoptotic BCL2L11 (BIM). Linear regression best fit values for goodness of 
fit (R2) and slope are reported for each transcript investigated. Averages of triplicate log2 
CPM measures were used for 5 independent tumor responses per PDX. 
(E) Changes in expression were compared between PDX models in the naïve and 
chemoresistant setting, as in Figure 4. Differences in aggregated between models were 
not significant; p-value reported for paired t-test comparison in BCL2 expression 
between naïve and resistance groups. 
  






















































































































BCL-2 specific inhibition by ABT-199 is inferior to BCL-2/xL inhibition by ABT-263 as a 
single agent or in combination with mTOR inhibitor. 
 With ample evidence for a high frequency genomic amplification of BCL-2 in 
SCLC cell lines and high level protein expression in primary SCLC (Ben-Ezra et al., 
1994; Breton et al., 1998; Byers et al., 2012; Ikegaki et al., 1994; Jiang et al., 1995; 
Sirzen et al., 1998; Takayama et al., 1996; Wang et al., 1998), it was reasonable to 
hypothesize that SCLC may be sensitive to BCL-2 specific inhibition by the small 
molecule ABT-199 (Souers et al., 2013). Further, emerging evidence suggested 
preclinical activity was not limited to hematologic malignancies alone (Vaillant et al., 
2013). We determined the relative activity of ABT-199 versus ABT-263 in a panel of 15 
SCLC cell lines, including those that had previously been characterized by other groups 
as being extremely sensitive to ABT-263/737 (Faber et al., 2015; Lin et al., 2007; 
Olejniczak et al., 2007; Shoemaker et al., 2008; Tahir et al., 2010). With the exception of 
one cell line – NCI-H889 known to have an amplification of BCL2 with an average copy 
number ~5 – all SCLC cell lines displayed an increased sensitivity to ABT-263 when 
compared to ABT-199 (Figure 32A). Moreover, when considering these agents are 
being proposed to be used in combination with other classes of mTOR inhibitors, we 
examined whether a pre-treatment period with a low dose of everolimus (1-10nM) was 
effectively sensitizing certain cell lines to BCL-2 or BCL-xL specific inhibition, through the 
use of the chemical tool WEHI-539, shown to be have ~1000X specificity for BCL-xL 
over other closely-related BCL-2 family members (Lessene et al., 2013). Interestingly, 
we observed differences in class specific sensitivity, such that one cell line (NCI-H146; 
Figure 32B) was more sensitive to BCL-xL inhibition versus BCL-2 inhibition, whereas 
another cell line (NCI-H187; Figure 32C) was more sensitive to BCL-2 versus BCL-xL-
specific inhibition. This was independent of dramatic differences in expression of core 
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anti-apoptotic proteins (Figure 32D). These data are important because they suggest 
certain pro-apoptotic BCL-2 family members are being parsed or “shuttled” from 
different, restraining anti-apoptotic proteins under the stress cells experience from low 
level inhibition of mTOR (Leverson, 2016). Therefore, a class-specific inhibitor, even if 
better tolerated clinically, may lose efficacy over time by a tumor repositioning binding 
partners for pro-apoptotic proteins. This is clearly demonstrated by the amount of 
evidence suggesting that MCL-1, an anti-apoptotic protein not targeted by ABT-263, is a 
candidate acquired resistance mechanism (Brumatti and Ekert, 2013; Punnoose et al., 
2016). We further show the superiority of combining ABT-263 with either an allosteric or 





Figure 32. Combined inhibition of BCL-2/xL with ABT-263 is superior to ABT-199 
in multiple in vitro models of SCLC. 
(A) IC50 values for ABT-199 and ABT-263 (red) reported from 72hr cell proliferation 
assays in multiple human or mouse SCLC cell lines. The human fibroblast WI-38 serves 
as a negative control and general indicator of compound pan-toxicity. 
(B) SCLC cell lines expressing both BCL-2 and BCL-xL are differentially sensitive to 
specific inhibitors of BCL-2 or BCL-xL as compared to the dual inhibitor ABT-263. In the 
above panels, IC50 cell viability curves for NCI-H146 (left)  
(C) or NCI-H187 (right) for the dual inhibitor ABT-263 (red line), BCL-xL inhibitor WEHI-
539 (magenta line) or BCL-2 inhibitor ABT-199 (blue line). Below: 72hrs pre-treatment 
with 10nM of the mTOR allosteric inhibitor everolimus differentially “primes” BCL-2 or 
BCL-xL, but is not easily observed with the dual inhibitor ABT-263. Largest individual 
effect highlighted by a red box. 
(D) Protein expression by Western blot for various ABT-263 or ABT-199 protein targets 
across a select group of human SCLC cell lines. A737RS in red is the isogenic NCI-
H146 cell line that has acquired resistance to ABT-737/263 via continuous in vitro 




Figure 33. Inhibition of mTOR with an allosteric or kinase inhibitor is superior in 
combination with ABT-263 versus ABT-199 in vitro. 
Combinatorial inhibition (synergy) plots versus highest single agent effect (HSA) for two 
BCL-2 expressing SCLC cell lines, NCI-H187 and NCI-H211. Dose range for the 
allosteric mTOR inhibitor everolimus and kinase inhibitor GDC-0980 ranges from 1000-
0.064nM; dose range for the BCL-2 selective ABT-199 or BCL-2/xL inhibitor ABT-263 
range from 10,000-0.64nM. On far right, synergy of BCL-2/xL inhibition with proteasome 
inhibition by carfilzomib. While highly active in vitro, the combination proved too toxic to 
explore preclinical efficacy (data not shown). Color-coded effect scale bar on right. 
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Loss of BAX permits resistance to BCL-2/xL inhibition as a single agent or in 
combination with mTOR inhibitors, but does not alter sensitivity to cytotoxic 
chemotherapy. 
 To address potential mechanisms of resistance to BCL-2/xL inhibition in vitro we 
chose to continuously culture one of the most sensitive SCLC cell lines, NCI-H146, 
under escalating doses of ABT-737. After approximately 6 month in culture, this isogenic 
cell line was robustly resistant to ABT-737 upon acute challenges (Figure 34A). When 
examining the protein expression of core pro- and anti-apoptotic proteins at the level of 
whole cell lysates and within mitochondrial membrane fractions, it was clear that 
although there were increases in MCL-1, BAX was completely lost in this cell line, which 
we confirmed by qPCR (Figure 34B; data not shown). This ABT-737 acquired resistant 
version of NCI-H146 (“A737R”) did not display differing growth kinetics in culture or in 
vivo when xenografted into the lungs or hind flanks of immunocompomised mice 
(Figures 34C-E), suggesting that a core phenotypic difference may be in programmed 
cell death response.  
 To determine the relative roles of the pro-apoptotic proteins BAK1 and BAX in 
affecting the sensitivity to ABT-737 in NCI-H146, we infected cell lines with lentiviruses 
expressing shRNAs against these genes, as well as a negative control. The stable cell 
lines were then challenged with ABT-737, and we noted that only complete suppression 
of BAX, but not BAK1, was capable of reducing the sensitivity of NCI-H146 to levels of 
that observed in the A737R line (Figures 35A-B). Further, when we compared the 
activity of a variety of combinations of mTOR inhibitors with ABT-263 versus that of 
cisplatin and etoposide, any drug combination containing the pro-apoptotic ABT-199 or 
ABT-263 was greatly reduced in the A737R cell line; however, the combined activity of 
cisplatin and etoposide was only marginally reduced in the A737R line (Figures 35C-D). 
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Taken together, these data suggest that loss of BAX can confer resistance to ABT-263 
alone or in combination with mTOR inhibitors, but does not greatly affect sensitivity to 




Figure 34. Acquired resistance to ABT-263/737 proceeds through the loss of BAX 
in SCLC. 
(A) Isogenic NCI-H146-A737R (red trace) cell line is highly resistant to ABT-737 in vitro 
(B) Isolation of crude mitochondria in paired parental and ABT-737-resistant versions of 
NCI-H146. WCL=whole cell lysate, cyto=cytoplasmic fraction, mito=crude mitochondrial 
fraction using a QProteome™ mitochondria isolation kit (Qiagen) 
(C) Acquired resistance to ABT-737 in vitro does not alter proliferation kinetics, but does 
change response to media exhaustion; 96 well plates were innoculated with 1,000-
10,000 cells per well and metabolic turnover of AlamarBlue was measured overtime 
(D) NCI-H146-A737R cell line does not show differences in growth kinetics in vivo when 
engrafted into the pleural space (orthotopic) or as a hind flank tumor in athymic mice. 
(E) Quantitation of luciferase signal flux from parental or A737R hind flank tumors at 5 
weeks post-engraftment of equivalent cell number per mouse. 5 animals were engrafted 
with 1*106 cells per flank per cell line (10 data points per cell line); groups are not 




Figure 35. Suppression of BAX – but not BAK – is sufficient to confer resistance 
to BCL-2/xL inhibition, but not cisplatin+etoposide. 
(A) Shift in IC50 cell viability curves for NCI-H146 with shRNAs against the pro-apoptotic 
proteins BAK1 or BAX, with an shRNA directed against LacZ as a negative control. Two 
independent shRNA sequences were used per target. A737R cell line included as a 
positive control/comparator. 
(B) Protein expression by Western blot of BAK1 and BAX from shRNA knockdown cell 
lines used in A 
(C) Combinatorial effect of ABT-199 or ABT-263 in combination with everolimus or GDC-
0980 is altered in NCI-H146-A737R cell line. Data falling above the trend line (slope=1) 
would indicate greater activity in the A737R cell lines (y-axis), whereas data falling below 
the trend line indicates greater activity in the parental cell line NCI-H146 (x-axis). 
(D) Example combinatorial response data sets for cisplatin+etoposide (left) or ABT-




Acute treatment with mTOR inhibitors does not strongly “prime” SCLC tumors for 
programmed cell death by ABT-263 
 One of the first observations for a differential apoptotic threshold in certain cell 
types came from the work of Anthony Letai in the lab of Stanley Korsmeyer. This work 
led to the development of methods focused on exploiting BH3 peptide binding affinities in 
ex vivo assays using whole cells or isolated mitochondria to determine relative ability to 
release cytochrome c upon manipulation of specific BCL-2 protein-protein interactions 
(Certo et al., 2006; Letai et al., 2002). Since then, these methods have progressed and 
been important in helping rationalize the relative sensitivity of certain tumor types, or 
populations of cells within a singular tumor type, to the activity of apoptotic stimuli 
(Chonghaile et al., 2014; Montero et al., 2015; Ni Chonghaile et al., 2011; Vo et al., 
2012), and have been critical in the validation of certain pro-apoptotic compounds, such 
as ABT-737 (Oltersdorf et al., 2005).  
An early observation in comparisons across tumor types was that certain SCLC 
cell lines were exquisitely sensitive to the pro-apoptotic effects of ABT-737, leading to 
clinical testing in a subset of relapsed SCLC. However, these efficacy data in SCLC were 
disappointing and safety was of a concern with all agent within this proposed class, 
leading our group to investigate why SCLC may not be as sensitive to ABT-737 in vivo, 
as was observed in vitro and in cell line xenografts (Gandhi et al., 2011; Hann et al., 
2008; Rudin et al., 2012b). These results led to work describing feedback mechanisms 
at the level of the tumor important in the regulation of pro-apoptotic protein function, that 
could effectively be counteracted through mTOR inhibition (Gardner et al., 2014). One 
unanswered question from this work was whether the combined inhibition of mTOR and 
BCL-2/xL was due to independently additive effects, possibly displaying pre-clinical 
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synergy, or whether mTOR inhibition was “priming” tumors to a greater extent, effectively 
sensitizing SCLC to the activity of ABT-236/737. 
Here we attempted to address these open questions through in vivo “run-in” 
experiments across 3 PDX models of SCLC that cover the hallmarks of gene/protein 
expression subtypes – including c-MYC and N-Myc expression, various levels of BCL-2, 
and varying levels of pro-apoptotic BIM (Figure 36A). Groups of size matched, tumor-
bearing animals were treated with a single dose of an agent affecting various aspects of 
apoptotic sensitivity (e.g. birinipant as a cIAP1 inhibitor, silvestrol as a eIF4A/translation 
inhibitor, carfilzomib as a proteasome inhibitor) and then given a single oral dose of 
ABT-263, collecting tumors within 24hrs post-dosing. As an example in JHU-LX92, we 
found no evidence for a greater level of apoptosis within tumors acutely (“single dose”) 
conditioned with such agents, measuring apoptosis indirectly by the presence of a 
caspase cleaved motif and cleaved-PARP in tumor lysates (Figure 36B). Further, as 
various classes of mTOR inhibitors did not show strong pre-clinical single agent activity 
in multiple PDX models of SCLC when administered daily for 7d (Figure 36C), we asked 
whether tumors were now differentially sensitized to ABT-263, after a one week “run-in” 
period. Again, using JHU-LX92, we could find no evidence for a greater degree of 
apoptosis in tumors treated for 7d with different classes of mTOR inhibitors that were 
then treated with a single dose of ABT-263 (Figure 36D). Interestingly, it appeared that 
at least in JHU-LX92, levels of caspase cleaved motifs were higher in tumors pre-treated 
with rapamycin for one week than those treated with the mTOR kinase inhibitors 
AZD8055 or GDC-0980. While speculative, this may suggest that mTOR kinase 
inhibitors do have some influence on apoptotic threshold in vivo, as caspase cleaved 
motif levels were similar to tumors treated for 7d with ABT-263, where we suspect this is 
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reflective of a depletion in pro-apoptotic reserve over time (compare ABT*1 versus 
ABT*7 lanes for cleaved-PARP and caspase cleaved motifs).  
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(E) A single weekly dose of MLN0128 (MLN*1) is inferior to daily administration when in 
combination with ABT-263. Tumor volume changes (percent baseline; randomization 
~100-150mm3) at d10 after 7d of treatment with indicated schedules (50% ABT-263 
indicated 50mg/kg oral dose). All treatment arms produce statistically significant tumor 
growth inhibitor versus control; however, only the daily MLN0128 in combination with 
100mg/kg ABT-263 dose produce tumor regression (data falling below green line); p-
value levels of significance shown for paired t-tests.  
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Combining an mTOR allosteric or kinase inhibitor with ABT-263 is effective and non-
inferior in SCLC 
 These observations of differences in apoptotic reserve between treatment groups 
challenged with a single dose of ABT-263 caused us to question whether combining an 
mTOR allosteric inhibitor (a “rapalog”) would have greater anti-tumor activity with ABT-
263, as compared to an equivalent schedule of a kinase inhibitor in combination. The 
clinical development of AZD8055 has largely been abandoned due to limited activity and 
modest toxicity (Asahina et al., 2013; Naing et al., 2012), leading to a renewed focus on 
a similar compound MLN0128, recently reformulated as TAK-228, for clinical 
development (Ghobrial et al., 2016). We first determined that we were able to observe 
on-target efficacy of MLN0128 in vivo performing a time course experiment in animals 
bearing size matched JHU-LX92 tumors, and treated these mice with or without a single 
administration of ABT-263. The timing of separation of MLN0128 and the following dose 
of ABT-263 was approximately 2 hours and would be used in a similar spaced daily 
schedule for efficacy experiments. As both agents were being administered orally, there 
is some concern for one agent’s effect on the other, especially if formulations vary widely 
and compounds are administered simultaneously or within the expected window of 
gastric emptying in the mouse (~30 min). We did not observe significant differences in 
the suppression of p-4E-BP1 or decrease in MCL-1 between single agent or combination 
treated tumors (Figure 37A). However, we did note that the on-target activity of 
MLN0128 varied between tumors, where certain SCLC PDX models, when treated in a 
size-matched fashion, such as JHU-LX44, did not completely suppress p-4E-BP1 nor 
suppress cap-dependent translation, as measured by MCL-1 level (Figure 37B). These 
data argue that certain subtypes of SCLC, especially those that lose dependence on 
cap-dependent translation may not benefit from MLN0128 as a single agent or in 
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combination with ABT-263. Moreover, it is likely that both agents must be administered 
daily, as the rebound of p-4E-BP1 was within 24 hours (Figure 37A) post-MLN0128 
administration, and the anti-tumor efficacy of daily administration was greater than 
weekly administration of MLN0128 in combination with daily ABT-263 (Figure 36E). 
 We extended these short-term comparative efficacy studies across those 3 SCLC 
PDX models previously introduced (Figure 36A) and were able to show that while highly 
active in JHU-LX92 and SCRX-Lu149, capable of producing tumor regressions, the 
combination of MLN0128 or everolimus with ABT-263 was not statistically different 
between treatment arms within individual PDX models, where the combinations were 
superior to single agent ABT-263. Moreover, the combination lacked efficacy in JHU-
LX33, a model shown to not express BCL-2 and have no response to single agent ABT-
263. Further, we chose to examine activity in two additional SCLC models where BCL-2 
is differentially expressed (BCL-2LOW JHU-LX22 and BCL-2HIGH JHU-LX44), observing no 
activity in JHU-LX22 and modest anti-tumor activity in JHU-LX44, but not capable of 
producing regressions (Figure 38B). In terms of tolerability, both combination regimens 
were well tolerated and acute or chronic thrombocytopenia was largely due to ABT-263, 
with no greater reduction in circulating, mature platelets in combination arms on chronic 






Figure 37. mTOR kinase inhibition by MLN0128 is variable across independent 
PDX models of SCLC.  
(A) A single oral dose of MLN0128 suppressed cap-dependent translation for <24hrs in 
vivo. Size matched groups of JHU-LX92 tumor-bearing animals were orally administered 
a dose of vehicle or 100mg/kg ABT-263 four hours before an additional oral dose of 
1mg/kg MLN0128, where tumor tissue was then collected at various time points (in 
hours) post-MLN dose and analyzed by Western blot for suppression of p-4E-BP1. 
(B) Size matched tumor bearing animals (~300-400mm3) were administered an oral dose 
of vehicle or 1mg/kg MLN0128 and tumors tissue was collected 4hrs post-dose. 
(C) Acute weight loss in non-tumor-bearing mice is resolved within 24hrs post-dose. 
Three 6-8 week old female NSG mice were administered a single dose of 0.3 (black 
trace) or 1.0 mg/kg (blue trace) MLN0128 and weights were monitored for acute drops 
over 48hrs.   
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Figure 38. The combinations of ABT-263 with an mTOR allosteric or kinase 
domain inhibitor are non-inferior in vivo and ineffective in certain SCLC models. 
(A) Tumor volume changes between 4 treatment arms across 3 PDX models of SCLC. 
Groups of tumor bearing animals were randomized to treatment arms when tumors 
approached ~300mm3 (larger volume to allow for quantifiable regressions) to vehicle, 
daily 100mg/kg ABT-263 PO, or the combinations of 10mg/kg everolimus or AZD8055 
PO with ABT-263. The rapalog and kinase inhibitor were administered two hours before 
the ABT-263 on a 24hr schedule for 7d. Response data are shown 24hrs after the final 
dose. P-values shown for paired t-tests between treatment groups within an individual 
PDX (color coded bars); n.s.=not significant. 
(B) The combination of everolimus or MLN0128 with ABT-263 does not have broad anti-
tumor activity in all models of SCLC. Groups of tumor bearing animals were randomized 
to treatment arms when tumors approached ~300mm3 as above, and responses are 
compared 24hrs after the final dose. Tumor growth inhibition was observed in JHU-LX44 
(BCL-2+ PDX), but no tumor regressions were noted, in contrast to SCRX-Lu149 or 
JHU-LX92. 
(C) Acute treatment with various classes of mTOR inhibitors alone or in combination with 
ABT-263 does not worsen immediate platelet apoptosis (4hr nadir). Classes of mTOR 
inhibitor compounds (10mg/kg PO) were dosed 6hrs prior to tail bleed. When used in 
combination with 100mg/kg ABT-263, mTOR inhibitors were administered 2 hours before 
ABT-263. All platelet measures were performed on a Heska HemaTrue™ veterinary 
chemistry analyzer from tail bleeds (~100uL) in EDTA-coated capillary tubes; n=5 non-
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(D) Chronic administration of ABT-263 in combination with various classes of mTOR 
inhibitors does not worsen thrombocytopenia. Four hours after the day 7 dose of ABT-
263 as a single agent or in combination with various mTOR inhibitors, mice were tail bled 
and platelets measured as above.  
(E) Acute and chronic anti-platelet activity of ABT-263 in immune competent 
B6129SF1/J female mice (JAX strain #101043). Mice were tail bled and platelets 
assayed at 4hrs following a single dose or 7d of daily dosing of indicated tiers of ABT-
263.  
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Acquired resistance to cisplatin and etoposide does not preclude activity of MLN0128 + 
ABT-263 in SCLC in vivo. 
 Once concern with moving a therapeutic strategy forward in SCLC is patient 
demographics. Virtually all patients with SCLC enrolled onto clinical trials of novel agents 
are being enrolled post-relapse with the randomization being at the level or 3rd or 4th line 
treatment. This yields a scenario where the patient’s tumor has seen chemotherapy, 
relapsed at some interval of resistance (chemosensitive or chemorefractory) and is now 
largely considered resistant to standard of care cisplatin+etoposide. In examining the 
combined activity of cisplatin+etoposide versus ABT-263+everolimus, we did not note a 
linear trend in the data, suggesting that sensitivity or resistance to one combination did 
not preclude activity of the other (Figure 39A). Moreover, we had previously 
demonstrated the ability to model acquired resistance in vivo in a panel of chemo-
sensitive PDX models of SCLC (Chapter 2 & Figures 39B,C).  
In parallel, we had also explored generating isogenic resistant versions of NCI-
H146, a SCLC cell line with de novo sensitivity to both the combinations of 
cisplatin+etoposide and ABT-263+everolimus. In vitro acquired resistance to etoposide 
or any class of mTOR inhibitor decrease the relative potency of etoposide in all isogenic 
versions tested, whereas these lines showed increased sensitivity to single agent ABT-
263 (Figure 39D). These data help to suggest that resistance to etoposide, which is 
likely to be acquired in some way in all patients this combination will be tested in, is 
unlikely to directly promote resistance to ABT-263. Finally, we show that the in vivo 
activity of MLN0128 + ABT-263 is effectively preserved in one version of acquired 
resistance to cisplatin and etoposide in a paired chemosensitive and chemoresistant 
version of JHU-LX48, a BCL-2 expressing SCLC PDX. A weekly course of daily 
MLN0128 in combination with ABT-263 was capable to producing regressions in 5/5 
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animals on treatment in either the chemosensitive or chemoresistant setting (Figures 
39E,F).   
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Figure 39. Acquired resistance to cisplatin/etoposide does not confer cross-
resistance to ABT-263/MLN0128 in vivo. 
(A) Effect size plot comparing the combinatorial activity of cisplatin+etoposide to 
everolimus+ABT-263 from a panel of SCLC cell lines (11 human SCLC cell lines). Data 
do not fit to a trend line 
(B) Example in vivo tumor growth kinetic data from chemosensitive and chemoresistant 
versions of JHU-LX48 PDX model. Point of treatment tumors passage (“transplant”) 
indicated along x-axis with vertical dashed line. 
(C) Survival differences between treatment arms in chemosensitive (CE phase 1; black 
dotted line) and chemoresistant (CE phase 3; blue dotted line) as a measure of time to 
reach 1000mm3. Tumors that did not reach endpoints (CE phase 1) are censored at the 
last point of measurement on protocol 
(D) In vitro acquired resistance to multiple classes of mTOR targeted agents decreases 
the relative sensitivity to etoposide (above) while increases the sensitivity to ABT-263 
(below). Data are shown for 72hrs cell proliferation assays (AlamarBlue). Cell lines were 
considered resistant when they were capable of doubling in at the same rate of the 
parental line under 100nM selection agent.  
(E) The combination of MLN0128 and ABT-263 has activity in vivo, independent of 
sensitivity to cisplatin and etoposide. Paired chemosensitive and chemoresistant (“R”) 
BCL-2 expressing SCLC PDXs were engrafted into mice and treated for 7d with 
100mg/kg ABT-263 + 1.0mg/kg MLN0128 daily for 7d. 
(F) Best responses of parental or resistant JHU-LX48 tumors are non-inferior. Tumor 



















































































































































































































show tumor regressions (data falling below green dotted line); p-value from paired t-test 
0.452 (not included on graph).  
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Discussion 
 As agents targeting programmed cell death move towards late stage clinical 
testing, development and FDA-approval, it is critical to understand what subtypes of 
patients within a given tumor histology are likely to benefit. Moreover, it is becoming 
increasingly clear that targeting such vulnerabilities in tumors must be weighed against 
the expected toxicities – all of these agents, even if selective for BCL-2 over both BCL-
2/xL, come with expectations of grade 3 or 4 hematologic toxicities (Konopleva et al., 
2016; Leverson, 2016; Roberts et al., 2016). This creates a challenge for combinations 
with any cytotoxic agents or small molecular that induces cellular stress. Here we 
describe an effort to compare the relative activities of an allosteric mTOR inhibitor 
(everolimus) versus a catalytic mTOR (MLN0128) in combination with ABT-263 in 
multiple PDX models of SCLC. We were able to show that while in vitro, the catalytic 
mTOR inhibitor combination looked slightly more effective, in vivo, the comparison was 
non-inferior. Further, we established a daily schedule of each agent as most beneficial 
and show that acquired resistance to first line cisplatin/etoposide does not generate 
cross-resistance to ABT-263 + MLN0128, a central concern for moving these studies 
forward. Finally, we show that not all PDX models of SCLC will benefit from this 
therapeutic combination – notably, models that do not express BCL-2 or that have low 
baseline levels of pro-apoptotic BIM are anticipated to be resistant. Interestingly, in 
generating in vitro resistant models to BCL-2/xL inhibitors we show that loss of BAX 
permits resistance to any class of agent in combination with ABT-263, suggesting 
patients with genomic loss of inactivation of BAX will not benefit from this approach.  
Loss of BAX is known to confer a greater resistance to chemotherapy and has 
been reported in several cancer types (Catasus et al., 1998; Rampino et al., 1997; 
Zhang et al., 2000). Several studies have shown that BAX levels can respond to various 
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insults including TRAIL (Liu et al., 2008), hypoxia (Erler et al., 2004), and p53-dependent 
apoptosis (Chipuk et al., 2004). Consensus in the literature has shown that BAX 
message levels do not change under these selective pressures. Interestingly, loss of 
BAX protein expression was observed in melanoma, another neural-crest-derived 
cancer, and this could be rescued with the proteasome inhibitor bortezomib (Chen et al., 
2011; Miller et al., 2009). Several other publications have proposed a mechanism of 
ubiquitin-proteasome-mediated regulation of BAX levels (Benard et al., 2010; Fu et al., 
2007; Li and Dou, 2000; Liu et al., 2008). While we have not explored the regulation of 
BAX in vivo to any exhaustive extent in SCLC, have been able to demonstrate acute 
down regulation at the protein level under treatment with the BCL-2/xL inhibitor ABT-737 
(Gardner et al., 2014). Further, using shRNAs against BAK1 and BAX, we were able to 
show that it was suppression of BAX, and not BAK1, that permitted resistance to ABT-
737 in our model systems. Importantly, suppression of either BAX or BAK1 did not 
greatly augment the responsiveness of multiple SCLC cell lines to cisplatin/etoposide, 
suggesting that the roles of these pro-apoptotic effector are likely to be cell intrinsic and 
should be examined thoroughly on the background of a given cell type.  
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 SCLC remains a highly lethal disease with limited therapeutic options, outside of 
first line platinum+etoposide chemotherapy, second line topoisomerase I poisons, and 
third line enrollment onto a clinical trial. One of the challenges in advancing therapeutic 
development in this cancer has been a poor understanding of how tumors change from 
being exquisitely sensitive to chemotherapy, to a chemo refractory progressive disease. 
This work has substantially advanced this understand through the use of a set of 
genetically annotated chemoresponsive PDX models of SCLC, generating and 
annotating chemoresistant versions of each. The development of these tools helped to 
identify down-regulation of a SLFN11, a gene involved in DNA damage response. With 
recent knowledge of the epigenetic landscape of SCLC, we tied the down regulation of 
SLFN11 to repressive histone methylation by the PRC2 component EZH2. Combining a 
clinical EZH2 inhibitor EPZ011989 with either first or second line chemotherapy in paired 
PDX models of chemosensitive or chemoresistant disease enabled complete disease 
control and prevented resistant outgrowth. This first part of this body of work has aided in 
uncovering one conserved mechanism of acquired resistance in vivo, with immediate 
clinical relevance. 
 The second half of this thesis has focused on targeting a resistance mechanism 
to programmed cell death, through the use of a small molecule BCL-2/xL inhibitor. The 
third chapter described an approach looking at the acute effects of single agent ABT-737 
on responsive PDX models, trying to understand what the acute changes during 
response and immediately preceding resistant outgrowth looked like at the level of the 
transcriptome (Figure 40). This work was able to show that a loss in critical HIF-1α 
transcripts and a down-regulation in protein levels of BAX were consistent changes 
observed across models. Combining an allosteric mTOR inhibitor with ABT-737 was 
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capable to reversing these gene expression changes, preserved BAX levels and led to 
durable tumor regressions in BCL-2 expressing PDX models. 
 The fourth chapter sought to address recent data from the Engelman group on 
broad activity of combining the BCL-2/xL inhibitor with AZD8055 in SCLC. These data 
slightly contradicted our findings in that they suggested ABT-263 would have activity in 
SCLC models with low levels of BCL-2 by the translational repression of AZD8055 on 
MCL-1 – effectively partnering pro-apoptotic effectors like BIM on BCL-xL, and 
sensitizing tumors to ABT-263. While their data were encouraging, we demonstrate that 
the combination of MLN0128 with ABT-263 is effectively non-inferior to combining ABT-
263 with everolimus in multiple PDX models of SCLC. Further, there are likely to be 
scenarios where this combination is not effective, even in the presence of BCL-2 
expression, as the ability of MLN0128 to suppress MCL-1 in vivo is variable across 
tumors due to variable use of cap-dependent translation. Unlike evidence in leukemia 
and lymphoma models where BCL-2 amplification or fusions are defining events, we 
show that SCLC does not exist in a “primed to die” state in vivo through sequential, time 
course analyses with or without various inhibitors of the mTOR pathway. The combined 
activity of an mTOR inhibitor with ABT-263 is something that required daily 
administration to achieve maximal anti-tumor effect, where loss of BAX was capable of 
promoting resistance to either single agent ABT-263 of the combination with various 
classes of mTOR inhibitors. Taken together, these studies demonstrate the utility of 
using SCLC PDX models in both a discovery mode, to determine mechanisms of 
acquired resistance to first line chemotherapy, and in an efficacy mode, to refine what 
subtypes of SCLC are likely to respond to combination therapies.  
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Figure 40. Approaches to studying mechanisms of acquired resistance in vivo 
using PDX models of SCLC. 
When choosing phenotypic response data as a measure of acquisition of resistance or 
de novo sensitivity to a given therapeutic challenge, it is important to consider sampling 
times and establishment of acquired resistance in vivo. For example, on the left panel, 
acute effects can be thought of as the gene expression changes and events within the 
tumor that are occurring during the initial period of response or treatment challenge, 
such that they need to be surveyed within a defined time window in parallel to a 
contemporaneous vehicle group. In contrast, acquiring resistance to a therapeutic can 
be examined over time through multiple passages of a given PDX on or off therapy, such 
as on the right panel. In this example, re-engraftment of previously-treated PDX 
materials (survival fraction) to determine the extent the mechanism of acquired 
resistance (for example, gene expression changes) are conserved in the next generation 
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